NO335263B1 - Peptiddeformylaseinhibitorer samt anvendelse derav - Google Patents

Peptiddeformylaseinhibitorer samt anvendelse derav Download PDF

Info

Publication number
NO335263B1
NO335263B1 NO20045675A NO20045675A NO335263B1 NO 335263 B1 NO335263 B1 NO 335263B1 NO 20045675 A NO20045675 A NO 20045675A NO 20045675 A NO20045675 A NO 20045675A NO 335263 B1 NO335263 B1 NO 335263B1
Authority
NO
Norway
Prior art keywords
hydroxy
formamide
hydrazinocarbonyl
heptyl
methyl
Prior art date
Application number
NO20045675A
Other languages
English (en)
Other versions
NO20045675L (no
Inventor
Kelly M Aubart
Domingos J Silva
Iv Siegfried Benjamin Christensen
Jinhwa Lee
Joseph M Karpinski
Andrew B Benowitz
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20045675L publication Critical patent/NO20045675L/no
Publication of NO335263B1 publication Critical patent/NO335263B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C23/00—Compounds containing at least one halogen atom bound to a ring other than a six-membered aromatic ring
    • C07C23/18—Polycyclic halogenated hydrocarbons
    • C07C23/20—Polycyclic halogenated hydrocarbons with condensed rings none of which is aromatic
    • C07C23/27—Polycyclic halogenated hydrocarbons with condensed rings none of which is aromatic with a bicyclo ring system containing seven carbon atoms
    • C07C23/28—Saturated bicyclo ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/22—Hydrazines having nitrogen atoms of hydrazine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Structural Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Nye PDF-inhibitorer og nye fremgangsmåter for deres anvendelse er tilveiebragt.

Description

Foreliggende oppfinnelse angår nye antibakterielle forbindelser, og anvendelse av disse forbindelsene for fremstilling av medikamenter for behandling av en bakteriell infeksjon, som peptiddeformylaseinhibitorer.
Bakteriell initiator metionyl tRNA blir modifisert ved metionyl tRNA-formyltransferase (FMT) for å gi formylmetionyl tRNA. Formylmetionin (f-met) blir deretter inkorporert ved N-terminalene til nylig syntetiserte polypeptider. Polypeptiddeformylase (PDF eller Def) fosforylerer deretter primære translasjonsprodukter for å gi N-metionylpolypeptider. De fleste intracellulære proteiner blir videre prosessert av me-tioninaminopeptidase (MAP) for å gi det ferdige peptidet og fritt metionin, som resir-kuleres. PDF og MAP er begge essensielle for bakterievekst og PDF kreves for MAP-aktivitet. Denne serien av reaksjoner refereres til som metioninsyklusen (fig. 1).
Pr. i dag har polypeptiddeformylasehomologe gener blitt funnet i bakterier, i kloroplast-inneholdende planter og hos mus og hos mennesker. Planteproteinene er nukleært kode-de, men synes å bære et kloroplastlokaliseringssignal. Dette er i overensstemmelse med observasjonen om at kloroplast RNA og proteinsynteseprosesser er svært tilsvarende de til eubakterier. Mens det er begrenset informasjon vedrørende proteinekspresjon av pat-tedyr PDF-genhomologer (Bayer Aktiengesellschaft, Pat. WO2001/42431), har ingen funksjonell rolle for slike proteiner blitt demonstrert pr. i dag (Meinnel, T., Parasitology Today 16(4), 165-168, 2000).
Polypeptiddeformylase har blitt funnet i alle eubakterier for hvilke høydeknings-genomsekvensinformasjon er tilgjengelig. Sekvensdiversitet blant PDF-homologer er høy, med så lite som 20% identitet mellom fjernt relaterte sekvenser. Imidlertid er kon-servering rundt det aktive setet svært høy, med flere fullstendig konserverte rester, som inkluderer et cystein og to histidiner som kreves for å koordinere aktivsetemetallet (Meinnel, T. et al., J. Mol. Biol. 267, 749-761, 1997).
PDF er anerkjent for å være et attraktivt antibakterielt middel, idet dette enzymet har blitt demonstrert å være essensielt for bakterievekst in vitro (Mazel, D. et al., EMBO J. 13 (4), 914-923, 1994), antas det ikke å være involvert i eukaryot proteinsyntese (Ra-jagopalan et al, J. Am. Chem. Soc. 119,12418-12419,1997) og blir universielt konser-vert i prokaryoter (Kozak, M., Microbiol. Rev. 47, 1-45, 1983). Derfor kan PDF-inhibitorer potensielt tjene som et bredt spekter av antibakterielle midler.
Foreliggende oppfinnelse omfatter nye antibakterielle forbindelser representert ved formel (1) nedenfor og deres anvendelse som PDF-inhibitorer.
I et aspekt ifølge oppfinnelsen er det tilveiebragt en forbindelse med formel (1):
hvori:
R er valgt fra:
C2-6alkyl; C2-6alkenyl; C2-6alkynyl; eller (CH2)n-C3-6karbocyklus;
hvor hver C2-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, (CH2)n-C3^-karbocyklus eventuelt er
substituert med Ci-3-alkoksy, halogen eller C1.3alkylsulfanyl eller (CH2)n-R4, hvor R4 er fenyl, furan, benzofuran, tiofen, benzotiofen, tetrahydrofuran, tetrahydropy-ran, dioksan, 1,4-benzodioksan eller benzo[l,3]dioksol;
hvor R4 eventuelt er substituert med en eller flere substituenter valgt fra Cl, Br, I, C1.3
alkyl eller C1.2alkoksy; hvor hver Ci_3-alkyl eller Ci_2-alkoksy som definert
ovenfor for R4 eventuelt er substituert med ett til tre F-atomer;
RI og R2 er uavhengig valgt fra:
hydrogen, C1.3substituert alkyl, C2-3substituert alkenyl, C2-3substituert alkylnyl,
(CH2)n-C3-6substituert karbocyklus, aryl, heteroaryl og heterocyklisk;
hvori
aryl er fenyl, naftyl, tetrahydronaftyl, bifenyl, indanyl, antracyl eller fenantryl;
heteraryl er benzimidazolyl, benzotiazolyl, benzoisotiazolyl, benzotiofenyl, benzopyra-zinyl, benzotriazolyl, benzotriazinyl, benzo[l,4]dioksanyl, benzofuranyl, 9H-a-karbolinyl, cinnolinyl, 2,3-dihydro[l,4]dioksino[2,3-b]-pyridinyl, furanyl, fu-ro[2,3-b]pyridinyl, imidazolyl, imidazolidinyl, imidazopyridinyl, isoksazolyl, isotiazolyl, isokinolinyl, indolyl, indazolyl, indolizinyl, naftyridinyl, oksazolyl, oksotiadiazolyl, oksadiazolyl, ftalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl, fenazinyl, pyrazolyl, pyridyl, pyrazolopyrimidinyl, pyrazolopyridinyl, pyrroli-zinyl, pyridazyl, pyrazinyl, pyrimidyl, 4-okso-l,2-dihydro-4H-pyrrolo[3,2,l-ij]-kinolin-4-yl, kinoksalinyl, kinazolinyl, kinolinyl, kinolizinyl, tiofenyl, triazolyl, triazinyl, tetrazolopyrimidinyl, triazolopyrimidinyl, tetrazolyl, tiazolyl eller
tiazolidinyl;
karbocyklisk er en ikke-aromatisk cyklisk hydrokarbonrest som har fra tre til syv karbonatomer,
heterocyklisk er en tre- til syv-leddet ring inneholdende en eller flere heteroatomære
enheter valgt fra S, SO, S02, O, N eller N-oksid;
hvori:
den tre- til 7-leddete ringen som definert for hver heterocyklisk er mettet eller har en eller flere grader av umettethet; eller hver heterocyklisk er kondensert til en eller flere eventuelt substituerte heterocykliske ring(er), arylring(er), heteroaryl-ring(er), eller karbocykliske ring(er) som definert ovenfor;
hvori
Ci-3substituert alkyl, som definert for RI og R2 ovenfor, eventuelt er substituert med minst en substituent valgt fra Ci.3-alkyl eventuelt substituert med ett til tre fluoratomer, C2-3-alkenyl, C2-3-alkynyl, Ci_2-alkoksy eventuelt substituert med ett til tre fluoratomer, sulfanyl, Ci-3-alkylsufanyl, sulfinyl, sulfonyl, okso, hydroksy, merkapto, amino, guanidino, karboksy, aminokarbonyl, aryl, aryloksy, heteroaryl, heteroaryloksy, heterocyklisk, aminosulfonyl, sulfonylamino, karboksyamid, ureido, nitro, cyano eller halogen;
C2-3substituert alkenyl, som definert for RI og R2, er eventuelt substituert med minst en substituent valgt fra Ci-3-alkyl eventuelt substituert med ett til tre F-atomer, amino, aryl, cyano eller halogen;
C2-3substituert alkynyl, som definert for RI og R2, er eventuelt substituert med minst en substituent valgt fra Ci-3-alkyl (eventuelt substituert med ett til tre F-atomer), amino, aryl eller halogen;
hvert aryl, heteroaryl, heterocyklyl, eller karbocyklisk, henholdsvis, som definert over,
er eventuelt videre substituert med minst en substituent valgt fra C1.3substituert alkyl, C2-3substituert alkenyl, C2-3substituert alkynyl, heteroaryl, usubstituert
heterocyklisk, aryl, Ci-3-alkoksy, aryloksy, aralkoksy, acyl, aroyl, heteroaroyl, acyloksy, aroyloksy, heteroaroyloksy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, karboksyamid, aminokarbonyl, karboksy, okso, hydroksy,
merkapto, amino, nitro, cyano, halogen eller ureido;
Y er O, CH2eller en kovalent binding; og
n er et heltall på fra 0 til 2;
eller et farmasøytisk aseptabelt salt derav.
Foreliggende oppfinnelse omfatter også anvendelse av en forbindelse med formel 1 som omtalt ovenfor, for fremstilling av et medikament for behandling av en bakteriell infeksjon.
Ifølge oppfinnelsen er den mest foretrukne R2-gruppen hydrogen. I foreliggende oppfinnelse er den mest foretrukne absolutte konfigurasjonen av forbindelsene med formel (1) som indikert nedenfor:
Slik det anvendes heri, refererer begrepet "alkyl" til et rett eller forgrenet mettet hydrokarbonradikal. Eksempler på "alkyl" slik det anvendes heri inkluderer metyl, etyl, n-propyl, isopropyl, n-butyl, iso-butyl, t-butyl, n-pentyl, isopentyl, heksyl og lignende.
Slik det anvendes heri, refererer begrepet "alkenyl" til et rett eller forgrenet hydrokarbonradikal som har minst en karbon-karbon-dobbelbinding. Eksempler på "alkenyl" slik det anvendes heri inkluderer etenyl og propenyl.
Slik det anvendes heri, refererer begrepet "alkynyl" til et rett eller forgrenet hydrokarbonradikal som har minst en karbon-karbon-trippelbinding. Eksempler på "alkynyl", slik det anvendes heri, inkluderer acetylenyl og 1-propynyl.
Slik det anvendes her, refererer begrepet "halogen" til fluor (F), klor (Cl), brom (Br), eller jod (I), og "halo" refererer til halogenradikalene fluor, klor, brom og jod.
Slik det anvendes heri, refererer begrepet "karbocykel" til et ikke-aromatisk cyklisk hydrokarbonradikal som har fra tre til syv karbonatomer. For karbocykler med fem- til syv leddede ringer, er en ringdobbelbinding mulig. Eksempler på "karbocykel"-grupper inkluderer cyklopropyl, cyklobutyl, cyklopentyl, cyklopentenyl, cykloheksyl og cyklo-heptyl.
Slik det anvendes heri, refererer begrepet "aryl" til en eventuelt substituert benzenring eller en eventuelt substituert benzenring kondensert til en eller flere eventuelt substituerte benzenringer for å danne et ringsystem. Eksempler på eventuelle substituenter inkluderer Ci-3substituert alkyl, C2-3substituert alkenyl, C2-3substituert alkynyl, heteroaryl, heterocyklisk, aryl, C1.3alkoksy (eventuelt substituert med en til tre F), aryloksy, aralkoksy, acyl, aroyl, heteroaryl, acyloksy, aryloksy heteroaroyloksy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, karboksyamid, aminokarbonyl, karboksy, okso, hydroksy, merkapto, amino, nitro, cyano, halogen, eller ureido, multiple grader av sub-stitusjon er mulig. Et slik ring eller ringsystem kan eventuelt kondenseres til en eller flere eventuelt substituerte ringer (som inkluderer benzenringer), karbocykliske ringer eller heterocykliske ringer
Slik det anvendes heri, refererer begrepet "heterocyklisk" til en tre- til syv-leddet ring som inneholder et eller flere heteroatomdeler utvalgt fra S, SO,S02, O, N eller N-oksid. En slik ring kan være mettet eller ha en eller flere grader av umettethet. En slik ring kan eventuelt kondenseres til en eller flere andre eventuelt substituerte "heterocykliske" ringer, arylringer, heteroarylringer eller karbocykliske ringer. Eksempler på "heterocykliske"enheter inkluderer 1,4-dioksanyl, 1,3-dioksanyl, pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, imidazolidin-2,4-dionpiperidinyl, piperazinyl, piperazin-2,5-dionyl, morfo-linyl, dihydropyranyl, dihydrocinnolinyl, 2,3-dihydrobenzo[l,4]dioksinyl, 3,4-dihydro-2H-benzo[b][l,4]-dioksepinyl, tetrahydropyranyl, 2,3-dihydrofuranyl, 2,3-dihydrobenzofuranyl, dihydroisoksazolyl, tetrahydrobenzodiazepinyl, tetrahydrotiopy-ranyl, tetrahydrotiofenyl, dihydrokinoksalinyl, tetrahydrokinoksalinyl, tetrahydropyri-dinyl, tetrahydrokarbolinyl, 4H-benzo[l,3]-dioksinyl, benzo[l,3]dioksonyl, 2,2-difluorbenzo-[l,3]-dioksonyl, 2,3-dihydro-ftalazin-l,4-dionyl, isoindol-l,3-dionyl, og lignende.
Slik det anvendes heri, refererer begrepet "alkoksy" til gruppen -ORa, hvor Ra er alkyl som definert ovenfor. Eksempler på alkoksygrupper anvendelige ifølge oppfinnelsen inkluderer metoksy, difluormetoksy, trifluormetoksy, etoksy, n-propoksy, isopropoksy, n-butoksy, og t-butoksy.
Slik det anvendes heri, refererer begrepet "aryloksy" til gruppen -ORaRb, hvor Ra er alkyl og Rber aryl som definert ovenfor.
Slik det anvendes heri, refererer begrepet "aryloksy" til gruppen -ORa, hvor Ra er aryl som definert ovenfor.
Slik det anvendes heri, refererer begrepet "merkapto" til gruppen -SH.
Slik det anvendes heri, refererer begrepet "sulfanyl" til gruppen -SRa, hvor Ra er substituert alkyl, substituert karbocykel, aryl, heteroaryl eller heterocyklisk, som definert ovenfor.
Slik det anvendes heri, refererer begrepet "sulfinyl" til gruppen -S(0)Ra, hvor Ra er substituert alkyl, substituert karbocykel, aryl, heteroaryl eller heterocyklisk, som definert ovenfor.
Slik det anvendes heri, refererer begrepet "sulfonyl" til gruppen -S(0)2Ra, hvor Ra er substituert alkyl, substituert karbocykel, aryl, heteroaryl eller heterocyklisk, som definert ovenfor.
Slik det anvendes heri, refererer begrepet "okso" til gruppen =0.
Slik det anvendes heri, refererer begrepet "hydroksy" til gruppen -OH.
Slik det anvendes heri, refererer begrepet "amino" til gruppen -NH2. Aminogruppen er eventuelt substituert med alkyl, substituert karbocykel, aryl, heteroaryl eller heterocyklisk, som definert ovenfor.
Slik det anvendes heri, refererer begrepet "cyano" til gruppen -CN.
Slik det anvendes heri, refererer begrepet "aminosulfonyl" til gruppen -S(0)2NH2. Ami-nosulfonylgruppen er eventuelt substituert med substituert alkyl, substituert karbocykel, aryl, heteroaryl eller heterocyklisk, som definert ovenfor.
Slik det anvendes heri, refererer begrepet "sulfonylamino" til gruppen -NHS(0)2Ra, hvor Ra er substituert alkyl, substituert karbocykel, aryl, heteroaryl eller heterocyklisk, som definert ovenfor.
Slik det anvendes heri, refererer begrepet "karboksyamid" til gruppen -NHC(0)Ra, hvor Ra er substituert alkyl, substituert karbocykel, aryl, heteroaryl eller heterocyklisk, som definert ovenfor.
Slik det anvendes heri, refererer begrepet "karboksy" til gruppen -C(0)OH. Karboksy-gruppen er eventuelt substituert med substituert alkyl, substituert karbocykel, aryl, heteroaryl eller heterocyklisk, som definert ovenfor.
Slik det anvendes heri, refererer begrepet "aminokarbonyl" til gruppen -C(0)NH2. Aminokarbonylgruppen er eventuelt substituert med substituert alkyl, substituert karbocykel, aryl, heteroaryl eller heterocyklisk, som definert ovenfor.
Slik det anvendes heri, refererer begrepet "ureido" til gruppen -NHC(0)NHRa, hvor Ra er hydrogen, alkyl, karbocykel eller aryl som definert ovenfor.
Slik det anvendes heri, refererer begrepet "guanidino" til gruppen -NHC(=NH)NH2.
Slik det anvendes heri, refererer begrepet "acyl" til gruppen -C(0)Ra, hvor Ra er alkyl, karbocykel eller heterocyklisk som definert heri.
Slik det anvendes heri, refererer begrepet "aroyl" til gruppen -C(0)Ra, hvor Ra er aryl som definert heri.
Slik det anvendes heri, refererer begrepet "heteroaroyl" til gruppen -C(0)Ra, hvor Ra er heteroaryl som definert heri.
Slik det anvendes heri, refererer begrepet "acyloksy" til gruppen -OC(0)Ra, hvor Raer alkyl, karbocykel eller heterocyklisk som definert heri.
Slik det anvendes heri, refererer begrepet "aroyloksy" til gruppen -OC(0)Ra, hvor Ra er aryl som definert heri.
Slik det anvendes heri, refererer begrepet "heteroaroyloksy" til gruppen -OC(0)Ra, hvor Ra er heteroaryl som definert heri.
Også inkludert innenfor foreliggende oppfinnelsen er farmasøytisk akseptable salter og komplekser, slik som hydroklorid-, hydrobromid- og trifluoracetatsalter og natrium-, kalium- og mangesiumsalter. Forbindelsene ifølge oppfinnelsen kan inneholde et eller flere asymmetriske karbonatomer og kan eksistere i racemiske og eventuelt aktive for-mer. Alle disse forbindelser og diastereomerene er omfattet av foreliggende oppfinnelse.
Foretrukne forbindelser ifølge oppfinnelsen er utvalgt fra gruppen som består av: N-hydroksy-N-[(R)-2-(N'-pyridin-2-yl-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-{(R)-2-[N'-(3-metoksy-fenyl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(4-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl]-heptyl} -formamid, N-{(R)-2-[N'-(4-cyano-fenyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid., N-{(R)-2-[N'-(2,6-dimetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydrolcsy-N-[(R)-2-(^'-ldnoksalin-2-yl-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-((2R)-2-{N'-(3,4-dihydro-kinoksalin-2-yl)-hydrazinokarbonyl}-heptyl)-formamid,
N-hydroksy-N-{(R)-2-[N'-(l,3,4-trimetyl-lH-pyrazolo[3,4-b]pyridin-6-yl)-hydrazinokarbonyl]-heptyl}-formamid,
4-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl-hydrazino)-benzensulfonamid,
N-hydroksy-N-[(2R)-2-(cykloheksylmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -propyl] -formamid,
N-hydroksy-N-[(2R)-2-(cykopentylmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -propyl]-formamid,
N-{(R)-2-[N'-(dimetyl-trifluormetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-[N'-(6-trifluormetyl-pyridazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N- {(R)-2 - [N' -(6-trifluormetyl-pyrimidin-4-y l)-hydrazinokarbony 1] - heptyl} -formamid,
N-hydroksy-N-{(R)-2-[N'-(5-metyl-[l,2,4]triazolo[1.5-a]pyrimidin-7-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N-{(R)-2-[N'-(9H-purin-6-yl)-hydrazinokarbonyl]-heptyl}-formamid. N-{(R)-2-[N'-(5-cyano-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-((2R)-2-{[N'-(pyrimidin-2-yl)-hydrazino]karbonyl}-heptyl)-formamid, N-hydrolcsy-N-((2R)-2-(c<y>klobut<y>lmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -propyl)-formamid, N-hydroksy-N-{(R)-2-[N'-(6-imidazol-l-yl-pyrimidin-4-yl)-hydrazinonkarbon heptyl} -formamid, N- [(R) -2-(N' -benzo [ 1,2,4] triazin-3 -yl-hydrazinokarbonyl)-heptyl] -N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(7-metoksy-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-hydroksy-N-{(R)-2-[N'-(l-metyl-lH-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-((R)-2-{N'-[6-(5-klor-pyridin-3-yl-oksy)-pyridazin-3-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-[(2R)-2-({N'-[6-(lH-pyrrol-l-yl)-3-pyridazinyl]-hydrazino}-karbonyl)-heptyl]-formamid., N-hydroksy-N-((2R)-2-{[N'-(9-metyl-9H-purin-6-yl)-hydrazino]-karbonyl}-heptyl)-formamid,
N-hydroksy-N- {(R)-2-[N-( {6-morfolin-4-yl} -9H-purin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid,
N-{(R)-2-[N'-(6-fluor-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-((2R)-2-{[N'-(l-metyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-hydrazino]-karbonyl} -heptyl)-formamid,
N- {(R)-2-[N' -(4-amino-6-isopropyl-[ 1,3,5 ]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-{(R)-2-[N'-(2,5-dimetyl-4-nitro-2H-pyrazol-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N- {(R)-2-[N' -(3-klor-1 -metyl-1 H-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-{(R)-2-[N'-(6-dimetylamino-9H-purin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-[(2R)-4-cyklopropyl-2-({N'-[4-(tirfluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-butyl]-formamid,
N-hydroksy-N-((2R)-2-(cyklopropylmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -propyl)-formamid,
N-hydroksy-N-{(R)-2-[N'-metyl-N'-(4-trifluometyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5 -karboksylsyre metylester,
2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-tri pyrimidin-5 -karboksylsyre,
N-{(R)-2-[N'-(5-fluor-4-metoksy-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-{(R)-2-[N'-(4-dimetylamino-pyridin-2-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid,
N-hydroksy-N-{(2R)-2-[(N'-{6-[(2-hydroksyetyl)arnino]-l,3-dihydro-2H-purin-2-yliden} -hydrazino)-karbonyl]-heptyl} -formamid,
N-{(R)-2-[N'-(5-fluor-4-morfolm-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-{(R)-2-[N'-(5-fluor-4-metylamino-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifiuormetyl-pyrimidin-5 -karboksylsyre dimetylamid,
N-hydroksy-N-{(R)-2-[N'-(3-okso-3,4-dihydro-kinoksalin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid,
N-{(R)-2-butoksy-2-[N'-(4-trilfuormetyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid,
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trilfuormetyl-pyrimidin-5 -karboksylsyre (2-fluor-fenyl)-amid,
2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trilfuormetyl-pyrimidin-5 -karboksylsyre tert-butylamid,
N-hydroksy-N-((R)-2- {N' -[(1 -piperidin-1 -yl-metanoyl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-{(R)-2-[N'-(5-cyano-4-trifluormetyl-pyirmidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-[(2R)-2-({N'-[9-(4,4.4-trifluorbutyl)-1.9-dihydro-2H-purin-2-yliden]-hydrazino} -karbonyl)-hepty 1] -formamid,
N-hydrolcsy-N-((R)-2-{N'-[(l-morfolin-4-yl-metanoyl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trilfuormetyl-pyrimidin-5-karboksylsyrebenzylamid,
N-hydrolcsy-N-[(2R)-3-[N'-(l,2,4-benzotriazin-3-yl)-hydrazino]-2-(cykloheksylmetyl)-3 -oksopropyl] -formamid,
N-hydroksy-N-((2R)-2-(cykloheksylmetyl)-3-{N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino}-3-oksopropyl)-formamid, 2-[2-((2R)-2-{[formyl(hydroksy)amino]metyl}heptanoyl)hydrø pyridinyl-4-(trifluormetyl)-5-pyrimidinkarboksamid,
2-[2-((2R)-2-{[formyl(hydroksy)amino]me1yl}heptanoyl)hydrazino]-N-me1yl-N-fen 4-(trifluormetyl)-5 -pyrimidinkarboks amid,
2-(N'-{(R)-2-[(formyl-hydroksy-amino)metyl]-heptan^ pyrimidin-5 -karboksylsyre morfolin-4-ylamid,
N-hydroksy-N-((R)-2-{N'-[(N'-fenyl-hydrazinokarbonyl)-trifluormetyl-pyrimidin-2-yl] -hydrazinokarbonyl} -heptyl)-formamid,
2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5 -karboksylsyre piperidin-1 -ylamid,
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl} -hydrazino-4-trifluormetyl-pyrimidin-5-karboksylsyre pyrrol-1 -ylamid,
N- {(R)-2- [N' -(dimetylamino-fluor-pyrimidin-2 -yl)-hydrazinokarbonyl] -hepty 1} -N-hydroksy-formamid,
N-((R)-2-{N'-[(etyl-me1yl-amino)-fluor-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid,
N-hydroksy-N-((2R)-2 -(cyklopentylmetyl)-3 - {N' - [7 -(metyloksy)-1,2,4-benzotriazin-3 - yl]-hydrazino}-3-oksopropyl)-formamid,
N-hydroksy-N- {(R)-2-[N'-(l -metyl- lH-benzoimidazol-2-yl)-hydrazinokarbonyl]-heptyl} -formamid,
N- {(R)-2-[N' -(4-azetidin-1 -yl-5 -fluor-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-{(R)-2-[N'-(4-cyklopropylamino-5-fluor-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-[(R)-2-(K-benzo[l,2,4]triazin-3-yl-hydrazinokarbonyl)-3-cyklopentyl-propyl]-N-hydroksy-formamid,
N-hydroksy-N- {(R)-2 - [N' -(morfolin-4-yl-trifluormetyl-pyrimidin-2 -yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N-[(R)-2-(N'- {[(2-hydroksy-etyl)-metyl-amino]-trifluormetyl-pyrimidiri-2-yl} -hydrazinokarbonyl)-heptyl} -formamid,
N-hydroksy-N-((R)-2-{N'-[(4-metyl-piperazin-l-yl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-hydroksy-N-((2R)-2-(cykloheksylmetyl)-3-{N'-[4-(cyklopropylamino)-5-fluor-pyrimidin-2-yl]hydrazino}-3-oksopropyl)-formamid,
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-(cyklopropylamino)-5-fluor-pyrimidin-2-yl]hydrazino}-3-oksopropyl)-formamid,
N-hydroksy-N-[(2R)-3-{N'-[4-(azatidin-l-yl)-5-fluor-pyrimidin-2^
(cyklopentylmetyl)-3-oksopropyl]-formamid,
N-hydroksy-N-[(2R)-5-metyl-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heksyl] -formamid,
N-[(R)-2-(K'-benzo[l,2,4]tirazin-3-yl-hydrazinokarbonyl)-5-metyl-heksyl]-N-hydroksy-formamid,
N-hydroksy-N-[(2R)-5-metyl-2-({N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino} -karbonyl)-heksyl] -formamid,
N- {(R)-2-[N'-(7-klor-benzo[l ,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-(morfolin-4-yl)-6-(trifluormetyl)-pyrimidin-1 -yl]-hydrazino} -3-oksopropyl)-formamid,
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-[(2-hydroksyetyl)-(metyl)-amino]-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-3-oksopropyl)-formamid, N-hydroksy-N-[(2R)-6-metyl-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid, N-hydroksy-N-((2R)-2- {[N'-(l ,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl} -6-metylheptyl)-formamid,
N-hydroksy-N- {(R)-2 - [N' -(5 -metyl-benzo[ 1,2,4]triazin-3 -yl)-hydrazinokarbonyl] - heptyl} -formamid,
N-((R)-2-{N' -[(4-etyl-piperazin-1 -yl)-trifiuormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-[N'-(piperazin-l-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-{(R)-2-[N'-(7-fluor-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,.
N-hydroksy-N-[(2R)-2-( {N'-[4-(4-etyl-1 -piperazinyl)-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -karbonyl)-6-metylheptyl] -formamid,
N-hydroksy-N-[(2R)-6-metyl-2-({N'-[4-(piperazin-l-yl)-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid,
N-hydroksy-N-[(2R)-6-metyl-2-({N'-[4-(4-metyl-piperazin-l-yl)-6-(trifluormetyl)-pyrimidin-2 -yl] -hydrazino } -karbonyl)-heptyl] -formamid,
N-hydroksy-N-((2R)-2- {[N'-(7-klor-1,2,4-benzotriazin-3-yl)hydrazino]karbonyl} -6-metylheptyl)-formamid,
N-hydroksy-N-((2R)-6-metyl-2-{[N'-(5-metyl-l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl} -heptyl)-formamid, N-hydroksy-N-((2R)-2-{[N'-(7-fluor-l,2,4-benzotriazin-3-yl)-hydrazino]-kaA metylheptyl)-formamid, N-hydroksy-N-((R)-2-{N'-[(2-metoksy-etylamino)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-[(2R)-6-metyl-2-({N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino} -karbonyl)-hepty 1] -formamid, N-hydroksy-N-[(R)-2-(N'-{[4-(2-hydroksy-etyl)-piperazin-l-yl]-trilfuorme1y^ pyrimidin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-((R)-2- {N' -[(4-pyirmidin-2-yl-piperazin-1 -yl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-((R)-2-{N'-[(2-hydroksy-etylamino)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-hydroksy-N- {(R)-2-[N'-(7-trifluormetyl-benzo[l ,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N- {(R)-2 - [N' -(6-metyl-benzo[ 1,2,4]triazin-3 -yl)-hydrazinokarbonyl] - heptyl} -formamid,
N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(5-metyl-l,2,4-benzotriazin-3-yl)hydrazino]-3-oksopropyl}-formamid,
N-hydroksy-N-[(2R)-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-oktyl]-formamid,
N-hydroksy-N-((2R)-2-{[N'-(l,2,4-benzotriazin-3-yl)hydrazino]-karbonyl}-oktyl)-formamid,
N-hydroksy-N-[(2R)-2-({N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino}-karbonyl)-oktyl]-formamid,
N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -formamid,
N- {(R)-2-[N'-(6-klor-benzo[l ,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-[N'-(5-metoksy-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -formamid,
N-hydroksy-N-{(R)-2-fN'-(l-metyl-2-okso-l,2-dihydro-pyridin-4-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N-((R)-2-{N'-[(^'-pyridin-2-yl-hydrazino)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-((R)-2- {N' -[4-(4-etyl-piperazin-1 -yl)-6-metyl-pyrimidin-2-yl]-hydrazinokarbonyl} - heptyl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(4,6-dime1yl-pyrimidin-2-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid,
N-hydroksy-N- {(R)-2 - [N' -(4-trilfuormetyl-pyridin-2 -yl)-hydrazinokarbonyl] -hepty 1} - formamid,
N-hydroksy-N-[(R)-2-(N'-isokinolin-l-yl-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-[(R)-2-CN'-kinolin-2-yl-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-2-[N'-(l-benzyl-2-okso-l,2-dihydro-pyridm-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-okso-4H-pyrido[ 1,2-a] [ 1,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(4-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-{(R)-2-[N'-(l-butyl-2-okso-l,2-dihydro-pyridin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-^'-(9-metyl-4-okso-4H-pyrido[l,2-a][l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(6-okso-4-trifluormetyl-l,6-dihydro-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N- {(R)-2 - [N' -(metyl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbony 1] - heptyl} -formamid, N-hydroksy-N- {(R)-2 - [N' -(5 -trifluormetyl-pyridin-2 -yl)-hydrazinokarbonyl] -heptyl} - formamid, N-{(R)-2-[N'-(6-etoksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-[(R)-2-(N'-pyrido[2,3-e]-[l,2,4]triazin-3-yl-hydrazinokarbonyl)-heptyl]-formamid, N-((R)-2-{N'-[l-(l-etyl-propyl)-2-okso-l,2-dihydro-pyridin-4-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-((R)-2-{N'-[2-okso-l-(3-trifluormetyl-benzyl)-l,2-dihydro-pyridin-4-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydrolcsy-N-{(R)-2-p^'-(4-metyl-pyridin-2-yl)-hydraziriokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(6-metoksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(2-okso-l-kinolin-8-yl-metyl-l,2-dmydro-pyridin hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-[(R)-2-(N'-{2-okso-l-[2-(5,6,7,8-tetrahydro-[1.8]natfyridin-2^ dihydro-pyridin-4-yl}-hydrazinokarbonyl)-heptyl]-formarnid, N- {(R)-2- [N' -(4,6-bis-etylamino- [1,3,5 ] triazin-2-yl)-hydrazinokarbonyl] -heptyl} -N-hydroksy-formamid, N-{(R)-2-[N'-(bis-dimetylamino-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(4,6-di-morfolin-4-yl-[^ hydroksy-formamid, N-hydroksy-N-((R)-2-{N'-[4-(4-metyl-piperazin-1 -yl)-6-propylamino-[ 1,3,5]triazin-2-yl] -hydrazinokarbonyl} -heptyl)-formamid, N-{(R)-2-[N'-(dimetylammo-morfolm-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydroksy-N-{(R)-2-<r>N'-(6-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-((R)-2-{N'-[5-(5-fenyl-[l,3,4]oksadiazol-2-yl)-pyridin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-{(R)-2-[N'-(7-tert-butyl-l,4-diokso-l,2,3,4-tetrahydro-pyrido[3,4-d]pyridazin-5-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-((R)-2- {N'-[4-etylamino-6-(4-metyl-[ 1,4]diazepan-l -yl)-[ 1,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-((R)-2-{N'-[4-etylamino-6-(4-etyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid,
N-hydroksy-N- {(R)-2 - [N' -(6-trifluormetyl-pyridin-2 -yl)-hydrazinokarbonyl] -heptyl} - formamid,
N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-morfolin-4-yl-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(4,6-dimetyl-2-pyrimidinyl)-hydrazino]-3-oksopropyl}-formamid,
N-hydroksy-N- {(R)-2 - [N' -(4-metyl-6-pyrrolidin-1 -yl-metyl-pyrimidin-2 -yl)-hydrazinokarbonyl]-heptyl}-formamid,
N- {(R)-2- [N' -(4-dimetylaminometyl-6-metyl-pyrimidin-2 -yl)-hydrazinokarbonyl] - heptyl} -N-hydroksy-formamid, N-hydroksy-N-((R)-2-{N'-[4-metyl-6-(4-metyl-piperazin-1 -yl-metyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-{(R)-2-[N'-(5-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-((R)-2-{N'-[dimetylamino-(4-metyl-[l,4]diazepan-l-yl)-[l,3,5]triazin-2-^^ hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-p^'-(4-metyl-6-pyrrolidin-l-yl-[13,5]triazin-2-^^^ hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N-((R)-2- {N' -[4-metyl-6-pyrrolidin-1 -yl-pipeirdin-1 -yl)-[ 1,3,5]triazin-2-yl] -hydrazinokarbonyl} -heptyl)-formamid,
N-((R)-2-{N'-[(etyl-metyl-amino)-metyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid,
N-((R)-2-{N'-[(4-(4-etyl-piperazin-l-yl)-6-metyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hq)tyl)-N-hydroksy-formamid,
N-hydroksy-N-[(2R)-7,7,7-trilfuor-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -karbonyl)-hepty 1] -formamid,
N-hydroksy-N-((2R)-7,7,7-tirfluor-2-{[N'-(5-metyl-l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-heptyl)-formamid,
N-hydroksy-N-((2R)-7,7,7-trifluor-2-{[N'-(7-metyl-l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-heptyl)-formamid,
N-hydroksy-N-{(R)-2-[N'-(4-metylamino-6-morfolin-4-yl-[l,3,5]-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-((R)-2-{N'-[4-(4-etyl-piperazin-l-yl)-6-metylamino-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hq)tyl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(4-etylammo-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-[N'-(4,6,7-trimetyl-7,8-dihydro-pterin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid,
N-hydroksy-N-{(R)-2-[N'-(4,6,7-trimetyl-pteridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N-{(R)-2-[N'-(metoksymetoksymetyl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N-((R)-2-{N'-[4-metyl-6-(l-piperidin-2-yl-metanoyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-6-metyl-pyrimidin-4-karboksylsyre cyklopropylamid,
2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazmo)-6-pyrimidin-4-karboksylsyre diisopropylamid,
N-{(R)-2-[N'-(5-cyano-pyridin-2-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid,
N-{(R)-2-[N'-(4,6-dietyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-{(R)-4-cyklopentyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-butyl} -N-hydroksy-formamid,
N-{(R)-4-cyklopentyl-2-[N'-(7-metyl-benzo[l,2,4]tirazin-3-yl)-hydrazinokarbonyl]-butyl} -N-hydroksy-formamid,
N-{(R)-4-cyklopentyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-butyl} -N-hydroksy-formamid,
N-hydroksy-N-((R)-2-{N'-[6-(4-metyl-piperazin-1 -yl-metyl)-pyridin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-((R)-2-{N'-[5-(4,6-dimetoksy-pyrimidin-2-yl)-pyridin-2-yl]-hydrazinonkarbonyl}-heptyl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(dietylamino-metyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-[(R)-2-(>['-{[(2-metoksy-etyl)-metyl-amino]-metyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid,
N-((R)-1 - {N' -[4-(2,6-dimetyl-morfolin-4-yl)-6-metyl-[ 1,3,5]triazin-2-yl]-hydrazinokarbonyl}-hq)tyl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(5-fluor-4-metyl-6-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-{(R)-2-[N'-(4-etyl-6-morfolm-4-y^ N-hydroksy-formamid,
N-{(R)-2-[N'-(etyl-me1yl-amino)-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid,
N-((R)-2-{N'-[4-etyl-6-(4-etyl-piperazin-1 -yl)-[ 1,3,5 ]triazin-2-yl]-hydrazinokarbonyl} - heptyl)-N-hydroksy-formamid,
N-((R)-2- {N'-[5-fluor-4-metyl-6-(4-metyl-piperazin-1 -yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-hq)tyl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-((R)-2- {N'-[5-fluor-4-metyl-6-(4-metyl-[l ,4]diazepan-l -yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-hq)tyl)-N-hydroksy-formamid, N-{(R)-4-cyklopentyl-2-[N'-(morfolin-4-yl-trifluormetyl-pyrirnidin-2-yl)-hydrazinokarbonyl]-butyl}-N-hydroksy-formamid,
N-[(R)-2-(N'-{etyl-[(2-metoksy-etyl)-metyl-arnino]-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid,
N-{(R)-2-[N'-(dimetylammo-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-{(R)-2-[N'-(4-cyklopropylarnino-6-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-{(R)-2-cykloheksyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid,
N-{(R)-2-cykloheksyl-2-<r>N'-(7-metoksy-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid,
N-{(R)-2-cykloheksyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid,
N-{(R)-4,4-dimetyl-2-[N'-(4-trifluorme1yl-pyrimidin-2-yl)-hydrazinokarbonyl]-pentyl}-N-hydroksy-formamid,
N-{(R)-4,4-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-pentyl} -N-hydroksy-formamid,
N-{(R)-4,4-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-pentyl} -N-hydroksy-formamid,
N-{(R)-4,4-dimetyl-2-p^'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-pentyl}-N-hydroksy-formamid,
N-((R)-2-{N'-[etyl-(me1yl-pyridin-2-yl-amino)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(4-cyklopropylamino-6-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-hydroksy-N-[(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-3-(l-metyl-cyklopentyl)-propyl]-formamid,
N-hydroksy-N-[(R)-2-[N'-(7-metoksy-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-3-(1 -metyl-cyklopentyl) -propyl]-formamid,
N-hydroksy-N- {(R)-3 -(1 -metyl-cyklopentyl)-2-[N' -(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-propyl}-formamid,
N-hydroksy-N-{(R)-2-[N'-(4-isopropyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(4-metyl-2-pyrimidinyl)-hydrazino]-3-oksopropyl} -formamid, N-hydroksy-N-[(2R)-6,6,6-trilfuor-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]^ hydrazino} -karbonyl)-heksyl] -formamid, N-{(R)-2-[N'-(5.7-dimetyl-benzo[l,2,4]tirazin-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(3.6-dimetyl-pyrazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-((R)-2-{N'-[4-(4-etyl-piperazin-l-yl)-6-isopropyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hep<y>tl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(4-dimetylamino-6-isopropyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-hydroksy-N- {(R)-2 - [N' -(metyl-trifluormetyl-pyridin-2 -yl)-hydrazinokarbonyl] - heptyl} -formamid,
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl} -hydrazino)-6.N.N-trimetyl-isonikotinamid,
N-hydroksy-N-[(2R)-2-({N'-[3-amino-6-(trifluorme1yl)-pyridin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid,
N-hydroksy-N-[(R)-2-(N'-{4-isopropyl-6-[(2-metoksy-etyl)-metyl-amino]-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid,
N-{(R)-3-cyklopentyl-2-[N'-(4-etyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-[N'-(4-morfolin-4-yl-6-propyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-((R)-2- {N' -[4-(4-etyl-piperazin-1 -yl)-6-propyl- [ 1,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid,
N-{(R)-5.5-dimetyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid,
N-{(R)-5.5-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid,
N-{(R)-5.5-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid,
N-{(R)-5.5-dimetyl-2-rN'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid,
N-{(R)-4-etyl-2-|^'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazino-karbonyl]-heksyl}-N-hydroksy-formamid,
N-{(R)-4-etyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid, N-{(R)-4-etyl-2-|^'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydra^ heksyl} -N-hydroksy-formamid,
N-((R)-3-cyklopentyl-2- {N-[4-etyl-6-(4-etyl-piperazin-1 -yl)-[ 1,3,5]triazin-2-yl]-hydrazinokarbonyl}-propyl)-N-hydroksy-formamid,
N-{(R)-3-cyklopentyl-2-[N'-(4-cyklopropylamino-6-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid,
N-{(R)-4-etyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-(N'-{[(2-metoksy-etyl)-metyl-amino]-propyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid,
N-{(R)-2-[N'-(dimetylamino-propyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid,
N-{(R)-2-[N'-(4-etyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-[N'-(4-isopropyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-{(R)-2-[N'-(4-cyklopropyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-hydroksy-N-[(2R)-2-({N'-[4-(pyridin-2-yl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl] -formamid,
N-((R)-2- {N' -[4-cyklopropyl-6-(4-etyl-piperazin-1 -yl)-[ 1,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(cyklopropyl-dime1ylamino-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-((R)-2-{N'-[cyklopropyl-(etyl-metyl-amino)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(4-cyklopropyl-6-pyrrolidin-l-yl[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-{(R)-2-[N'-(4,6-dicyklopropyl-[l,3,5]tirazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-[(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-3-(2-metyl-cyklopentyl)-propyl]-formamid,
N-[(R)-2-[N'-(dimetylamino-etyl-[l,3,5]tirazin-2-yl)-hydrazinokarbonyl]-3-(2-metyl-cyklopentyl)-propyl]-N-hydroksy-formamid,
N-hydroksy-N-[(R)-2-[N'-(4-trilfuorme1yl-pyrimidin-2-yl)-hydrazinokarbonyl]-3-(2-metyl-cyklopentyl)-propyl]-formamid, N-{(R)-2-[N'-(5-etyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N- {(2R)-2-(cyklopentylmetyl)-3-[N'-(7-metyl-1,2,4-benzotriazin-3-yl)-hydrazino]-3-oksopropyl}-formamid,
N-hydroksy-N-[(2R)-2-(cyMopentylmetyl)-3-(^'-{4-etyl-6-[etyl(metyl)amm^ triazin-2-yl}-hydrazino)-3-oksopropyl]-formamid,
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-(dimetylamino)-6-etyl-l,3,5-triazin-2-yl]-hydrazino}-3-oksopropyl)-formamid,
N-((R)-2-{N'-[4-etyl-6-(4-isopropyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid,
N-hydroksy-N-[(2R)-3-[N' -(6-klor-1,2,4-benzotriazin-3-yl)-hydrazino]-2-(cyklopentylmetyl)-3-oksopropyl]-formamid,
N-{(R)-4,4-dimetyl-2-p^'-(4-trifluormetyl-pyrimidm-2-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid,
N-{(R)-4,4-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid.
N-{(R)-4,4-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid,
N-{(R)-4,4-dimetyl-2-<r>N'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-p^'-(5-fenyl-[l,2,4]triazin-3-yl)-hydrazmokarbonyl]-hepty^ formamid,
N-{(R)-2-[N'-(4-e1yl-6-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-((R)-2-{N'-[4-etyl-6-(4-metyl-piperazin-1 -yl)-pyrimidin-2-yl]-hydrazinokarbonyl} - heptyl)-N-hydroksy-formamid,
N-{(R)-2-[N'-(5-etyl-4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-((R)-2-{N'-[4-etyl-6-(4-propyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid,
N-hydroksy-N-((R)-2-{N'-[6-(4-pyrimidin-2-yl-piperazin-l-yl-metyl)-pyridin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-hydroksy-N-((R)-2-{N'-[6-(3-[l,2,4]triazol-l-yl-metyl-[l,2,4]triazol-l-yl)-pyridin-2-yl] -hydrazinokarbonyl} -heptyl)-formamid,
N-{(R)-3-bicyklo[2,2,l]hept-7-yl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid, N-{(R)-3-bicyklo[2,2,l]hept-7-yl-2-[N'-(morfolin-4-yl-trifluormetyl-^ hydrazinokarbonyl]-propyl}-N-hydroksy-formamid, N-hydroksy-N-[(R)-2-(N'-pyirdin-3-yl-hydrazinokarbonyl)-heptyl]-formamid, 4-{4-etyl-6-[2-((2R)-2-{[formyl(hydroksy)amino]-mety^ triazin-2-yl} -1 -metyl-1 -propylpiperazin-1 -iumj odid, N-{(R)-3-bicyklo[2,2,l]hept-7-yl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid, N- {(R)-2-[N'-(4-azetidin-1 -yl-6-etyl-[ 1,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} - N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(morfolin-4-yl-4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid. N-hydroksy-N-{(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl} -formamid, N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl} -formamid, N-hydroksy-N-{(R)-2-(4-me1yl-cykloheksyl)-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-formamid, N-hydroksy-N- {(R)-2 -(4-metyl-cykloheksyl)-2- [N' -(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-formamid, N-hydroksy-N-{(R)-2-(4-metyl-cykloheksyl)-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-formamid, N-{(R)-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl]-N-hydroksy-formamid, N-{(R)-2-[N'-(6.7-dihydro-5H-cyklopentapyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-((R)-2-[N^[4-etyl-6-((S)-2-hydroksymetyl-pyrrolidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl]-heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(dimetylamino-pyridin-3-yl-pyirmidin-2-yl)-hydrazinokaA N-hydroksy-formamid, N-{(R)-2-[N'-(dimetylamino-pyirdin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-N'-(5,6,7,8-tetrahydro-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-{(R)-2-[N'-(5.6-dihydro-[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-[5-(4-hydroksy-fenyl)-[l,2,4]triazin-3-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-[(R)-2-(^'-{[(2-dimetylamino-etyl)-metyl-amino]-etyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(2-dimetylamino-kinazolin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(3-metansulfonyl-4,6-dimetyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-((R)-2-{N'-[4-etyl-6-(3-hydroksy-piperidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid, N- [(R) -2-(N' - [4.5' ]bipyrimidiny 1-2-y l-hydrazinokarbonyl)-heptyl] -N-hydroksy-formamid, N-((R)-2-{N'-[(cyklopropyl-metyl-amino)-etyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid,
N-((R)-2- {N'-[4-etyl-6-((R)-3-hydroksy-pyrrolidin- l-yl)-[l ,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid,
N-hydroksy-N-[(R)-2-(^'-[33']bipyridmyl-5-yl-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-[(R)-2-CN'-(5-morfolin-4-yl-pyridin-3-yl)-hydrazinokarbonyl)-heptyl]-formamid,
N-hydroksy-N-{(R)-2-[N'-(4-pyridin-3-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-hq)tyl}-formamid,
N-hydroksy-N-{(R)-2-[N'-(5,6,7,8-tetrahydro-kinazolin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid,
N-[(R)-2-(K'-{[cyklopropyl-l-(l-metyl-pipeirdin-4-yl)-amino]-etyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid,
N-((R)-2-{N'-[4-((R)-3-dimetylamino-pyrrolidin-l-yl)-6-etyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid,
N-hydroksy-N-[(R)-2-(N'-[5-(lH-pyrrol-2-yl)-pyridin-3-yl]-hydrazinokarbonyl)-heptyl] -formamid, N-hydroksy-N-[(R)-2-(N'-[(4-metyL hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-[(R)-2-(N'-(5-fAaran-3-yl-pyridin-3-yl)-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-5.5-dimetyl-2-p^'-(4-trifluormetyl-pyrimidm-2-yl)-hydrazinokarbon N-hydroksy-formamid, N-{(R)-5.5-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-{(R)-5.5-dimetyl-2-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-cykloheptyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cykloheptyl-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cykloheptyl-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cykloheptyl-2-[N'-(7-metyl-benzo[l,2,4]tirazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid, N-((R)-2- {N' - [4-etyl-6-(4-hydroksy-piperidin-1 -yl)-[ 1,3,5 ]triazin-2-yl]-hydrazinokarbonyl}-hq)tyl)-N-hydroksy-formamid, N-{(R)-5.5-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-{(R)-2-[N'-(4-dimetylamino-kinazolin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-pyridin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-hq)tyl}-formamid,
N-hydroksy-N-((R)-2-{N'-[4-(3-hydroksymetyl-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-hydroksy-N-((R)-2-{N'-[4-(4-hydroksymetyl-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-((R)-2- {N'-[4-etyl-6-(3-metoksy-piperidin-l -yl)-[l ,3,5]triazin-2-yl-hydrazinokarbonyl}-hq)tyl)-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl} -formamid,
N-[(R)-2-{N'-[etyl-(etyl-metylamino)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-2-(4-metyl-cykloheksyl)-etyl}-N-hydroksy-formamid, N-[(R)-2-{N'-[etyl-(etyl-metylamino)-[l^^ metyl-cykloheksyl)-etyl} -N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl} -formamid, N-((R)-2-{N'-[4-(2.6-dimetoksy-fenyl)-pyirmidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-((R)-2-{N'-[4-etyl-6-((R)-3-metoksy-pyrrolidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid, N-((R)-2-{N'-[4-etyl-6-(4-metoksy-piperidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid, N-hydroksy-N-[(R)-2-(N'-(6-pyrrolidin-l-yl-pyrimidin-4-yl)-hydrazinokarbonyl)-heptyl] -formamid, N-hydroksy-N-[(R)-2-(T^'-[6-(4-metyl-piperazin-l-yl)-pyrimidin-4-yl])-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-2-[N'-(6-dimetylamino-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(pyridin-4-yl-trilfuormetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(pyridin-3-yl-trifluormetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(2-etylammo-6-trifluormetyl-pyrimidm-4-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydroksy-N-((R)-2-{N'-[5-(4-metoksy-fenyl)-[l,2,4]triazin-3-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-hydroksy-N-((R)-2- {N' -[4-(2,3,4-trimetoksy-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid,
N-{(R)-4,4-dimetyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-{(R)-4,4-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-{(R)-4,4-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid,
N-{(R)-4,4-dimetyl-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-[N'-(6-morfolin-4-yl-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-hydroksy-N-[(R)-2-(^'-{5-[4-(2-hydroksy-etoksy)-fenyl]-[l,2,4]triazm-^ hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-2-[N'-(4-ftiran-2-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-hep1yl}-N-h formamid, N-((R)-2-{N'-[4-(3.5-dimetyl-isoksazol-4-yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-metyl-oksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-6-metyl-nikotinsyre,
N-hydroksy-N-{(R)-2-[N'-(3-metoksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-hydroksy-N- {(2R)-2-[(N'- {4-[4-(metylsulfonyl)fenyl]-pyrimidin-2-yl} -hydrazino)-karbonyl]-heptyl} -formamid,
N-hydroksy-N-[(2R)-2-({N'-[4-(furan-3-yl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl] -formamid,
N-[(2R)-2-({N'-[4-(2-aminofenyl)-pyrimidiri-2-yl]-hydrazino}-karbonyl)-heptyl]-N-hydroksy-formamid,
N-hydroksy-N-[(2R)-2-({N'-[5-(5-metyl-l,3,4-oksadiazol-2-yl)-4-(trifluormetyl)-pyrimidin-2 -yl] -hydrazino } -karbonyl)-heptyl] -formamid,
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[5-(5-metyl-l,3,4-oksadiazol-2-yl)-4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-3-oksopropyl)-formamid, N-[(2R)-2-({N'-[6-(dimetylamino)-2-metyl-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl] -N-hydroksy-formamid, N-[(2R)-2-({N'-[2-cyklopropyl-6-(dimetylamino)-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl]-N-hydroksy-formamid, N-hydroksy-N-[(2R)-4-(2-tienyl)-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-butyl]-formamid, N-hydroksy-N-[(2R)-2-{[N'-(4-metyl-pyrimidin-2-yl)-hydrazino]karbonyl}-4-(2-tienyl)-butyl]-formamid, N-[(2R)-2-[(^'-{4-etyl-6-[etyl(metyl)amino]-l,3,5-triazin-2-yl}-hydrazino)-karbonyl]-4-(2-tienyl)butyl]-N-hydroksy-formamid, N-hydroksy-N-((2R)-3-okso-2-(2-tienylmetyl)-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -propyl)-formamid, N-hydroksy-N-[(2R)-3-[N'-(4-metyl-pyrimidin-2-yl)hydrazino]-3-okso-2-(2-tienylmetyl)-propyl]-formamid, N-[(2R)-3-(N'-{4-etyl-6-[etyl(metyl)amino]-1,3,5-triazin-2-yl} -hydrazino)-3-okso-2-(2-tienylmetyl)-propyl]-N-hydroksy-formamid, N-hydroksy-N-[(2R)-2-({N'-[2-me1yl-6-(pyridin-2-yl)-pyrimidin-4-yl]-hyd^ karbonyl)-heptyl]-formamid, N-hydroksy-N- [(2R)-2-({N' - [6-(pyridin-2-yl-metyl)-pyridazin-3 -yl] -hydrazino} - karbonyl)-heptyl]-formamid, N-hydroksy-N-[(2R)-2-({N'-[2-me1yl-6-(rnorfolin-4-yl)-pyrirnidin-4-yl]-hydrazino}-karbonyl)-heptyl]-formamid, N-hydrolcsy-N-[(2R)-2-({N'-[6-(morfolin-4-yl)-2-(trifluormetyl)-pyrimidin-4-yl]-hydrazino} -karbonyl)-hepty 1] -formamid, N-hydroksy-N-{(2R)-2-[(>['-{4-[metyl-(pyridin-2-yl)-amino]-pyrimidin-2-yl}-hydrazino)-karbonyl]-heptyl}-formamid, N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-cyklopropyl-6-(dimetylamino)-1,3,5-triazin-2-yl]-hydrazino} -3-3-oksopropyl)-formamid, N-benzo[l,3]dioksol-5-yl-metyl-hydrazinkarboksylsyre tert-butylester, N- [(R) -2-(N' -benzo [1,3 ]dioksol-5 -yl-metyl-hydrazinokarbony l)-heptyl] -N-hydroksy-formamid,
N-{(R)-2-[N'-(2,3-dihydro-[l,4]dioksino[2,3-b]pyridin-7-yl-metyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-{(R)-2-[N'-(4-dimetylamino-benzyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-((R)-2-{N'-[2-(5,6,7,8-tetrahydro-[1.8]naftyridin-2-yl)-etyl]-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-[(R)-2-(N'-kinolin-2-yl-metyl-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N- {(R)-2 - [N' -(1,2,3,4-tetrahydro-kinolin-2-y l-metyl)-hydrazinokarbonyl] - heptyl} -formamid, N-hydroksy-N-[(R)-2-(N'-kinolin-6-yl-metyl-hydrazinokarbonyl)-heptyl]-formamid, N- [(R) -2-(N' -benzofuran-2 -yl-metyl-hydrazinokarbonyl)-heptyl] -N-hydroksy-formamid, N-[(R)-2-(N'-cyklopropylmetyl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid, N-{(R)-2-[N'-(6-fluor-4H-benzo[l,3]dioksin-8-yl-metyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-metoksy-benzyl)-hydrazinokarbonyl]-heptyl}-formamid. N-hydroksy-N-{(R)-2-[N'-(2-metoksy-benzyl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(tetrahydro-furan-3-yl-metyl)-hydrazinokarbonyl]-heptyl}-formamid,
N-[(R)-2-(K'-furan-3-yl-metyl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid,
N-{(R)-2-[N'-(2,3-dmydro-benzo[l ,^ N-hydroksy-formamid,
N-{(R)-2-[N'-(2,3-dihydro-benzo[l,4]dioksin-2-yl-metyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-[N'-(2-fenoksy-etyl)-hydrazinokarbonyl]-heptyl}-formamid, N-{(R)-2-[N'-((S)-2,3-dihydroksy-propyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(5-metyl-isoksazol-3-yl-metyl)-hydrazinokarbonyl]-heptyl}-formamid,
N-((R)-2-{N'-[ 1-(1-benzo[ 1,3]dioksol-5-yl-metanoyl)-piperidin-4-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid,
N-((R)-2-{N'-[l-(l-benzofuran-2-yl-metanoyl)-piperidin-4-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid,
N-hydroksy-N-{(R)-2-(N'-{l-[l-(7-metoksy-benzofuran-2-yl)-metanoyl}-piperidin-4-yl} -hydrazinokarbonyl)-heptyl] -formamid,.
N-{(R)-2-[N'-(l-benzyl-piperidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-[(R)-2-(N'- {1 -[1 -(3,4-diklor-fenyl)-metanoyl]-piperidin-4-yl} -hydrazinokarbonyl)-heptyl] -N-hydroksy-formamid,
N-[(R)-2-(N'- {1 -[1 -(2,3-diklor-fenyl)-metanoyl]-piperidin-4-yl} -hydrazinokarbonyl)-heptyl] -N-hydroksy-formamid,
N-hydroksy-N-[(R)-2-(N'- {1 -[ 1 -(4-metyl-piperazin-1 -yl)-metanoyl]-pentyl} - hydrazinokarbonyl)-heptyl]-formamid,
N- [(R) -2-(N' -benzyl-hydrazinokarbonyl)-hepty 1] -N-hydroksy-formamid.
Forbindelsene ifølge oppfinnelsen og fremstillingen derav vil være lettere å forstå i forbindelse med følgende synteseskjemaer, som illustratrerer fremgangsmåtene hvorved forbindelsene ifølge oppfinnelsen kan fremstilles.
Foreliggende oppfinnelse tilveiebringer forbindelser med formel (1) som kan fremstilles fra det vanlige racemiske intermediatet (8), eller vanlige kirale intermediater (17) og (25). (1) Y = O, CH2eller en binding
Slik det er vist i skjema 1, kan intermediatet (8) fremstilles ved å omsette det monosubs-tituerte dialkylmalonatet (2) med en base, slik som kaliumhydroksid, i et passende lø-semiddel, slik som etanol/vann, for å gi monosyren (3). Kobling av (3) med O-benzylhydroksylamin eller 0-(tetrahydro-2H-pyran-2-yl)hydroksylamin i nærvær av et koblingsreagens, slik som l-[3-(dimetylamino)propyl]-3-etylkarbodiimid hydroklorid (ECCI), og en base, slik som 4-dimetylaminopyridin (DMAP), i et passende løsemiddel, slik som diklormetan, gir amidet (4), hvor P er benzyl eller tetrahydro-2H-pyran-2-yl. Reduksjon av esterfunksjonalitetet til forbindelse (4) med et reduksjonsmiddel, slik som litiumborhydrid, i et passende løsemiddel, slik som tetrahydrofuran, ved romtemperatur, gir alkoholen (5). Behandling av alkoholen (5) under Mitsunobu-betingelser gir laktamet (6). Samme omdannelse kan oppnås ved behandling av (5) med trifenylfosfin, kar-bontetraklorid og en base, slik som trietylamin, for å oppnå (6). Hydrolyse av laktamet (6) f.eks. ved anvendelse av litiumhydroksid i en passende løsemiddelblanding, slik som THF-H20-MeOH, gir syre (7). Formylering av amingruppen (7) oppnås ved anvendelse av maursyre og eddiksyreanhydrid i et løsemiddel slik som diklormetan, for å gi den formylerte forbindelsen (8).
Et hvilket som helst racemat kan løses opp på stadiet for et hvilket som helst intermediat i løpet av syntesen eller ved sluttproduktet f.eks. ved anvendelse av en kiral kromatogra-fisk fremgangsmåte, for å tilveiebringe forbindelse (8) i en av de to enantiomere forme-ne.
Alternativt kan en enantiomer av intermediat (8), slik som (18) i skjema 2 eller (27) i skjema 3, fremstilles ved å omsette et passende syreklorid (9) med et kiralt middel, slik som Evans' kirale oksazolidinon, under nærvær av en base slik som n-butyllitium, for å gi det kirale intermediatet (10) i skjema 2 eller (19) i skjema 3. Behandling av forbin- deise (10) eller (19) med en base, slik som diisopropyletylamin, under nærvær av et chelateringsmiddel, slik som titantetraklorid, i et løsemiddel, slik som tetrahydrofuran, fulgt av tilsetning av en elektrofil bestanddel, slik som benzyloksymetylklorid, gir en av de to kirale forbindelsene (11) eller (20), avhengig av valg av kirale hjelpestoffer. Omdannelse av forbindelse (11) eller (20) til den tilsvarende hydroksysyren (14) eller (23) kan oppnås ved en sekvens som innbefatter oksidativ spalting av det kirale oksazolidinon, f.eks. ved anvendelse av H2O2og litiumhydroksid, til de respektive intermediatene (12) eller (21), fulgt av hydrogenolyse, for å gi henholdsvis intermediatene (13) eller (21). Forbindelsene (10) eller (19) kan også omdannes til intermediatene henholdsvis (14) eller (23), i en to-trinnsfremgangsmåte. For denne omdanningen kan (10) eller (19) behandles med en base, slik som diisopropyletylamin, under nærvær av chelateringsmiddel, slik som titantetraklorid, i et løsemiddel, slik som tetrahydrofuran, fulgt av tilsetning av trioksan eller en hvilken som helst annen formaldehydekvivalent for å gi forbindelsene (13) eller (22), som deretter underkastes oksidativ spalting av det kirale oksazolidinonet, f.eks. ved anvendelse av H2O2og litiumhydroksid, til de respektive syrene (14) eller (23).
Kobling av syren (14) eller (23) med benzyloksyamin eller 0-(tetrahydro-2H-pyran-2-yl)hydroksylamin under nærvær av koblingsmidler, slik som EDCI-DMAP, gir amidene henholdsvis (15) eller (24). Disse kan ringsluttes til azetidin-2-oner (16) eller (25) ved anvendelse av Mitsunobu-betingelser eller en kombinasjon av trifenylfosfinkarbon te-traklorid trietylamin. Hydrolyse av azetidin-2-onet (16) eller (25), ved anvendelse f.eks. av litiumhydroksid, i et passende løsemiddel gir den tilsvarende syren, henholdsvis (17) eller (26). Omdannelse av forbindelse (17) eller (26) til karboksylsyren (18) eller (27) kan oppnås ved anvendelse av et passende formyleringsmiddel, slik som maursy-re/eddiksyreanhydrid eller metylformat, i rene reagenser eller i et passende løsemiddel, slik som diklormetan.
Som vist i skjema 4, kan forbindelse (8) kobles til CBZNHNH2, ved anvendelse av betingelser slike som DMAP-EDCI eller EDCI-HOAt-NMM, og debenzyleres for å gi forbindelse (28). Reaksjon mellom (28) og halidet eller triflurometyl R1X gir (1) hvor R2 er H. Tilsvarende kan forbindelsene (18) og (27) underkastes samme fremgangsmåte for å gi, respektivt, (31), hvor R2 er H og (32) hvor R2 er H.
Alternativt, som vist i skjema 5, kan forbindelse (28) underkastes en reduktiv alkylering med ketonet R1C(0)R2 ved anvendelse som reduksjonsmiddel av, f.eks. natriumcyanoborhydrid, for å gi forbindelse (1). Hvis aldehydet R1C(0)H anvendes i den redukti-ve alkyleringen isteden, blir forbindelse (1) hvor R2 er H dannet. Tilsvarende kan forbindelse (29) underkastes reduktiv alkylering med ketonet R1C(0)R2 for å gi forbindelse (31), eller med aldehydet R1C(0)H for å gi forbindelse (31) hvor R2 er H. Tilsvarende kan forbindelse (30) underkastes reduktiv alkylering med ketonet R1C(0)R2 for å gi forbindelse (32) eller med aldehydet R2C(0)H for å gi forbindelse (32) hvor R2 er H.
Alternativt, som vist i skjema 6, kan det monobeskyttede hydrazinet GINHNH2(33), hvor Gl er benzyloksykarbonyl eller tert-butoksykarbonyl, omsettes med ftalsyreanhydrid for å gi intermediatet (34). (34) kan kobles til alkoholen RIOH under Mitsunobu-betingelser for å gi (35), som etter hydrazinolyse gir hydrazinet (36). Kobling av (36) til syre (8) ved anvendelse av betingelser slike som DMAP/EDCI eller EDCI/HOAt/NMM gir (37). (37) kan fullt avbeskyttes i ett trinn ved anvendelse av hydrogenolyse når Gl er benzyloksykarbonyl og P er benzyl, i ett trinn ved anvendelse av sure betingelser når Gl er tert-butoksykarbonyl og P er 0-(tetrahydro-2H-pyran-2-yl), eller i to trinn (ved syre-behandling og hydrogenolyse) når Gl er benzyloksykarbonyl og P er 0-(tetrahydro-2H-pyran-2-yl), eller Gl er tert-butoksykarbonyl og P er benzyl. I alle tre tilfeller, blir forbindelse (1) hvor R2 er H dannet. Tilsvarende kan forbindelser (18) og (27) underkastes samme fremgangsmåte for å gi, henholdsvis, (31) hvor R2 er H eller (32) hvor R2 er H.
Som vist i skjema 7, gir kobling av syren (8) med hydrazinet R1R2NNH2(40), ved anvendelse av betingelser slike som DMAP-EDCI eller EDCI-HOAt-NMM, hydrazidet (41). Endelig avbeskyttelse (hydrogenolyse ved anvendelse av en katalysator, slik som 10% Pd/C, i et passende løsemiddel, slik som etanol, i tilfellet at P er Bn; behandling med 80% eddiksyre-vann ved romtemperatur eller 40°C i tilfelle at P er THP) gir ønsket forbindelse (1). Tilsvarende, gir kobling av den kirale syren (18) eller (27) med hydrazinet (40) det tilsvarende hydrazidet (42) eller (43). Endelig avbeskyttelse gir den ende-lige ønskede forbindelsen (31) eller (32).
Hydrazinene med generell struktur RIR2NNH2(40) kan leveres fra tilgjengelige kommersielle kilder eller fremstilles i henhold til litteraturfremgangsmåter kjente for fagmannen. Følgende eksempler på spesifikke strukturer av hydrazin (40) og syntetiske fremgangsmåter anvendt for å generere dem er ment som illustrasjon.
Hydraziner (40) hvor R2 er alkyl eller hydrogen, og RI har generell struktur (44) kan fremstilles fra passende forløpere vist i skjema 8, 9 og 10.
Som vist i skjema 8, kan hydrazin (40) hvor RI er (44) fremstilles fra forløper (45) ved behandling med et passende hydrazin, slik som hydrazinmonohydrat, i et passende lø-semiddel, slik som metanol. Alternativt, som vist i skjema 9, kan hydrazin (40) hvor RI er (44) fremstilles fra forløper (46) ved oksidering til sulfonet via behandling med et passende oksidasjonsmiddel, slik som meta-klorperbenzosyre (m-CPBA) i et passende løsemiddel, slik som metylenklorid. Ytterligere behandling med et passende hydrazin, slik som hydrazinmonohydrat, i et passende løsemiddel slik som metanol, gir deretter ønsket produkt (40) hvor RI er (44). Alternativt, som vist i skjema 10, kan hydrazin (40) hvor RI =(44) fremstilles fra (47) ved behandling med natriumnitrat i et passende løsemiddel, slik som vandig svovelsyre, for å gi (48). Forbindelse (48) kan deretter behandles med et passende halogeneringsreagens slik som fosforoksyklorid til refluks fulgt av behandling med et passende hydrazin, slik som hydrazinmonohydrat, i et pas sende løsemiddel, slik som metanol, for å gi intermediat (40) hvor RI er (44). Forbindelser (45), (46), (47) og (48) er tilgjengelig fra kommersielle kilder eller kan fremstilles via litteraturfremgangsmåter kjente for fagmannen (Pyridines. Brown, D.J. i "The Chemistry of Heterocyclic Compounds", bind 52, Taylor, E.C., red., Wiley: New York, 1994).
X = halogen; LI, L2, L3 = binding, N-G5, O, S; G2, G3, G4, G5 = H, alkyl, acyl, heterocyklisk, aryl, heteroaryl
L4, L5, L6 = binding, N-G10, O;
G6, G7, G8, G10 = H, alkyl, acyl, heterocyklisk, aryl, heteroaryl; G9 = alkyl, aryl.
L7, L8, L9 = binding, O, S;
Gil, G12, G13 = H, alkyl, acyl, heterocyklisk, aryl, heteroaryl.
Hydraziner (40) hvor R2 er hydrogen og RI har den generelle strukturen (49) kan fremstilles fra passende forløpere vist i skjema 11 og 12.
(49) G14, G15 = H, alkyl, aryl, heteroaryl, heterocyklisk
Som vist i skjema 11, kan 4,6-diklorpyrimidin (50) omsettes med tert-butylkarbazat under nærvær av base, slik som diisopropyletylamin, ved 100°C i passende løsemiddel slik som etanol for å gi forbindelse (51). Aminet G14G15NH kan omsettes med (51) for å gi forbindelse (52) som kan avbeskyttes under sure betingelser, slik som trifluoreddiksyre i diklormetan, for å gi forbindelse (40), hvor R2 er hydrogen og RI er (49).
Alternativt, som vist i skjema 12, kan 4,6-diklorpyrimidin (50) omsettes med en ekvivalent av amin G14G15NH under nærvær av base, slik som trietylamin eller diisopropyletylamin, for å gi forbindelse (53), som kan behandles med overskudd hydrazin for å gi forbindelse (40), hvor R2 er hydrogen og RI er (49).
Skjema 12
Hydraziner (40) hvor R2 er hydrogen og RI har generell struktur (54) kan fremstilles fra en passende forløper slik som (55), ved behandling med vannfritt hydrazin i et passende løsemiddel slik som etanol, som vist i skjema 13.
Hydraziner (40) hvor R2 er hydrogen og RI har generell struktur (56) kan fremstilles fra en passende forløper vist i skjema 14.
Som vist i skjema 14, kan 4-klor-2-metylsulfanyl-6-trifluormetyl-pyrimidin (57) behandles med tert-butylkarbazat ved 100°C i et passende løsemiddel slik som etanol, for å gi intermediatet (58). Behandling av (58) med et oksidasjonsmiddel, slik som meta-klorperbenzosyre, gir (59), som etter behandling med amin G19G20NH i et passende løsemiddel, slik som metanol eller etanol, gir (60). Avbeskyttelse under sure betingelser, slik som trifluoreddiksyre i diklormetan, gir (40), hvor R2 er hydrogen og RI er (56).
Hydraziner (40) hvor R2 er hydrogen og RI har generell struktur (61) kan fremstilles ved å følge fremgangsmåten angitt i skjema 15 (Pauldler, W. et al., J. Het. Chem. 767-771, 1970;Lieber, E. et al., J. Org. Chem. 17, 518-522, 1952; Chem. Abstr. 87, 68431, 1977; Taylor, E.C., J. Org. Chem. 52, 4287-4292, 1987).
Som vist i skjema 15, kan forbindelse (62) omsettes med (63) under nærvær av en mild base, slik som vandig natriumbikarbonat, for å gi (64). Behandling av (64) med hydrazin under mikrobølgebetingelser gir (40) hvor R2 er H og RI er (61). Alternativt kan (62) omsettes med (65) for å gi (40), hvor R2 er H og RI er (61). Alternativt kan (62) kondenseres med (66) for å gi (67), som etter behandling med fosforoksyklorid danner (68). Behandling av (68) med hydrazin gir (40) hvor R2 er H og RI er (61). Alternativt kan oksosyren (69) kondenseres med (63) for å danne (70), som kan omdannes til (71) ved reaksjon med oksalylklorid eller fosforoksyklorid. Kobling av (71) med borsyre G22B(OH)2under standard Suzuki-betingelser gir (72), som kan omsettes med hydrazin for å gi (40), hvor R2 er H og RI er (61) og G22 er alkyl, heteroaryl alene.
Hydraziner (40) hvor R2 er hydrogen og RI har generell struktur (73) kan fremstilles ved å følge fremgangsmåtene angitt i skjema 16.
(73) G23, G24, G25, G26 = H, alkyl, aryl, heteroaryl, heterocyklisk Som vist i skjema 16, kan cyanursyreklorid (74) behandles med en ekvivalent av amin (75) under milde betingelser, slik som 0°C i aceton under nærvær av vandig kaliumkarbonat, for å gi (76). Behandling av (76) med amin (77) under betingelser slike som 25°C i aceton under nærvær av kaliumkarbonat gir (78). Erstatning av resten av kloridet i (78) med hydrazin gir (40) hvor R2 er H og RI er (73).
Hydraziner (40) hvor R2 er hydrogen og RI har den generelle strukturen (79) kan fremstilles ved å følge fremgangsmåtene angitt i skjema 17 (Menicagli, R. et al., Tetrahed-ron, 56, 9705-9711,2000).
(79) G25, G26 = H, alkyl, aryl, heteroaryl, heterocyklisk; G27 = alkyl, heterocyklisk Som vist i skjema 17, kan cyanursyreklorid (74) omsettes med Grignard-forbindelsen (80) for å danne (81), som etter behandling med amin (77) gir monokloridet (82). Hydrazinolyse av (82) gir (40) hvor R2 er H og RI (73).
Hydraziner (40) hvor R2 er hydrogen og RI har den generelle strukturen (83) kan fremstilles ved å følge fremgangsmåtene angitt i skjema 18 (Kobe, J. et al., Monatsh. Chem. 101, 724-735, 1970; Janietz, D. og Bauer, M., Synthesis 33-34, 1993).
(83) G28 = aryl, heteroaryl; G29 = alkyl, aryl, heteroaryl, heterocyklisk, NG30G31; G30, G31 = aryl, aryl, heteroaryl, heterocyklisk
Som vist i skjema 18 kan forbindelse (84) kobles til borsyre G28B(OH)2eller ekvivalent under Suzuki-koblingsprotokoller for å gi (85), som etter hydrazinolyse gir (40) hvor R2 er H og RI er (83).
Hydraziner (40) hvor R2 er hydrogen og RI har generell struktur (86) kan fremstilles ved å følge fremgangsmåter angitt i skjema 19.
(86) G30, G31 = alkyl, heterocyklisk
Som vist i skjema 19, gir sekvensiell reaksjon mellom cyanursyreklorid (74) med Grignard-forbindelsene G30MgX og G31MgX i et løsemiddel slik som benzenmonokloridet (87) , som kan behandles med hydrazid for å gi (40), hvori R2=H og Rl=(86).
Hydraziner (40) hvor R2 er hydrogen og RI har generell struktur (88) kan fremstilles ved å følge fremgangsmåtene angitt i skjema 20. (88) G32 = alkyl, aryl, heteroaryl, heterocyklisk;
G33 = hydrogen, alkyl, aryl, heteroaryl, heterocyklisk; G34 = alkyl
Som vist i skjema 20, kan (89) reduseres til (90) ved anvendelse av reduksjonsbetingel-ser, slike som jern og eddiksyre. Sekvensiell behandling av (90) med alkyleringsmidler G32X og G33X (hvor X er halid eller trifluormetylsulfonat) gir (91). Alternativt, gir behandling av (90) med en ekvivalent G32X (91) hvor G33 er H. Oksidering av (91) til det tilsvarende sulfoksidet eller sulfonet ved anvendelse av meta-klorperbenzosyre som oksidasjonsmiddel, og etterfølgende behandling med hydrazin gir dette (40) hvor R2 er H og RI (88).
Skjema 20
Hydraziner (40) hvor R2 er hydrogen og RI har generell struktur (92) kan fremstilles ved å følge fremgangsmåtene angitt i skjema 21 (Wolf, F.J. et al., J. Am. Chem. Soc. 76,3551-3553,1954; Hay, M. et al, J. Med. Chem. 46,169-182,2003) og skjema 22 (Ley, K. et al, Angew. Chem. Int. Ed. 11, 1009-1010, 1972).
(92) G35 = alkyl, aryl, heteroaryl, heterocyklisk, alkoksy, halogen, amin; m, q = 0,1
Som vist i skjema 21, kan (93) omsettes med cyanamid under nærvær av en base slik som vandig natriumhydroksid for å gi (95). Alternativt, gir behandling av (94) med guanidin og en base slik som kalium tert-butoksid, fulgt av surgjøring, (95) i tillegg. Reaksjon mellom (95) og natriumnitritt i sur løsning gir (96). Omdannelse av (96) til det respektive kloridet (97) kan oppnås med for eksempel fosforoksyklorid. Hydrazinolyse av (97) gir (40) hvor R2 er H og RI er (92) og m=0 og q=l; N-oksidet i molekylet reduseres ved hydrogenolyse under nærvær av Pd på karbon og det resulterende hydrazinet kan deretter kobles til syre (8), (18) eller (27). Alternativt, kan 1-N-oksidbenzotriazinhydrazinet kobles til syrene (8), (18) eller (27), og de resulterende forbindelsene kan deretter underkastes hydrogenolyse under nærvær av Pd på karbon for å redusere N-oksidgruppen.
Skjema 21
Alternativt, som vist i skjema 22, kan (98) omsettes med dinatriumcyanamid i et løse-middel slik som en blanding av metanol og vann for å gi (99), samt tautomerisering til
(100) under nærvær av syre. Behandling av (100) med natriumnitritt i surt medium gir
(101) . Reaksjon mellom (101) og fosforoksyklorid, fulgt av hydrazinolyse, gir (40), hvor R2 er H og RI er (92) og m=q=l; N-oksidgruppene i dette molekylet kan reduseres ved hydrogenolyse under nærvær av Pd på karbon og det resulterende hydrazinet kan deretter kobles til syren (8), (18) eller (27). Alternativt, kan 1,4-bis-N-oksid benzotria-zinhydrazinet kobles til syre (8), (18) eller (27), og den resulterende forbindelsen kan deretter reduseres ved hydrogenolyse under nærvær av Pd på karbon.
Foreliggende oppfinnelse vil nå bli beskrevet med referanse til følgende, illustrerende, eksempler.
Slik det anvendes heri, er symboler og konvensjoner anvendt i fremgangsmåter, skje-maer og eksempler i henhold til de som anvendes i vitenskapelig litteratur, f.eks. " Journal of the American Chemical Society" eller " Journal o/ Biological Chemistry". Standard enbokstavs- eller trebokstavsforkortelser blir generelt anvendt for å betegne amino-syrerester, som antas å være i L-konfigurasjon med mindre annet er angitt. Med mindre annet er angitt, blir alle utgangsmaterialer oppnådd fra kommersielle leverandører og anvendt uten rensing.
Hz (hertz); TLC (tynnsjiktkromatografi);
Tr(retensjonstid); RP (omvendt fase);
MeOH (metanol); i-PrOH (isopropanol);
EtOH (etanol); TEA (trietylamin);
TFA (trifluoreddiksyre); THF (tetrahydrofuran);
DMSO (dimetylsulfoksid); AcOEt eller EtOAc (etylacetat);
DCM (diklormetan); DMF (N,N-dimetylformamid);
CDI (1,1 -karbonyldiimidazol); HO Ac (eddiksyre);
HOSu (N-hydroksysuksinimid); Ac (acetyl);
HOBT (1-hydroksybenzotriazol); BOC (tert-butyloksykarbonyl);
mCPBA (meta-klorperbenzosyre); FMOC (9-fluorenylmetoksykarbonyl);
DCC (dicykloheksylkarbodiimid); CBZ (benzyloksykarbonyl);
NMM (N-metylmorfolin); HOAt (l-hydroksy-7-azabenzotriazol);
DMAP (4-dimetylaminopyridin); Bn (benzyl);
TBAF (tetra-n-butylammonium- THP (tetrahydro-2H-pyran-2-yl)
fluorid)
HPLC (høytrykks væskekromatografi);
BOP (bis(2-okso-3-oksazolidinyl)fosfinsyreklorid);
EDCI (l-etyl-3-[3-dimetylaminopropyl]karbodiimid hydroklorid); HBTU (O-benzotriazol-1 -yl-N,N,N' ,N '-tetrametyluronium heksafluorfosfoat).
Alle referanser til eter er dietyleter; saltvann refererer til mettet vandig løsning av NaCl. Med mindre annet er angitt er alle temperaturer angitt i °C (grader celsius). Alle reaksjoner utføres i en inert atmosfære ved romtemperatur med mindre annet er angitt og alle løsemidler er av høyeste renhetsgrad med mindre annet er angitt.
<!>H NMR (heretter også "NMR") spektere ble avlest på et Varian VXR-300, et Varian Unity-300, et Varian Unity-400-instrument, et Brucker AVANCE-400, et General Electric QE-300 eller et Bruker AM-400 spektrometer. Kjemiske skift er uttrykt i deler pr. million (ppm, 8-enheter). Koblingskonstanter er i hertz (Hz). Splittemønstere beskri-ver tilsynelatende multiplisiteter og er betegnet som s (singlett), d (dublett), t (triplett), q (kvartett), quint (kvintett), m (multiplett), br (bred).
Massespektra ble tatt opp på et åpent aksess LC-MS-system ved anvendelse av elektro-sprayionisasjon. LC-betingelser: 4,5% til 90% CH3CN (0,02% TFA) i 3,2 min. med et 0,4 min. opphold og 1,4 min. likevektsinnstilling; deteksjon med MS, UV ved 214 nm, og lysspredningsdetektor (ELS). Kolonne: 1 x 40 mm Aquasil (Cl8).
For preparativ (prep) hplc; blir ca. 50 mg av sluttproduktene injisert i 500 ul DMSO på en 50x20 mm LD. YMC CombiPrep ODS-A-kolonne ved 20 ml/min. med en 10 min. gradient fra 10% CH3CN (0,1% TFA) til 90% CH3CN (0,1% TFA) i H20 (0,1% TFA) og et 2 min. opphold. Flashkromatografi ble kjørt over Merck Silika-gel 60 (230-400 mesh).
Infrarøde (IR) spektra ble oppnådd på et Nicolet 510 FT-IR-spektrometer ved anvendelse av en 1 mm NaCl-celle. De fleste reaksjonene ble overvåket med tynnsjiktkromatografi på 0,25 mm E. Merck silikagelplater (60F-254), visualisert med UV-lys, 5% eta-nolisk fosfomolybdensyre eller p-anisaldehydløsning.
Følgende synteseskjemaer er kun illustrative for fremgangsmåtene hvorved forbindelsene ifølge oppfinnelsen kan fremstilles..
Forbindelsen beskrevet i eksemplene 2 til 353 ble fremstilt ved å følge generelle fremgangsmåter beskrevet i eksempel 1. Forbindelsene beskrevet i eksempel 355 til 379 ble fremstilt ved å følge generelle fremgangsmåter beskrevet i eksempel 354.
Fremstilling 1
(4S)-benzyl-3-heptanoyl-oksazolidin-2-on
Til en løsning av (S)-(-)-4-benzyl-2-oksazolidinon (3,3 g, 18,6 mmol) i THF (50 ml) ble det ved -78°C dråpevis tilsatt n-BuLi (7,4 ml, 2,5M løsning i heksan, 18,6 mmol). Etter røring i 30 minutter ved samme temperatur, ble reaksjonsblandingen behandlet med heptanoylklorid (2,76 g, 18,6 mmol). Reaksjonsblandingen ble rørt og varmet til 10°C i løpet av 5 timer og reaksjonen ble stoppet med mettet vandig NH4Cl-løsning (100 ml). Det vandig sjiktet ble ekstrahert med EtOAc (100 ml x 2). De kombinerte organiske sjiktene ble vasket med saltvann og tørket over MgSC^. Fjerning av løsemidlet under redusert trykk ga 4,63 g (86%) av tittelforbindelsen.
<J>H NMR (400 MHz, CDC13) 5 7,37-7,22 (m, 5H), 4,69 (m, 1H), 4,19 (m, 2H), 3,31 (dd, J=13,4, 3,3Hz, 1H), 2,95 (m, 2H), 2,79 (dd, J=13,4, 9,7Hz, 1H), 1,71 (m, 2H), 1,42-1,32 (m, 6H), 0,92 (t, J=6,8Hz, 3H).
MH+ 290.
Fremstilling 2
(4S)-benzyl-3-[(2R)-benzyloksymetylheptanoyl]oksazolidin-2-on Til en løsning av (S)-4-benzyl-3-heptanoyloksazolidin-2-on (4,63 g, 16,02 mmol) og titan(IV)klorid (1,9 ml, 16,82 mmol) i diklormetan (55 ml) ble det ved 0°C dråpevis tilsatt diisopropyletylamin (3,1 ml, 17,62 mmol). Etter røring ved 0°C i 1 time, ble det resulterende titanenolatet omsatt med benzylklormetyleter (TCI-America, 4,9 ml, 32,04
mmol) ved 0°C i 6 timer. Reaksjonen ble deretter stoppet med vann (100 ml). Det vandige sjiktet ble ekstrahert med diklormetan (100 ml x 2). De organiske sjiktene ble vasket med saltvann og tørket over MgSCv Etter fjerning av løsemidlet under redusert trykk, ga rensing ved flashkolonnekromatografi ved anvendelse av et elueringssystem av heksan/EtOAc (5:1) 4,39 g (67%) av tittelforbindelsen.
<J>H NMR (400 MHz, CDC13) 5 7,38-7,21 (m, 10H), 4,74 (m, 1H), 4,57 (m, 2H), 4,28-4,13 (m, 3H), 3,82 (t, J=8,7Hz, 1H), 3,68 (dd, J=9,0, 4,9Hz, 1H), 3,25 (dd, J=13,5, 3,1Hz, 1H), 2,71 (dd, J=13,5, 9,3Hz, 1H), 1,74 (m, 1H), 1,54 (m, 1H), 1,31-1,28 (m, 6H9, 0,89 (t, J=6,7Hz, 3H).
MH+410.
Fremstilling 3
(3R)-benzyloksy-2-pentylpropionsyre
En 0,05M løsning av (S)-4-benzyl-3-[(R)-2-benzyloksymetylheptanoyl]oksazolidin-2-on (2,0 g, 4,89 mmol) i en 3:1 blanding av THF og H20 ble behandlet med 30% H202(4,5 ml, 39,12 mmol), fulgt av LiOH (0,48 g, 9,78 mmol) ved 0°C. Den resulterende blandingen ble rørt og varmet til romtemperatur over natten. THF ble deretter fjernet under vakuum. Resten ble vasket med diklormetan (50 ml x 2) for å fjerne (S)-4-benzyloksazolidin-2-on. Det ønskede produktet ble isolert ved EtOAc-ekstraksjon av den surgjorte (pH 1~2) vandige fasen. Ingen ytterligere rensing var påkrevet. Henstand under høyvakuum ga 1,16 g (95%) av tittelforbindelsen.
<J>H NMR (400 MHz, CDC13) 8 11,1 (br s, 1H), 7,36 (m, 5H), 4,57 (s, 2H), 3,69 (m, 1H), 3,58 (dd, J=9,2, 5,2Hz, 1H), 2,74 (m, 1H), 1,66 (m, 1H), 1,54 (m, 1H), 1,34-1,30 (m, 6H), 0,90 (t, J=6,7Hz, 3H).
MH+251.
Fremstilling 4
3-hydroksy-(2R)-pentylpropionsyre
Til en løsning av (R)-3-benzyloksy-2-pentyl-propionsyre (1,54 g, 6,16 mmol) i EtOH (100 ml) ble det tilsatt 10% Pd/C (310 mg). Reaksjonsblandingen ble hydrogenert over natten ved romtemperatur. Etter fullstendig reaksjon, ble reaksjonsblandingen filtrert gjennom en celittpute og vasket med EtOH (50 ml x 3). Fjerning av løsemidlet ga tittelforbindelsen (0,92 g, 93%). Ingen ytterligere rensing var påkrevet.
<J>H NMR (400 MHz, CDCI3) 5 6,30 (br s, 1H), 3,81 (d, J=5,4Hz, 2H), 2,64 (m, 1H), 1,69 (m, 1H), 1,56 (m, 1H), 1,41-1,27 (m, 6H), 0,91 (t, J=7,7Hz, 3H).
MH+ 161.
Fremstilling 5
N-benzyloksy-3-hydroksy-(2R)-pentylpropionamid
Til en blanding av (R)-3-hydroksy-2-pentylpropionsyre (0,92 g, 5,75 mmol), O-benzyl-hydroksylamin hydroklorid (0,92 g, 5,75 mmol) og 4-(dimetylamino)pyridin (1,41 g, 11,50 mmol) i diklormetan (25 ml) ble det ved 0°C tilsatt l-[3-(dimetylamino)propyl]-3-etylkarbodiimid hydroklorid (1,11 g, 5,75 mmol). Etter røring ved romtemperatur over natten, ble reaksjonen stoppet med IN vandig HCl-løsning (25 ml) og blandingen ble ekstrahert ved anvendelse av diklormetan (25 ml x 2). De organiske ekstraktene ble vasket med vann, saltvann og tørket over MgS04. Fjerning av løsemidlet under redusert trykk ga tittelforbindelsen (1,43 g, 94%).
<J>H NMR (400 MHz, CDC13) 5 9,22 (br s, 1H), 7,41-7,28 (m, 5H), 4,89 (q, J=10,6Hz, 2H), 3,70-3,37 (m, 3H), 2,17 (m, 1H), 1,54 (br s, 1H), 1,27 (m, 6H), 0,88 (t, J=6,9Hz, 3H).
MH+ 266.
Fremstilling 6
l-benzyloksy-(3R)-pentylazetidin-2-on
Til en blanding av (R)-N-benzyloksy-3-hydroksy-3-pentylpropionamid (1,41 g, 5,32 mmol) og trifenylfosfin (1,68 g, 6,39 mmol) i THF (53 ml) ble det dråpevis tilsatt diety-lazodikarboksylat (1,1 ml, 6,39 mmol) ved 0°C. Reaksjonsblandingen ble rørt og varmet til romtemperatur over natten. Reaksjonen ble stoppet med vann (50 ml). Det vandige sjiktet ble ekstrahert med EtOAc (50 ml x 2). De kombinerte organiske sjiktene ble vasket med saltvann, og tørket over MgSC«4. Etter fjerning av løsemidlet under vakuum, ble resten renset med flashkolonnekromatografi (heks:EtOAc 5/1) hvilket ga tittelforbindelsen (1,17 g, 89%).
<J>H NMR (400 MHz, CDC13) 5 7,35-7,25 (m, 5H), 4,87 (s, 2H), 3,28 (t, J=4,85Hz, 1H), 2,84 (q, J=2,35Hz, 1H), 2,77 (m, 1H), 1,62 (m, 1H), 1,36 (m, 1H), 1,25-1,16 (m, 6H), 0,88 (t, J=6,9Hz, 3H).
MH+ 248.
Fremstilling 7
3-benzyloksyamino-(2R)-pentylpropionsyre
Til en løsning av (R)-l-benzyloksy-3-pentylazetidin-2-on (0,96 g, 3,89 mmol) i en blanding av THF-H20-MeOH (50 ml, 3:1:1 v/v) ble det tilsatt litiumhydroksidmono-hydrat (1,91 g, 38,9 mmol). Etter røring ved romtemperatur over natten ble vann (25 ml) tilsatt til blandingen. Løsningen ble surgjort til pH 5~6 med 3N vandig HCl-løsning. Blandingen ble ekstrahert med EtOAc (50 ml x 2). De kombinerte organiske sjiktene ble tørket over MgSCv Fjerning av løsemidlet under vakuum ga tittelforbindelsen (0,98 g, 95%).
<J>H NMR (400 MHz, CDC13) 5 9,80 (br s, 1H), 7,37 (m, 5H), 4,75 (m, 2H), 3,14 (m 2H), 2,74 (m, 1H), 1,70 (m, 1H), 1,53 (m, 1H), 1,38-1,25 (m, 6H), 0,91 (t, J=6,8Hz, 3H). MH+ 266.
Fremstilling 8
(2R)- [(benzyloksyformylamino)metyl] heptansyre
Til en kald løsning av (R)-3-benzyloksyamino-2-pentylpropionsyre (1,03 g, 3,89 mmol) i HC02H (19 ml) og diklormetan (19 ml) ble det ved 0°C tilsatt eddiksyreanhydrid (3,9 ml, 41,2 mmol). Blandingen ble rørt ved 0°C i 3 timer. De flyktige komponentene ble fjernet ved fordamping under vakuum. Diklormetan (50 ml) ble tilsatt. Den organiske løsningen ble vasket med saltvann (50 ml x 2), og tørket over MgSC*4. Filtrering og fordamping under vakuum ga tittelforbindelsen (1,08 g, 95%).
<J>H NMR (400 MHz, CDC13) 5 8,07 (br s, 1H), 7,29 (m, 5H), 4,91-4,71 (m, 2H), 3,76 (m, 2H), 2,67 (m, 1H), 1,54 (m, 1H), 1,41 (m, 1H), 1,20 (m, 6H), 0,80 (t, J=7,0Hz, 3H). MH+ 294.
Eksempel 1
N-hydroksy-N-[(R)-2-(N'-pyridin-2-yl-hydrazinokarbonyl-heptyl]-formamid (2R)-[(benzyloksyformylamino)metyl]heptansyre (1,2 mol), HO At (1,3 mmol), N'-pyridin-2-yl-hydrazin (1,2 mmol) og NMM (5 mmol) ble løst i DMF og behandlet med EDCI (1,3 mmol) ved romtemperatur i 12 timer. Koblingsproduktet N-benzyloksy-N-[(R)-2-(N'-pyridin-2-yl-hydrazinokarbonyl)-heptyl]-formamid ble isolert ved preparativ hplc av den urene reaksjonsblandingen. Denne forbindelsen ble underkastet atmosfære-trykkhydrogenering over Pd/C i metanol i 1 time hvilket ga tittelforbindelsen. MH+295.
Fremstilling 9
2-hydrazino-5-etylpyrimidin
Til en løsning av 2-klor-5-etylpyrimidin (0,31 g, 2,2 mmol) i MeOH (5 ml) ble det tilsatt hydrazinmonohydrat (1,0 ml, 20,6 mmol). Etter røring i 16 timer ved 50°C, ble løs-ningen avkjølt til romtemperatur og renset med omvendt fase HPLC hvilket ga 0,24 g (80%) av tittelforbindelsen som et hvitt fast stoff.
MH+ 139.
Fremstilling 10
2-hydrazino-4-metylpyrimidin
Til en fint dispergert suspensjon av 2-klorpyrimidin (8,01 g, 69,9 mmol) i en 10:1 blanding av Et20-THF (500 ml) ble det ved -30°C dråpevis tilsatt MeLi (46 ml, 1,6M i Et20, 73,6 mmol). Reaksjonsblandingen ble rørt ved -30°C i 30 minutter og ble deretter varmet til 0°C og rørt i 30 minutter. Reaksjonsblandingen ble deretter tilsatt til en 1:1:20 blanding av H20-HOAc-THF (100 ml) og blandingen ble rørt ved 0°C i 10 minutter. Til blandingen ble det deretter tilsatt en løsning av DDQ (16,7 g, 73,6 mmol) i THF (100 ml) og blandingen ble rørt og varmet til romtemperatur i 30 minutter. Blandingen ble deretter fortynnet med Et20 (300 ml) og vasket med IN vandig NaOH (3 x 100 ml) et-terfulgt av saltvann (300 ml). Den organiske fasen ble deretter tørket over vannfri MgSCU, filtrert, konsentrert i vakuum og renset med flashkromatografi ved anvendelse av EtOAc-heksan (1:2) som eluent hvilket ga 6,06 g av 2-klor-4-metylpyrimidin (67%) som hvite krystallinske plater.
Til en løsning av 2-klor-4-metylpyrimidin (6,06 g, 47,1 mmol) i MeOH (40 ml) ble det tilsatt hydrazinmonohydrat (10 ml, 206 mmol). Løsningen ble rørt i 16 timer ved romtemperatur og deretter renset med omvendt fase HPLC hvilket ga 4,43 g av tittelforbindelsen (76) som et hvitt fast stoff.
MH+ 125.
Fremstilling 11
2-hydrazino-4-morfolino-6-metylpyrimidin
Til en løsning av 2,4-diklor-6-metylpyrimidin (0,41 g, 2,50 mmol) i MeOH (5 ml) ble det tilsatt morfolin (0,5 ml, 5,73 mmol). Løsningen ble rørt i 30 minutter ved romtemperatur og deretter ble hydrazinmonohydrat (1,0 ml, 20,6 mmol) tilsatt. Løsningen ble deretter varmet til 60°C og rørt i 16 timer. Løsningen ble avkjølt til romtemperatur og renset med omvendtfase HPLC hvilket ga 0,31 g av tittelforbindelsen (59%) som et voksaktig hvitt fast stoff.
MH+210.
Fremstilling 12
2-hydrazino-4-(2,3,4-trimetoksyfenyl)pyrimidin
Til en løsning av 2-tiometyl-4-klorpyrimidin (0,3410 g, 2,12 mmol) i 1,4-dioksan (21 ml) ble det tilsatt 2,3,4-trimetoksyfenylborsyre (0,4950 g, 2,33 mmol) og vandig Na2C03(2,3 ml, 2,0M i vann, 4,60 mmol). Blandingen ble overstrømmet med tørr ni-trogengass i 5 minutter og deretter ble Pd(PhaP)4(123 mg, 0,106 mmol) tilsatt. Blan dingen ble beskyttet mot lys og varmet til 110°C i 16 timer. Blandingen ble deretter av-kjølt til romtemperatur, filtrert, konsentrert i vakuum og renset ved flashkromatografi ved anvendelse av EtOAc-heksan (1:4) som eluent hvilket ga 0,5920 g 2-tiometyl-4-(2,3,4-trimetoksyfenyl)pyrimidin (95%) som et gult fast stoff.
Til en løsning av 2-tiometyl-4-(2,3,4-trimetoksyfenyl)pyrimidin (0,5920 g, 2,02 mmol) i CH2CI2(10 ml) ble det tilsatt m-klorperbenzosyre (1,05 g, 6,08 mmol), og løsningen ble rørt i 3 timer hvorved den ble observert å være en hvit suspensjon. Suspensjonen ble konsentrert i vakuum og MeOH (10 ml) ble tilsatt fulgt av hydrazinmonohydrat (2 ml, 41,2 mmol). Den resulterende løsningen ble rørt i 16 timer og deretter konsentrert til tilnærmet halve volumet i vakuum. Blandingen ble stående i 1 time og det resulterende faste stoffet ble samlet opp ved vakuumfiltrering og vasket med vann.Tørking i vakuum ga 0,3330 g av tittelforbindelsen (60%) som et lyst brunt fast stoff.
MH+ 277.
Fremstilling 13
2-hydrazino-4-morfolin-4-trifluormetylpyrimidin
Til en løsning av 2-tiometyl-4-klor-6-trifluormetylpyrimidin (1,9996 g, 8,75 mmol) i MeOH (50 ml) ble det tilsatt morfolin (1,5 ml, 17,2 mmol). Løsningen ble rørt over natten, konsentrert i vakuum og det resulterende hvite faste stoffet ble samlet opp ved vakuumfiltrering og vasket med vann. Til en løsning av det faste stoffet i CH2CI2(50 ml) ble det tilsatt m-klorperbenzosyre (4,53 g, 26,3 mmol), og den resulterende løsningen ble rørt i 2 timer hvorved den ble observert å være en hvit suspensjon. Løsemidlet ble fjernet i vakuum og deretter ble MeOH (50 ml) tilsatt, fulgt av hydrazinmonohydrat (3,0 ml, 61,8 mmol). Løsningen ble rørt i 16 timer og deretter konsentrert til ca. halve volumet i vakuum. Vann (100 ml) ble deretter tilsatt til den resulterende suspensjonen og det observerte hvite faste stoffet ble samlet opp ved vakuumfiltrering. Dette materialet ble deretter vasket med vann og tørket i vakuum hvilket ga 1,7193 g av tittelforbindelsen (75%) som et hvitt fast stoff.
MH+ 264.
Fremstilling 14
2-hydrazino-5,6,7,8-tetrahydrokinazolin
Til en blanding av etyl 2-cykloheksanonkarboksylat (3,00 g, 17,6 mmol) og 2-metyl-2-tiopseudoureasulfat (3,68 g, 13,2 mmol) ble det tilsatt en løsning av kaliumkarbonat (7,31 g, 52,9 mmol) i vann (60 ml). Reaksjonsløsningen ble rørt ved romtemperatur i 16 timer, hvorved den ble observert til å være en suspensjon. Det hvite faste stoffet ble samlet opp ved vakuumfiltrering, vasket med vann og tørket i vakuum. Blandingen av det faste stoffet i fosforoksyklorid (20 ml) ble varmet til 110°C i et forseglet rør, hvorved den ble observert til å være en løsning. Løsningen ble avkjølt til romtemperatur og ble deretter heilt over i knust is og vann (300 ml). Blandingen ble rørt kraftig ved 0°C i 1 time og det resulterende presipitatet ble samlet opp ved vakuumfiltrering, vasket med vann og tørket i vakuum hvilket ga 1,61 g av 2-tiometyl-4-klor-5,6,7,8-tetrahydrokinazolin (43%) som et off-white fast stoff.
Til en løsning av 2-tiometyl-4-klor-5,6,7,8-tetrahydrokinazolin (0,5121 g, 2,39 mmol) i en 10:1 blanding av MeOH-HOAc (30 ml) ble det tilsatt aktivert sinkstøv (500 mg, 7,65 mmol). Blandingen ble varmet til 70°C i 1 time, og deretter avkjølt til romtemperatur og filtrert. Den resulterende løsningen ble konsentrert i vakuum og azeotropisk tørket med toluen (50 ml). Resten ble fordelt mellom EtOAc (150 ml) og IN vandig HC1 (50 ml), og den organiske fasen ble deretter vasket med mettet vandig NaHC03og saltvann. Den organiske fasen ble deretter tørket over vannfri MgS04og konsentrert i vakuum hvilket ga 0,1461 g 2-tiometyl-5,6,7,8-tetrahydrokinazolin (34%) som en purpurfarvet olje.
Til en løsning av 2-tiometyl-5,6,7,8-tetrahydrokinazolin (0,1461 g, 0,81 mmol) i CH2CI2(5 ml) ble det tilsatt m-klorperbenzosyre (0,462 g, 2,68 mmol). Løsningen ble rørt ved romtemperatur i 3 timer, hvorved den ble observert til å være en suspensjon. Løsemidlet ble deretter fjernet i vakuum og MeOH (5 ml) ble tilsatt fulgt av hydrazinmonohydrat (1 ml, 20,6 mmol). Løsningen ble deretter varmet til 50°C og rørt i 16 timer. Løsningen ble avkjølt til romtemperatur og renset med omvendt fase HPLC hvilket ga 0,1126 g av tittelforbindelsen (85%) som en farveløs olje.
MH+ 165.
Fremstilling 15
2-hydrazino-4-(2-pyridyl)pyrimidin
Til en løsning av 2-amino-4-(2-pyirdyl)pyrimidin (10,10 g, 58,66 mmol) i 5% vandig svovelsyre (200 ml) ble det tilsatt natriumnitrat (20,24 g, 293,3 mmol) porsjonsvis i løpet av 10 minutter. Løsningen ble rørt ved romtemperatur i 2 timer og deretter justert til pH 10 ved tilsetning av 6N vandig NaOH. Den resulterende blandingen ble deretter ekstrahert med 30% i-PrOH i CHCI3(10 x 300 ml) og den kombinerte organiske fasen ble tørket over vandig MgS04og konsentrert i vakuum. Resten ble triturert med heksan og samlet opp ved vakuumfiltrering hvilket ga 6,89 g av 4-(2-pyridyl)pyrimid-2-on (68%) som et beige faststoff.
En blanding av 4-(2-pyridyl)pyrimid-2-on (6,89 g, 39,8 mmol) i fosforoksyklorid (30 ml) ble varmet til 110°C i 90 minutter i et forseglet rør. Den mørke brune løsningen ble deretter avkjølt til romtemperatur og heilt over knust is og vann (500 ml). Blandingen ble rørt kraftig ved 0°C i 1 time og ble deretter justert til pH 14 med 6N vandig NaOH. Blandingen ble ekstrahert med CH2CI2(2 x 300 ml) og den kombinerte organiske fasen ble tørket over MgSC«4 og konsentrert i vakuum. Til en løsning av resten i CH2CI2(10 ml) og MeOH (30 ml) ble det tilsatt hydrazinmonohydrat (7,0 ml, 144,2 mmol) og løs-ningen ble rørt i 16 timer hvorved et hvitt presipitat ble observert. Det faste stoffet ble samlet opp ved vakuumfiltrering, vasket med vann og tørket i vakuum hvilket ga 2,20 g av tittelforbindelsen (30%) som et off-white fast stoff.
MH+ 188.
Fremstilling 16
(6-morfolin-4-yl-pyrimidin-4-yl)-hydrazin
En løsning av 4,6-diklorpyrimidin (300 mg, 2 mmol), tert-butylkarbazat (280 mg, 2,1 mmol) og Hunig's base (435 ul, 2,6 mmol) i etanol (3 ml) ble rørt ved 120°C i 1 time under mikrobølgebetingelser. Etter tilsetning av morfolin (700 ul, 8 mmol) ble blandingen underkastet samme mikrobølgebetingelser en gang til i ytterligere 1 time. Fordamping av løsemidlet i vakuum ga et hvitt fast stoff som ble behandlet med TFA (3 ml) i DCM (3 ml) i 20 minutter. Etter fordamping av løsemidlet ble resten gjenoppløst i metanol. Behandling med fast NaHC03fjernet dette spor av TFA som kunne være igjen. Filtrering fulgt av fordamping av løsemidlet ga resten som ble underkastet omvendtfase HPLC-rensing hvilket ga (6-morfolin-4-yl-pyrimidin-4-yl)-hydrazin (200 mg, 1 mmol, 50% i 3 trinn) som et hvitt fast stoff.
MH+ 196.
Alternativt kan samme forbindelse genereres ved omrøring av en løsning av 4,6-diklorpyrimidin (300 mg, 2 mmol), morfolin (280 mg, 2,1 mmol) og diisopropyletylamin (453 ul, 2,6 mmol) i etanol (3 ml) i 1 time. Etter tilsetning av hydrazin (370 ul, 6 mmol), ble blandingen rørt ved 120°C i 1 time under mikrobølgebetingelser. Etter fordamping av løsemiddel ble forbindelsen løst i DMSO før den ble underkastet preparativ HPLC-rensing hvilket deretter ga (6-morfolin-4-yl-pyirmidin-4-yl)hydrazin.
MH+ 196.
Fremstilling 17
(2-etylamin-6-trifluormetyl-pyrimidin-4-yl)-hydrazin
En løsning av (4-klor-6-trifluormetyl-pyrimidin-2-yl)-etylamin (10 mg, 0,38 mmol), hydrazin (87 ul, 3,8 mmol) i etanol ble varmet til 70°C over natten. Fordamping av lø-semiddel under vakuum ga en rest som ble renset med preparativ HPLC hvilket ga (2-etylamin-6-trifluormetyl-pyrimidin-4-yl)-hydrazin (74 mg, 75%).
MH+ 256.
Fremstilling 18
[(4-metyl-piperazin-l-yl)-trifluormetyl-pyrimidin-4-yl]-hydrazin En blanding av 4-klor-2-metyltiol-6-(trifluormetyl)pyrimidin (228 mg, 1 mmol), tert-butylkarbazat (159 mg, 6, 1,2 mmol) i etanol ble varmet til 100°C i en mikrobølgereak-tor i 20 minutter. Fordamping av løsemidlet ga et hvitt fast stoff. Det faste stoffet ble behandlet med MCPBA i DCM ved romtemperatur over natten. Fordamping av løse-midlet ga et hvitt fast stoff som ble behandlet med 1-metylpiperazin ved 140°C i 20 minutter og i etanol under mikrobølgebetingelser. Fordamping av løsemidlene ga et fast stoff som ble behandlet med TFA (3 ml) i DCM (3 ml) i 20 minutter. Etter reaksjonen ble det meste av TFA og DCM fjernet under vakuum. Resten ble gjenoppløst i metanol og behandlet med fast NaHCC«3 for å fjerne TFA-resten til ingen gass ble generert. Filtrering og vakuumfordamping av filtratet ga en rest som ble renset med preparativ HPLC hvilket ga [(4-metyl-piperazin-l-yl)-trifiuormetyl-pyrimidin-4-yl]-hydrazin (100 mg, 36%).
MH+ 277.
Eksempel 2
N-hydroksy-N-{(R)-2-[N'-(3-metoksy-fenyl)-hydrazinokarbonyl]-heptyl}-formamid
MH+ = 324.
Eksempel 3
N-hydroksy-N-{(R)-2-[N'-(4-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 364.
Eksempel 4
N-{(R)-2-[N'-(4-cyano-fenyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid. MH+ = 319.
Eksempel 5
N-{(R)-2- [N '-(2,6-dimetyl-pyrimidin-4-yl)-hydrazinokarbonyl] -heptyl}-N-hydroksy-formamid.
MH+ = 324.
Eksempel 6
N-hydroksy-N-[(R)-2-(N'-kinoksalin-2-yl-hydrazinokarbonyl)-heptyl]-formamid. MH+ = 346.
Eksempel 7
N-hydroksy-N-((2R)-2-{N'-(3,4-dihydro-kinoksalin-2-yl)-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 348.
Eksempel 8
N-hydroksy-N-{(R)-2-[N'-(l,3,4-trimetyl-lH-pyrazolo[3,4-b]pyridin-6-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ 377.
Eksempel 9
4-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl-hydrazino)-benzensulfonamid.
MH+ = 373.
Eksempel 10
N-hydroksy-N-[(2R)-2-(cykloheksylmetyl)-3-okso-3-{N'-[4-(trinuormetyl)-pyrimidin-2-yl]-hydrazino}-propyl]-formamid.
MH+ = 390.
Eksempel 11
N-hydroksy-N-[(2R)-2-(cyklopentylmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-propyl]-formamid.
MH+ = 376.
Eksempel 12
N-{(R)-2-[N'-(dimetyl-trifluormetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 392.
Eksempel 13
N-hydroksy-N-{(R)-2-[N'-(6-trifluormetyl-pyridazin-3-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 364.
Eksempel 14
N-hydroksy-N-{(R)-2-[N'-(6-trifluormetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 364.
Eksempel 15
N-hydroksy-N-{(R)-2-[N'-(5-metyl-[l,2,4]triazolo[l,5-a]pyrimidin-7-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 350.
Eksempel 16
N-hydroksy-N-{(R)-2-[N'-(9H-purin-6-yl)-hydrazinokarbonyl]-heptyl}-formamid. MH+ = 336.
Eksempel 17
N-{(R)-2-[N'-(5-cyano-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 321.
Eksempel 18
N-hydroksy-N-((2R)-2-{[N'-(pyrimidin-2-yl)-hydrazino]karbonyl}-heptyl)-formamid.
MH+ = 296.
Eksempel 19
N-hydroksy-N-((2R)-2-(cyklobutylmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamid.
MH+ = 362
Eksempel 20
N-hydroksy-N-{(R)-2-[N'-(6-imidazol-l-yl-pyrimidin-4-yl)-hydrazinonkarbonyl]-heptyl} -formamid.
MH+ = 362.
Eksempel 21
N-[(R)-2-(N'-benzo[l,2,4]triazin-3-yl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid.
MH+ = 347.
Eksempel 22
N-hydroksy-N-{(R)-2- [N'-(7-metoksy-benzo [1,2,4] triazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 377.
Eksempel 23
N-hydroksy-N-{(R)-2-[N'-(l-metyl-lH-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 350.
Eksempel 24
N-((R)-2-{N'-[6-(5-klor-pyridin-3-yl-oksy)-pyridazin-3-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 423.
Eksempel 25
N-hydroksy-N-[(2R)-2-({N'-[6-(lH-pyrrol-l-yl)-3-pyridazinyl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 361.
Eksempel 26
N-hydroksy-N-((2R)-2-{[N'-(9-metyl-9H-purin-6-yl)-hydrazino]-karbonyl}-heptyl)-formamid.
MH+ = 350.
Eksempel 27
N-hydroksy-N-{(R)-2-[N-({6-morfolin-4-yl}-9H-purin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 421.
Eksempel 28
N-{(R)-2- [N '-(6-fluor-pyridin-2-yl)-hydrazinokarbonyl] -heptyl} -N-hydroksy-formamid.
MH+ = 313.
Eksempel 29
N-hydroksy-N-((2R)-2-{[N'-(l-metyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-hydrazino]-karbonyl}-heptyl)-formamid.
MH+ = 350.
Eksempel 30
N-{(R)-2- [N '-(4-amino-6-isopropyl- [1,3,5] triazin-2-yl)-hydrazinokarbonyl] - heptyl} -N-hydroksy-formamid.
MH+ = 354.
Eksempel 31
N-{(R)-2-[N'-(2,5-dimetyl-4-nitro-2H-pyrazol-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 357.
Eksempel 32
N-{(R)-2-[N'-(3-klor-l-metyl-lH-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 384.
Eksempel 33
N-{(R)-2-[N'-(6-dimetylamino-9H-purin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 379.
Eksempel 34
N-hydroksy-N-[(2R)-4-cyklopropyl-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-butyl]-formamid.
MH+ = 362.
Eksempel 35
N-hydroksy-N-((2R)-2-(cyklopropylmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-propyl)-formamid.
MH+ = 348.
Eksempel 36
N-hydroksy-N-{(R)-2-[N'-metyl-N'-(4-trinuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 378.
Eksempel 37
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptaiioyl}-hydrazino)-4-trifluormetyl-pyrimidin-5-karboksylsyre metylester.
MH+ = 422.
Eksempel 38
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5-karboksylsyre.
MH+ = 408.
Eksempel 39
N-{(R)-2-[N'-(5-fluor-4-metoksy-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 344.
Eksempel 40
N-{(R)-2-[N'-(4-dimetylamino-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 339.
Eksempel 41
N-hydroksy-N-{(2R)-2-[(N'-{6-[(2-hydroksyetyl)amino]-l,3-dihydro-2H-purin-2-yliden}-hydrazino)-karbonyl]-heptyl}-formamid.
MH+ = 395.
Eksempel 42
N-{(R)-2-[N'-(5-fluor-4-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 399.
Eksempel 43
N-{(R)-2-[N'-(5-fluor-4-metylamino-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 343.
Eksempel 44
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptaiioyl}-hydrazino)-4-trifluormetyl-pyrimidin-5-karboksylsyre dimetylamid.
MH+ = 435.
Eksempel 45
N-hydroksy-N-{(R)-2-[N'-(3-okso-3,4-dihydro-kinoksaKn-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 362.
Eksempel 46
N-{(R)-2-butoksy-2-[N'-(4-trilfuormetyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid.
MH+ = 366.
Eksempel 47
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5-karboksylsyre (2-fluor-fenyl)-amid.
MH+ = 501.
Eksempel 48
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptaiio<y>l}-h<y>drazino)-4-trifluormetyl-pyrimidin-5-karboksylsyre tert-butylamid.
MH+ = 463.
Eksempel 49
N-hydroksy-N-((R)-2-{N'-[(l-piperidin-l-yl-metanoyl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 475.
Eksempel 50
N-{(R)-2-[N'-(5-cyano-4-trilfuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 389.
Eksempel 51
N-hydroksy-N-[(2R)-2-({N'-[9-(4,4,4-trifluorbutyl)-l,9-dihydro-2H-purin-2-yliden]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 446.
Eksempel 52
N-hydroksy-N-((R)-2-{N'-[(l-morfolin-4-yl-metanoyl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 477.
Eksempel 53
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5-karboksylsyrebenzylamid.
MH+ = 497.
Eksempel 54
N-hydroksy-N-[(2R)-3-[N'-(l,2,4-benzotriazin-3-yl)-hydrazino]-2-(cykloheksylmetyl)-3-oksopropyl]-formamid.
MH+ =373.
Eksempel 55
N-hydroksy-N-((2R)-2-(cykloheksylmetyl)-3-{N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino}-3-oksopropyl)-formamid.
MH+ = 403.
Eksempel 56
2- [2-((2R)-2-{ [formyl(hydroksy)amino] metyl} heptanoyl)hydrazino] -N-metyl-N-2-pyridinyl-4-(trifluormetyl)-5-pyrimidinkarboksamid.
MH+ = 498.
Eksempel 57
2- [2-((2R)-2-{ [formyl(hydroksy)amino] metyl} heptanoyl)hydrazino] -N-metyl-N-fenyl-4-(trifluormetyl)-5-pyrimidinkarboksamid.
MH+ = 497.
Eksempel 58
2-(N'-{(R)-2-[(formyl-hydroksy-amino)metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5-karboksylsyre morfolin-4-ylamid.
MH+ = 492.
Eksempel 59
N-hydroksy-N-((R)-2-{N'-[(N'-fenyl-hydrazinokarbonyl)-trilfuormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 498.
Eksempel 60
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5-karboksylsyre pip eridin-1-ylamid.
MH+ = 490.
Eksempel 61
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino-4-trifluormetyl-pyrimidin-5-karboksylsyre pyrrol-l-ylamid.
MH+ = 472.
Eksempel 62
N-{(R)-2-[N'-(dimetylamino-fluor-pyrimidiii-2-yl)-hydraziiiokarboiiyl]-heptyl}-N-hydroksy-formamid.
MH+ = 357.
Eksempel 63
N-((R)-2-{N'-[(etyl-metyl-amino)-fluor-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 371.
Eksempel 64
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino}-3-oksopropyl)-formamid.
MH+ = 389.
Eksempel 65
N-hydroksy-N-{(R)-2-[N'-(l-metyl-lH-benzoimidazol-2-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 348.
Eksempel 66
N-{(R)-2-[N'-(4-azetidin-l-yl-5-fluor-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 369.
Eksempel 67
N-{(R)-2- [N '-(4-cyklopropylamino-5-fluor-pyrimidin-2-yl)-hydrazinokarbonyl] - heptyl}-N-hydroksy-formamid.
MH+ = 369.
Eksempel 68
N-[(R)-2-(N-benzo[l,2,4]triazin-3-yl-hydrazinokarbonyl)-3-cyklopentyl-propyl]-N-hydroksy-formamid.
MH+ = 359.
Eksempel 69
N-hydroksy-N-{(R)-2-[N'-(morfolin-4-yl-trilfuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 449.
Eksempel 70
N-hydroksy-N-[(R)-2-(N'-{[(2-hydroksy-etyl)-metyl-amino]-trifluormetyl-pyrimidin-2-yl}-hydrazinokarbonyl)-heptyl}-formamid.
MH+ = 437.
Eksempel 71
N-hydroksy-N-((R)-2-{N'-[(4-metyl-piperazin-l-yl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 462.
Eksempel 72
N-hydroksy-N-((2R)-2-(cykloheksylmetyl)-3-{N'-[4-(cyklopropylamino)-5-fluor-pyrimidin-2-yl]hydrazino}-3-oksopropyl)-formamid.
MH+ = 395.
Eksempel 73
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-(cyklopropylamino)-5-fluor-pyrimidin-2-yl]hydrazino}-3-oksopropyl)-formamid.
MH+ = 381.
Eksempel 74
N-hydroksy-N- [ (2R)-3- {N'- [4-(azetidin-l -yl)-5-fluor-pyrimidin-2-yl] -hy drazino} -2-(cyklopentylmetyl)-3-oksopropyl]-formamid.
MH+ = 381.
Eksempel 75
N-hydroksy-N- [(2R)-5-metyl-2-({N'- [4-(trifluormetyl)-pyrimidin-2-yl] -hydrazino}-karbonyl)-heksyl]-formamid.
MH+ = 364.
Eksempel 76
N-[(R)-2-(N'-benzo[l,2,4]triazin-3-yl-hydrazinokarbonyl)-5-metyl-heksyl]-N-hydroksy-formamid.
MH+ = 347.
Eksempel 77
N-hydroksy-N-[(2R)-5-metyl-2-({N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino}-karbonyl)-heksyl]-formamid.
MH+ = 377.
Eksempel 78
N-{(R)-2- [N '-(7-klor-benzo [1,2,4] triazin-3-yl)-hydrazinokarbonyl] -heptyl}-N-hydroksy-formamid.
MH+ = 381.
Eksempel 79
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-(morfolin-4-yl)-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-3-oksopropyl)-formamid.
MH+ = 461.
Eksempel 80
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-[(2-hydroksyetyl)-(metyl)-amino]-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-3-oksopropyl)-formamid. MH+ = 449.
Eksempel 81
N-hydroksy-N- [(2R)-6-metyl-2-({N'- [4-(trifluormetyl)-pyrimidin-2-yl] -hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 378.
Eksempel 82
N-hydroksy-N-((2R)-2-{[N'-(l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-6-metylheptyl)-formamid.
MH+ = 361.
Eksempel 83
N-hydroksy-N-{(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarboiiyl]-heptyl} -formamid.
MH+ = 361.
Eksempel 84
N-((R)-2-{N'-[(4-etyl-piperazin-l-yl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 476.
Eksempel 85
N-hydroksy-N-{(R)-2-[N'-(piperazin-l-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 448.
Eksempel 86
N-{(R)-2-[N'-(7-fluor-benzo[l,2,4]triaziii-3-yl)-hydrazinokarboiiyl]-heptyl}-N-hydroksy-formamid.
MH+ = 365.
Eksempel 87
N-hydroksy-N-[(2R)-2-({N'-[4-(4-etyl-l-piperazinyl)-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-6-metylheptyl]-formamid.
MH+ = 490.
Eksempel 88
N-hydroksy-N-[(2R)-6-metyl-2-({N'-[4-(piperazin-l-yl)-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 462.
Eksempel 89
N-hydroksy-N-[(2R)-6-metyl-2-({N'-[4-(4-metyl-piperazin-l-yl)-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 476.
Eksempel 90
N-hydroksy-N-((2R)-2-{[N'-(7-klor-l,2,4-benzotriazin-3-yl)hydrazino]karbonyl}-6-metylheptyl)-formamid.
MH+ = 395.
Eksempel 91
N-hydroksy-N-((2R)-6-metyl-2-{[N'-(5-metyl-l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-heptyl)-formamid.
MH+ = 375.
Eksempel 92
N-hydroksy-N-((2R)-2-{[N'-(7-nuor-l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-6-metylheptyl)-formamid.
MH+ = 379.
Eksempel 93
N-hydroksy-N-((R)-2-{N'-[(2-metoksy-etylamino)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 437.
Eksempel 94
N-hydroksy-N-[(2R)-6-metyl-2-({N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 391.
Eksempel 95
N-hydroksy-N-[(R)-2-(N'-{[4-(2-hydroksy-etyl)-piperazin-l-yl]-trilfuormetyl-pyrimidin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 492.
Eksempel 96
N-hydroksy-N-((R)-2-{N'-[(4-pyrimidin-2-yl-piperazin-l-yl)-trilfuormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 526.
Eksempel 97
N-hydroksy-N-((R)-2-{N'-[(2-hydroksy-etylamino)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 423.
Eksempel 98
N-hydroksy-N-{(R)-2-[N'-(7-trinuormetyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 415.
Eksempel 99
N-hydroksy-N-{(R)-2-[N'-(6-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 361.
Eksempel 100
N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(5-metyl-l,2,4-benzotriazin-3-yl)hydrazino]-3-oksopropyl}-formamid.
MH+ = 373.
Eksempel 101
N-hydroksy-N-[(2R)-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-oktyl] -formamid.
MH+ = 378.
Eksempel 102
N-hydroksy-N-((2R)-2- {[N '-(1,2,4-b enzotriazin-3-yl)hydrazino] -karb onyl} -oktyl)-formamid.
MH+ = 361.
Eksempel 103
N-hydroksy-N-[(2R)-2-({N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino}-karbonyl)-oktyl] -formamid.
MH+ = 391.
Eksempel 104
N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarboiiyl]-heptyl} -formamid.
MH+ = 361.
Eksempel 105
N-{(R)-2- [N '-(6-klor-benzo [1,2,4] triazin-3-yl)-hydrazinokarbonyl] -heptyl}-N-hydroksy-formamid.
MH+ = 381.
Eksempel 106
N-hydroksy-N-{(R)-2- [N'-(5-metoksy-benzo [1,2,4] triazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 377.
Eksempel 107
N-hydroksy-N-{(R)-2-[N'-(l-metyl-2-okso-l,2-dihydro-pyridin-4-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 325.
Eksempel 108
N-hydroksy-N-((R)-2-{N'-[(N'-pyridin-2-yl-hydrazino)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 471.
Eksempel 109
N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 395.
Eksempel 110
N-((R)-2-{N'-[4-(4-etyl-piperazin-l-yl)-6-metyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 422.
Eksempel 111
N-{(R)-2-[N'-(4,6-dimetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 324.
Eksempel 112
N-hydroksy-N-{(R)-2-[N'-(4-trifluormetyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 363.
Eksempel 113
N-hydroksy-N-[(R)-2-(N'-isoqkinolin-l-yl-hydrazinokarbonyl)-heptyl]-formamid. MH+ = 345.
Eksempel 114
N-hydroksy-N-[(R)-2-(N'-kinolin-2-yl-hydrazinokarbonyl)-heptyl]-formamid. MH+ = 345.
Eksempel 115
N-{(R)-2- [N '-(l-benzyl-2-okso-l ,2-dihydro-pyridin-4-yl)-hydrazinokarbonyl] - heptyl} -N-hydroksy-formamid.
MH+ = 401.
Eksempel 116
N-hydroksy-N-{(R)-2-[N'-(4-okso-4H-pyrido[l,2-a][l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 363.
Eksempel 117
N-hydroksy-N-{(R)-2-[N'-(4-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 310.
Eksempel 118
N-{(R)-2-[N'-(l-butyl-2-okso-l,2-dihydro-pyridin-4-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 367.
Eksempel 119
N-hydroksy-N-{(R)-2-[N'-(9-metyl-4-okso-4H-pyrido[l,2-a][l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 377.
Eksempel 120
N-hydroksy-N-{(R)-2-[N'-(6-okso-4-trilfuormetyl-l,6-dihydro-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ =380.
Eksempel 121
N-hydroksy-N-{(R)-2-[N'-(metyl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 378.
Eksempel 122
N-hydroksy-N-{(R)-2-[N'-(5-trifluormetyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 363.
Eksempel 123
N-{(R)-2-[N'-(6-etoksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 339.
Eksempel 124
N-hydroksy-N-[(R)-2-(N'-pyrido[2,3-e]-[l,2,4]triazin-3-yl-hydrazinokarbonyl)-heptyl] -formamid.
MH+ = 348.
Eksempel 125
N-((R)-2-{N'-[l-(l-etyl-propyl)-2-okso-l,2-dihydro-pyridin-4-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 381.
Eksempel 126
N-hydroksy-N-((R)-2-{N'-[2-okso-l-(3-trifluormetyl-benzyl)-l,2-dihydro-pyridin-4-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 469.
Eksempel 127
N-hydroksy-N-{(R)-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ =309.
Eksempel 128
N-hydroksy-N-{(R)-2-[N'-(6-metoksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 325.
Eksempel 129
N-hydroksy-N-{(R)-2-[N'-(2-okso-l-kinoUn-8-yl-metyl-l,2-dihydro-pyridin-4-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 452.
Eksempel 130
N-hydroksy-N-[(R)-2-(N'-{2-okso-l-[2-(5,6,7,8-tetrahydro-[l,8]naftyridin-2-yl)-etyl]-dihydro-pyridin-4-yl}-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 471.
Eksempel 131
N-{(R)-2-[N'-(4,6-bis-etylamino-[l,3»5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 383.
Eksempel 132
N-{(R)-2- [N '-(bis-dimetylamino- [1,3,5] triazin-2-yl)-hydrazinokarbonyl] -heptyl}-N-hydroksy-formamid.
MH+ =383.
Eksempel 133
N-{(R)-2-[N'-(4,6-di-morfoUn-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 467.
Eksempel 134
N-hydroksy-N-((R)-2-{N'-[4-(4-metyl-piperazin-l-yl)-6-propylamino-[l,3»5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 452.
Eksempel 135
N-{(R)-2-[N'-(dimetylamino-morfolin-4-yl-[l,3»5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 425.
Eksempel 136
N-hydroksy-N-{(R)-2-[N'-(6-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 309.
Eksempel 137
N-hydroksy-N-((R)-2-{N'-[5-(5-fenyl-[l,3,4]oksadiazol-2-yl)-pyridin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 439.
Eksempel 138
N-{(R)-2-[N'-(7-tert-butyl-l,4-diokso-l,2,3,4-tetrahydro-pyrido[3,4-d]pyridazin-5-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 435.
Eksempel 139
N-((R)-2-{N'-[4-etylamino-6-(4-metyl-[l,4]diazepan-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 452.
Eksempel 140
N-((R)-2-{N'-[4-etylamino-6-(4-etyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 452.
Eksempel 141
N-hydroksy-N-{(R)-2-[N'-(6-trifluormetyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 363.
Eksempel 142
N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-morfolin-4-yl-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 409.
Eksempel 143
N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 396.
Eksempel 144
N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(4,6-dimetyl-2-pyrimidinyl)-hydrazino]-3-oksopropyl}-formamid.
MH+ = 336.
Eksempel 145
N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-pyrrolidin-l-yl-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 393.
Eksempel 146
N-{(R)-2-[N'-(4-dimetylaminometyl-6-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 367.
Eksempel 147
N-hydroksy-N-((R)-2-{N'-[4-metyl-6-(4-metyl-piperazin-l-yl-metyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 422.
Eksempel 148
N-hydroksy-N-{(R)-2-[N'-(5-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 309.
Eksempel 149
N-((R)-2-{N'-[dimetylamino-(4-metyl-[l,4]diazepan-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 452.
Eksempel 150
N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-pyrroUdin-l-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 380.
Eksempel 151
N-hydroksy-N-((R)-2-{N'-[4-metyl-6-pyrroKdin-l-yl-piperidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 463.
Eksempel 152
N-((R)-2-{N'-[(etyl-metyl-amino)-metyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 368.
Eksempel 153
N-((R)-2-{N'-[(4-(4-etyl-piperazin-l-yl)-6-metyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 423.
Eksempel 154
N-hydroksy-N-[(2R)-7,7,7-trinuor-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 418.
Eksempel 155
N-hydroksy-N-((2R)-7,7,7-trinuor-2-{[N'-(5-metyl-l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-heptyl)-formamid.
MH+ = 415.
Eksempel 156
N-hydroksy-N-((2R)-7,7,7-trinuor-2-{[N'-(7-metyl-l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-heptyl)-formamid.
MH+ = 415.
Eksempel 157
N-hydroksy-N-{(R)-2-[N'-(4-metylamino-6-morfolin-4-yl-[l,3,5]-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 411.
Eksempel 158
N-((R)-2-{N'-[4-(4-etyl-piperazin-l-yl)-6-metylamino-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+=438.
Eksempel 159
N-{(R)-2-[N'-(4-etylamino-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 425.
Eksempel 160
N-hydroksy-N-{(R)-2-[N'-(4,6,7-trimetyl-7,-dihydro-pterin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 392.
Eksempel 161
N-hydroksy-N-{(R)-2-[N'-(4,6,7-trimetyl-pteridin-2-yl)-hydraziiiokarboiiyl]-heptyl} -formamid.
MH+ = 390.
Eksempel 162
N-hydroksy-N-{(R)-2-[N'-(metoksymetoksymetyl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 438.
Eksempel 163
N-hydroksy-N-((R)-2-{N'-[4-metyl-6-(l-piperidin-2-yl-metanoyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 421.
Eksempel 164
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptaiioyl}-hydrazino)-6-metyl-pyrimidin-4-karboksylsyre cyklopropylamid.
MH+ = 393.
Eksempel 165
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-6-metyl-pyrimidin-4-karboksylsyre diisopropylamid.
MH+ = 437.
Eksempel 166
N-{(R)-2-[N'-(5-cyano-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 320.
Eksempel 167
N-{(R)-2-[N'-(4,6-dietyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 353.
Eksempel 168
N-{(R)-4-cyklopentyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarboiiyl]-butyl}-N-hydroksy-formamid.
MH+ = 390.
Eksempel 169
N-{(R)-4-cyklopentyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-butyl}-N-hydroksy-formamid.
MH+ = 387.
Eksempel 170
N-{(R)-4-cyklopentyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-butyl}-N-hydroksy-formamid.
MH+ = 387.
Eksempel 171
N-hydroksy-N-((R)-2-{N'-[6-(4-metyl-piperazin-l-yl-metyl)-pyridin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 407.
Eksempel 172
N-((R)-2-{N'-[5-(4,6-dimetoksy-pyrimidin-2-yl)-pyridin-2-yl]-hydrazinonkarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 433.
Eksempel 173
N-{(R)-2-[N'-(dietylamino-metyl-[l,3»5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 382.
Eksempel 174
N-hydroksy-N-[(R)-2-(N'-{[(2-metoksy-etyl)-metyl-amino]-metyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 397.
Eksempel 175
N-((R)-l-{N'-[4-(2,6-dimetyl-morfoUn-4-yl)-6-metyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 424.
Eksempel 176
N-{(R)-2- [N '-(5-fluor-4-metyl-6-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 413.
Eksempel 177
N-{(R)-2- [N '-(4-etyl-6-morfolin-4-yl-[l ,3,5] triazin-2-yl)-hydrazinokarbonyl] - heptyl} -N-hydroksy-formamid.
MH+ = 410.
Eksempel 178
N-{(R)-2-[N'-(etyl-metyl-amino)-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 382.
Eksempel 179
N-((R)-2-{N'-[4-etyl-6-(4-etyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 437.
Eksempel 180
N-((R)-2-{N'-[5-fluor-4-metyl-6-(4-metyl-piperazin-l-yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 426.
Eksempel 181
N-{(R)-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 368.
Eksempel 182
N-((R)-2-{N'-[5-nuor-4-metyl-6-(4-metyl-[l,4]diazepan-l-yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 440.
Eksempel 183
N-{(R)-4-cyklopentyl-2-[N'-(morfolin-4-yl-trinuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-butyl}-N-hydroksy-formamid.
MH+ = 475.
Eksempel 184
N-[(R)-2-(N'-{etyl-[(2-metoksy-etyl)-metyl-amino]-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid.
MH+ = 412.
Eksempel 185
N-{(R)-2-[N'-(dimetylamino-metyl-pyrimidiii-2-yl)-hydrazinokarboiiyl]-heptyl}-N-hydroksy-formamid.
MH+ = 353.
Eksempel 186
N-{(R)-2- [N '-(4-cyklopropylamino-6-metyl-pyrimidin-2-yl)-hydrazinokarbonyl] - heptyl} -N-hydroksy-formamid.
MH+ = 365.
Eksempel 187
N-{(R)-2-cykloheksyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid.
MH+ = 376.
Eksempel 188
N-{(R)-2-cykloheksyl-2-[N'-(7-metoksy-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl] -etyl} -N-hydroksy-formamid.
MH+ = 389.
Eksempel 189
N-{(R)-2-cykloheksyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid.
MH+ = 373.
Eksempel 190
N-{(R)-4,4-dimetyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-pentyl} -N-hydroksy-formamid.
MH+ = 364.
Eksempel 191
N-{(R)-4,4-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-pentyl} -N-hydroksy-formamid.
MH+ = 361.
Eksempel 192
N-{(R)-4,4-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-pentyl} -N-hydroksy-formamid.
MH+ = 361.
Eksempel 193
N-{(R)-4,4-dimetyl-2-[N'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-pentyl}-N-hydroksy-formamid.
MH+ = 449.
Eksempel 194
N-((R)-2-{N'-[etyl-(metyl-pyridin-2-yl-amino)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 431.
Eksempel 195
N-{(R)-2-[N'-(4-cyklopropylamino-6-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 380.
Eksempel 196
N-hydroksy-N-[(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-3-(l-metyl-cyklopentyl)-propyl]-formamid.
MH+ = 387.
Eksempel 197
N-hydroksy-N-[(R)-2- [N'-(7-metoksy-benzo [1,2,4] triazin-3-yl)-hydrazinokarbonyl]-3-(l-metyl-cyklopentyl)-propyl]-formamid.
MH+ = 403.
Eksempel 198
N-hydroksy-N-{(R)-3-(l-metyl-cyklopentyl)-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-propyl}-formamid.
MH+ = 390.
Eksempel 199
N-hydroksy-N-{(R)-2-[N'-(4-isopropyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ =424.
Eksempel 200
N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(4-metyl-2-pyrimidinyl)-hydrazino]-3-oksopropyl}-formamid.
MH+ = 322.
Eksempel 201
N-hydroksy-N-[(2R)-6,6,6-trinuor-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heksyl]-formamid.
MH+ = 404.
Eksempel 202
N-{(R)-2-[N'-(5,7-dimetyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 375.
Eksempel 203
N-{(R)-2-[N'-(3,6-dimetyl-pyrazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 324.
Eksempel 204
N-((R)-2-{N'-[4-(4-etyl-piperazin-l-yl)-6-isopropyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 451.
Eksempel 205
N-{(R)-2-[N'-(4-dimetylamino-6-isopropyl-[l,3»5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 382.
Eksempel 206
N-hydroksy-N-{(R)-2-[N'-(metyl-trifluormetyl-pyridiii-2-yl)-hydrazinokarboiiyl]-heptyl} -formamid.
MH+ = 377.
Eksempel 207
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-6,N,N-trimetyl-isonikotinamid.
MH+ = 380.
Eksempel 208
N-hydroksy-N- [(2R)-2-({N'- [3-amino-6-(trifluormetyl)-pyridin-2-yl] -hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 378.
Eksempel 209
N-hydroksy-N-[(R)-2-(N'-{4-isopropyl-6-[(2-metoksy-etyl)-metyl-amino]-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 426.
Eksempel 210
N-{(R)-3-cyklopentyl-2-[N'-(4-etyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid.
MH+ = 422.
Eksempel 211
N-hydroksy-N-{(R)-2-[N'-(4-morfolin-4-yl-6-propyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 424.
Eksempel 212
N-((R)-2-{N'-[4-(4-etyl-piperazin-l-yl)-6-propyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 451.
Eksempel 213
N-{(R)-5,5-dimetyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 378.
Eksempel 214
N-{(R)-5,5-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 375.
Eksempel 215
N-{(R)-5,5-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 375.
Eksempel 216
N-{(R)-5,5-dimetyl-2-[N'-(morfolin-4-yl-trinuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 463.
Eksempel 217
N-{(R)-4-etyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazino-karbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 378.
Eksempel 218
N-{(R)-4-etyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 375.
Eksempel 219
N-{(R)-4-etyl-2-[N'-(morfoKn-4-yl-trinuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 463.
Eksempel 220
N-((R)-3-cyklopentyl-2-{N-[4-etyl-6-(4-etyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-propyl)-N-hydroksy-formamid.
MH+ = 449.
Eksempel 221
N-{(R)-3-cyklopentyl-2-[N'-(4-cyklopropylamino-6-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid.
MH+ = 392.
Eksempel 222
N-{(R)-4-etyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 375.
Eksempel 223
N-hydroksy-N-{(R)-2-(N'-{[(2-metoksy-etyl)-metyl-amino]-propyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 426.
Eksempel 224
N-{(R)-2-[N'-(dimetylamino-propyl-[l,3»5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 382.
Eksempel 225
N-{(R)-2-[N'-(4-etyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 324.
Eksempel 226
N-hydroksy-N-{(R)-2-[N'-(4-isopropyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 338.
Eksempel 227
N-{(R)-2-[N'-(4-cyklopropyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 422.
Eksempel 228
N-hydroksy-N-[(2R)-2-({N'-[4-(pyridin-2-yl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 373.
Eksempel 229
N-((R)-2-{N'-[4-cyklopropyl-6-(4-etyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 449.
Eksempel 230
N-{(R)-2- [N '-(cyklopropyl-dimetylamino-[l ,3»5] triazin-2-yl)-hydrazinokarbonyl] - heptyl} -N-hydroksy-formamid.
MH+ = 380.
Eksempel 231
N-((R)-2-{N'-[cyklopropyl-(etyl-metyl-amino)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 394.
Eksempel 232
N-{(R)-2-[N'-(4-cyklopropyl-6-pyrrolidin-l-yl[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 406.
Eksempel 233
N-{(R)-2-[N'-(4,6-dicyklopropyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 377.
Eksempel 234
N-hydroksy-N-[(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-3-(2-metyl-cyklopentyl)-propyl]-formamid.
MH+ = 387.
Eksempel 235
N-[(R)-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-3-(2-metyl-cyklopentyl)-propyl]-N-hydroksy-formamid.
MH+ = 394.
Eksempel 236
N-hydroksy-N-[(R)-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-3-(2-metyl-cyklopentyl)-propyl]-formamid.
MH+ = 390.
Eksempel 237
N-{(R)-2-[N'-(5-etyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 324.
Eksempel 238
N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(7-metyl-l,2,4-benzotriazin-3-yl)-hydrazino]-3-oksopropyl}-formamid.
MH+ = 373.
Eksempel 239
N-hydroksy-N-[(2R)-2-(cyklopentylmetyl)-3-(N'-{4-etyl-6-[etyl(metyl)amino]-l,3,5-triazin-2-yl}-hydrazino)-3-oksopropyl]-formamid.
MH+ = 394.
Eksempel 240
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-(dimetylamino)-6-etyl-l,3,5-triazin-2-yl]-hydrazino}-3-oksopropyl)-formamid.
MH+ = 380.
Eksempel 241
N-((R)-2-{N'-[4-etyl-6-(4-isopropyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 451.
Eksempel 242
N-hydroksy-N-[(2R)-3-[N'-(6-klor-l,2,4-benzotriazin-3-yl)-hydrazino]-2-(cyklopentylmetyl)-3-oksopropyl]-formamid.
MH+ = 393.
Eksempel 243
N-{(R)-4,4-dimetyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 378.
Eksempel 244
N-{(R)-4,4-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 375.
Eksempel 245
N-{(R)-4,4-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 375.
Eksempel 246
N-{(R)-4,4-dimetyl-2-[N'-(morfolin-4-yl-trilfuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid.
MH+ = 463.
Eksempel 247
N-hydroksy-N- {(R)-2- [N '-(5-fenyl- [1,2,4] triazin-3-yl)-hydrazinokarb onyl] -hep tyl}-formamid.
MH+ = 373.
Eksempel 248
N-{(R)-2-[N'-(4-etyl-6-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 409.
Eksempel 249
N-((R)-2-{N'-[4-etyl-6-(4-metyl-piperazin-l-yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 422.
Eksempel 250
N-{(R)-2-[N'-(5-etyl-4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 338.
Eksempel 251
N-((R)-2-{N'-[4-etyl-6-(4-propyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 451.
Eksempel 252
N-hydroksy-N-((R)-2-{N'-[6-(4-pyrimidin-2-yl-piperazin-l-yl-metyl)-pyridin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 471.
Eksempel 253
N-hydroksy-N-((R)-2-{N'-[6-(3-[l,2,4]triazol-l-yl-metyl-[l,2,4]triazol-l-yl)-pyridin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 443.
Eksempel 254
N-{(R)-3-bicyklo[2,2,l]hept-7-yl-2-[N'-(4-trilfuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid.
MH+ = 402.
Eksempel 255
N-{(R)-3-bicyklo[2,2,l]hept-7-yl-2-[N'-(morfoUn-4-yl-trinuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid.
MH+ = 487.
Eksempel 256
N-hydroksy-N-[(R)-2-(N'-pyridin-3-yl-hydrazinokarbonyl)-heptyl]-formamid. MH+ = 295.
Eksempel 257
4-{4-etyl-6-[2-((2R)-2-{[formyl(hydroksy)amino]-metyl}-heptanoyl)-hydrazino]-l,3,5-triazin-2-yl}-l-metyl-l-propylpiperazin-l-iumjodid.
MH+ = 465.
Eksempel 258
N-{(R)-3-bicyklo[2,2,l]hept-7-yl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid.
MH+ = 399.
Eksempel 259
N-{(R)-2-[N'-(4-azetidin-l-yl-6-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 380.
Eksempel 260
N-{(R)-2-cyklopentyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid.
MH+ = 362.
Eksempel 261
N-{(R)-2-cyklopentyl-2-[N'-(morfolin-4-yl-4-trinuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl] -etyl} -N-hydroksy-formamid.
MH+ = 447.
Eksempel 262
N-{(R)-2-cyklopentyl-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid.
MH+ = 307.
Eksempel 263
N-{(R)-2-cyklopentyl-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl] -etyl} -N-hydroksy-formamid.
MH+ = 366.
Eksempel 264
N-{(R)-2-cyklopentyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid.
MH+ = 359.
Eksempel 265
N-{(R)-2-cyklopentyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid.
MH+ = 359.
Eksempel 266
N-hydroksy-N-{(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl}-formamid.
MH+ = 387.
Eksempel 267
N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarboiiyl]-2-(4-metyl-cykloheksyl)-etyl}-formamid.
MH+ = 387.
Eksempel 268
N-hydroksy-N-{(R)-2-(4-metyl-cykloheksyl)-2-[N'-(4-trinuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-formamid.
MH+ = 390.
Eksempel 269
N-hydroksy-N-{(R)-2-(4-metyl-cykloheksyl)-2-[N'-(morfolin-4-yl-trilfuormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-formamid.
MH+ = 475.
Eksempel 270
N-hydroksy-N-{(R)-2-(4-metyl-cykloheksyl)-2-[N'-(4-metyl-pyridin-2-yl)-hy drazinokarbonyl] -etyl} -f orm amid.
MH+ = 335.
Eksempel 271
N-{(R)-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl}-N-hydroksy-formamid.
MH+ = 394.
Eksempel 272
N-{(R)-2- [N '-(6,7-dihydro-5H-cyklopentapyrimidin-2-yl)-hydrazinokarbonyl] - heptyl} -N-hydroksy-formamid.
MH+ = 336.
Eksempel 273
N-((R)-2-[N'-[4-etyl-6-((S)-2-hydroksymetyl-pyrrolidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl]-heptyl)-N-hydroksy-formamid.
MH+ = 424.
Eksempel 274
N-{(R)-2-[N'-(dimetylamino-pyridin-3-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 416.
Eksempel 275
N-{(R)-2-[N'-(dimetylamino-pyridin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 416.
Eksempel 276
N-hydroksy-N-{(R)-2-N'-(5,6,7,8-tetrahydro-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 351.
Eksempel 277
N-{(R)-2-[N'-(5,6-dihydro-[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 353.
Eksempel 278
N-hydroksy-N-{(R)-2-[N'-[5-(4-hydroksy-fenyl)-[l,2,4]triazin-3-yl]-hydrazinokarbonyl}-heptyl]-formamid.
MH+ = 389.
Eksempel 279
N-[(R)-2-(N'-{[(2-dimetylamino-etyl)-metyl-amino]-etyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid.
MH+ = 425.
Eksempel 280
N-{(R)-2-[N'-(2-dimetylamino-kinazolin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 389.
Eksempel 281
N-hydroksy-N-{(R)-2-[N'-(3-metansulfonyl-4,6-dimetyl-pyridiii-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 401.
Eksempel 282
N-((R)-2-{N'-[4-etyl-6-(3-hydroksy-piperidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 424.
Eksempel 283
N-[(R)-2-(N'-[4,5']bipyrimidinyl-2-yl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid.
MH+ = 374.
Eksempel 284
N-((R)-2-{N'-[(cyklopropyl-metyl-amino)-etyl-[l,3,5]triaziii-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 394.
Eksempel 285
N-((R)-2-{N'-[4-etyl-6-((R)-3-hydroksy-pyrrolidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 410.
Eksempel 286
N-hydroksy-N-[(R)-2-(N'-[3,3']bipyridinyl-5-yl-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 372.
Eksempel 287
N-hydroksy-N-[(R)-2-(N'-(5-morfolin-4-yl-pyridin-3-yl)-hydrazinokarbonyl)-heptyl] -formamid.
MH+ = 380.
Eksempel 288
N-hydroksy-N-{(R)-2-[N'-(4-pyridin-3-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 373.
Eksempel 289
N-hydroksy-N-{(R)-2-[N'-(5,6,7,8-tetrahydro-kinazolin-2-yl)-hydrazinokarbonyl]-heptylj-formamid.
MH+ = 350.
Eksempel 290
N-[(R)-2-(N'-{[cyklopropyl-l-(l-metyl-piperidin-4-yl)-amino]-etyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid.
MH+ = 477.
Eksempel 291
N-((R)-2-{N'-[4-((R)-3-dimetylamino-pyrrolidin-l-yl)-6-etyl-[l,3,5]triaziii-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 437.
Eksempel 292
N-hydroksy-N-[(R)-2-(N'-[5-(lH-pyrrol-2-yl)-pyridin-3-yl]-hydrazinokarbonyl)-heptyl] -formamid.
MH+ = 360.
Eksempel 293
N-hydroksy-N-[(R)-2-(N'-[(4-metyl-piperazin-l-yl)-trifluormetyl-pyrimidin-4-yl]-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 462.
Eksempel 294
N-hydroksy-N-[(R)-2-(N'-(5-furan-3-yl-pyridin-3-yl)-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 361.
Eksempel 295
N-{(R)-5,5-dimetyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 392.
Eksempel 296
N-{(R)-5,5-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 389.
Eksempel 297
N-{(R)-5,5-dimetyl-2-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 337.
Eksempel 298
N-{(R)-2-cykloheptyl-2-[N'-(4-trifluormetyl-pyrimidiii-2-yl)-hydrazinokarboiiyl]-etyl}-N-hydroksy-formamid.
MH+ = 390.
Eksempel 299
N-{(R)-2-cykloheptyl-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid.
MH+ = 335.
Eksempel 300
N-{(R)-2-cykloheptyl-2-[N '-(dimetylamino-etyl- [1,3,5] triazin-2-yl)-hydrazinokarbonyl] -etyl} -N-hydroksy-formamid.
MH+ = 394.
Eksempel 301
N-{(R)-2-cykloheptyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid.
MH+ = 387.
Eksempel 302
N-((R)-2-{N'-[4-etyl-6-(4-hydroksy-piperidin-l-yl)-[l,3,5]triaziii-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 424.
Eksempel 303
N-{(R)-5,5-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 389.
Eksempel 304
N-{(R)-2-[N'-(4-dimetylamino-kinazolin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 389.
Eksempel 305
N-hydroksy-N-{(R)-2-[N'-(4-pyridin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+ = 373.
Eksempel 306
N-hydroksy-N-((R)-2-{N'-[4-(3-hydroksymetyl-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 402.
Eksempel 307
N-hydroksy-N-((R)-2-{N'-[4-(4-hydroksymetyl-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 402.
Eksempel 308
N-((R)-2-{N'-[4-etyl-6-(3-metoksy-piperidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 438.
Eksempel 309
N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarboiiyl]-2-(4-metyl-cykloheksyl)-etyl}-formamid.
MH+ = 387.
Eksempel 310
N-[(R)-2-{N'-[etyl-(etyl-metylamino)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-2-(4-metyl-cykloheksyl)-etyl}-N-hydroksy-formamid.
MH+ = 408.
Eksempel 311
N-[(R)-2-{N'-[etyl-(etyl-metylamino)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-2-(4-metyl-cykloheksyl)-etyl}-N-hydroksy-formamid.
MH+ = 408.
Eksempel 312
N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarboiiyl]-2-(4-metyl-cykloheksyl)-etyl}-formamid.
MH+ = 387.
Eksempel 313
N-((R)-2-{N'-[4-(2,6-dimetoksy-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 432.
Eksempel 314
N-((R)-2-{N'-[4-etyl-6-((R)-3-metoksy-pyrrolidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 424.
Eksempel 315
N-((R)-2-{N'-[4-etyl-6-(4-metoksy-piperidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 438.
Eksempel 316
N-hydroksy-N-[(R)-2-(N'-(6-pyrrolidin-l-yl-pyrimidin-4-yl)-hydrazinokarbonyl)-heptyl] -formamid.
MH+ = 365.
Eksempel 317
N-hydroksy-N-[(R)-2-(N'-[6-(4-metyl-piperazin-l-yl)-pyrimidin-4-yl])-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 394.
Eksempel 318
N-{(R)-2-[N'-(6-dimetylamino-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 339.
Eksempel 319
N-{(R)-2-[N'-(pyridin-4-yl-trifluormetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 441.
Eksempel 320
N-{(R)-2-[N'-(pyridin-3-yl-trifluormetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 441.
Eksempel 321
N-{(R)-2- [N '-(2-etylamino-6-trifluormetyl-pyrimidin-4-yl)-hydrazinokarbonyl] - heptyl} -N-hydroksy-formamid.
MH+ = 407.
Eksempel 322
N-hydroksy-N-((R)-2-{N'-[5-(4-metoksy-fenyl)-[l,2,4]triazin-3-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 403.
Eksempel 323
N-hydroksy-N-((R)-2-{N'-[4-(2,3,4-trimetoksy-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid.
MH+ = 462.
Eksempel 324
N-{(R)-4,4-dimetyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 392.
Eksempel 325
N-{(R)-4,4-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 389.
Eksempel 326
N-{(R)-4,4-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ = 389.
Eksempel 327
N-{(R)-4,4-dimetyl-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 337.
Eksempel 328
N-hydroksy-N-{(R)-2-[N'-(6-morfolin-4-yl-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 381.
Eksempel 329
N-hydroksy-N-[(R)-2-(N'-{5-[4-(2-hydroksy-etoksy)-fenyl]-[l,2,4]triazin-3-yl}-hydrazinokarbonyl)-heptyl]-formamid.
MH+ = 433.
Eksempel 330
N-{(R)-2-[N'-(4-furan-2-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ = 362.
Eksempel 331
N-((R)-2-{N'-[4-(3,5-dimetyl-isoksazol-4-yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ = 391.
Eksempel 332
N-hydroksy-N-{(R)-2-[N'-(4-metyl-oksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 325.
Eksempel 333
2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-6-metyl-nikotinsyre.
MH+ = 353.
Eksempel 334
N-hydroksy-N-{(R)-2-[N'-(3-metoksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ = 325.
Eksempel 335
N-hydroksy-N-{(2R)-2-[(N'-{4-[4-(metylsulfonyl)fenyl]-pyrimidin-2-yl}-hydrazino)-karbonyl]-heptyl}-formamid.
MH+ = 450.
Eksempel 336
N-hydroksy-N-[(2R)-2-({N'-[4-(furan-3-yl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl] -formamid.
MH+ = 362.
Eksempel 337
N- [(2R)-2-( {N'- [4-(2-aminofenyl)-pyrimidin-2-yl] -hydrazino} -karbonyl)-hepty 1] -N-hydroksy-formamid.
MH+ = 387.
Eksempel 338
N-hydroksy-N-[(2R)-2-({N'-[5-(5-metyl-l,3,4-oksadiazol-2-yl)-4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 446.
Eksempel 339
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[5-(5-metyl-l,3,4-oksadiazol-2-yl)-4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-3-oksopropyl)-formamid.
MH+ = 458.
Eksempel 340
N-[(2R)-2-({N'-[6-(dimetylamino)-2-metyl-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl] -N-hydroksy-formamid.
MH+ = 353.
Eksempel 341
N-[(2R)-2-({N'-[2-cyklopropyl-6-(dimetylamino)-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl]-N-hydroksy-formamid.
MH+ = 379.
Eksempel 342
N-hydroksy-N-[(2R)-4-(2-tienyl)-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-butyl]-formamid.
MH+ = 404.
Eksempmel 343
N-hydroksy-N-[(2R)-2-{[N'-(4-metyl-pyrimidin-2-yl)-hydrazino]karbonyl}-4-(2-tienyl)-butyl] -formamid.
MH+ = 350.
Eksempel 344 N-[(2R)-2-[(N'-{4-etyl-6-[etyl(metyl)amino]-l,3,5-triazin-2-yl}-hydrazino)-karbonyl]-4-(2-tienyl)butyl]-N-hydroksy-formamid.
MH+ = 422.
Eksempel 345
N-hydroksy-N-((2R)-3-okso-2-(2-tienylmetyl)-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl] -hydrazino} -p ropyl)-formamid.
MH+ = 390.
Eksempel 346
N-hydroksy-N-[(2R)-3-[N'-(4-metyl-pyrimidin-2-yl)hydrazino]-3-okso-2-(2-tienylmetyl)-propyl] -formamid.
MH+ = 336.
Eksempel 347
N-[(2R)-3-(N'-{4-etyl-6-[etyl(metyl)amino]-l,3,5-triazin-2-yl}-hydrazino)-3-okso-2-(2-tienylmetyl)-propyl]-N-hydroksy-formamid.
MH+ = 408.
Eksempel 348
N-hydroksy-N-[(2R)-2-({N'-[2-metyl-6-(pyridin-2-yl)-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 387.
Eksempel 349
N-hydroksy-N-[(2R)-2-({N'-[6-(pyridin-2-yl-metyl)-pyridazin-3-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 387.
Eksempel 350
N-hydroksy-N-[(2R)-2-({N'-[2-metyl-6-(morfolin-4-yl)-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 395.
Eksempel 351
N-hydroksy-N-[(2R)-2-({N'-[6-(morfolin-4-yl)-2-(trinuormetyl)-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl]-formamid.
MH+ = 449.
Eksempel 352
N-hydroksy-N-{(2R)-2-[(N'-{4-[metyl-(pyridin-2-yl)-amino]-pyrimidin-2-yl}-hydrazino)-karbonyl]-heptyl}-formamid.
MH+ = 402.
Eksempel 353
N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-cyklopropyl-6-(dimetylamino)-l,3,5-triazin-2-yl]-hydrazino}-3-3-oksopropyl)-formamid.
MH+ = 392.
Fremstilling 19
(l,3-diokso-l,3-dihydro-isoindol-2-yl)-karbaminsyre tert-butylester Til en løsning av tert-butylkarbazat (5,15 g, 38,97 mmol) og ftalsyreanhydrid (5,77 g, 38,97 mmol) ble det tilsatt CHC13(70 ml). Reaksjonsblandingen ble refluksert i 18 timer. Fjerning av løsemidlet under redusert trykk ga 8,20 g (80%) av tittelforbindelsen som et hvitt fast stoff.
MH+263.
Fremstilling 20
Benzo[l,3]dioksol-5-yl-metyl-(l,3-diokso-l,3-dihydro-isoindol-2-yl)-karbaminsyre dimetyl-etylester
Til en løsning av (l,3-diokso-l,3-dihydro-isoindol-2-yl)-karbaminsyre tert-butylester (0,31 g, 1,18 mmol), piperonylalkohol (0,18 g, 1,18 mmol) og trifenylfosfin (0,40 g, 1,54 mmol) i THF (12 ml) ble det ved 0°C dråpevis tilsatt diisopropylazodikarboksylat (0,30 ml, 1,54 mmol). Reaksjonsblandingen ble omrørt og varmet til romtemperatur over natten. Fjerning av løsemidlet under redusert trykk, fulgt av rensing med HPLC ga 0,28 g (60%) av tittelforbindelsen.
MH+ 397.
Fremstilling 21
N-benzo [1,3] dioksol-5-yl-metyl-hydrazinkarboksylsyre tert-butylester
Til N-benzo[l ,3]dioksol-5-yl-metyl-(l ,3-diokso-l ,3-dihydro-isoindol-2-yl)-karbaminsyre dimetyl-etylester (0,28 g, 0,71 mmol) i EtOH (3,6 ml) ble det tilsatt hydrazinmonohydrat (0,14 ml, 2,84 mmol) i en porsjon ved romtemperatur. Reaksjonsblandingen ble omrørt i 21 timer. Toluen (5 ml) ble tilsatt til blandingen og det hvite faste stoffet ble samlet opp ved filtrering. Filtratet ble fordampet i vakuum. Ytterligere henstand under høyvakuum ga 0,17 g (89%) av tittelforbindelsen.
MH+ 267.
Fremstilling 22
N-benzo [1,3] dioksol-4-yl-metyl-N'- {(R)-2- [(benzyloksy-formyl-amino)-metyl] - heptanoyl}-hydrazinkarboksylsyre tert-butylester
Til en blanding av N-benzo[l,3]dioksol-5-yl-metyl-hydrazinkarboksylsyre tert-butylester (168 mg, 0,32 mmol), (R)-2-[(benzyloksy-formyl-amino)-metyl]-heptansyre (185 mg, 0,632 mmol), 4-dimetylaminopyridin (100 mg, 0,822 mmol) i metylenklorid
(7 ml) ble det tilsatt l-(3-dimetylaminopropyl)-3-etylkarbodiimid hydroklorid (158 mg, 0,822 mmol) ved romtemperatur. Reaksjonsblandingen ble rørt i 19 timer ved romtemperatur og deretter behandlet med vandig IN HCl-løsning. Separasjon av det organiske sjiktet, tørking over vannfri MgS04og fjerning av løsemidlet ga tittelforbindelsen. Ingen ytterligere rensing var påkrevet.
MH+ 542.
Fremstilling 23
N-[(R)-2-(N'-benzo[l,3]dioksol-5-yl-metyl-hydrazinokarbonyl)-heptyl]-N-benzyloksy-formamid
Til urent N-benzo[ 1,3]dioksol-4-ylmetyl-N'- {R-2-[(benzyloksy-formyl-amino)-metyl]-heptanoyl}-hydrazinkarboksylsyre tert-butylester oppnådd i fremstilling 12, ble det tilsatt 5% TFA i metylendiklorid (20 ml) ved romtemperatur. Den resulterende løsningen ble omrørt i 6 timer og deretter vasket med mettet, vandig NaHC03-løsning (20 ml x 3). Det organiske sjiktet ble separert og tørket (MgS04). Filtrering og fordamping ga tittelforbindelsen (0,221 g, 79% i to trinn).
MH+ 442.
Eksempel 354
N-[(R)-2-(N'-benzo[l,3]dioksol-5-yl-metyl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid
Til en løsning av N-[(R)-2-(N'-benzo[l,3]dioksol-5-yl-metyl-hydrazinkarbonyl)-heptyl]-N-benzyloksy-formamid (0,221 g, 0,501 mmol) i EtOH (10 ml) ble det tilsatt 10% Pd/C (50 mg). Blandingen ble hydrogenert i 5 timer ved romtemperatur. Blandingen ble filtrert gjennom celitt. Filtratet ble fordampet og renset ved HPLC hvilket ga tittelforbindelsen (0,10 g, 57%) som et hvitt fast stoff.
MH+ 352.
Eksempel 355
N-{(R)-2-[N'-(2,3-dihydro-[l,4]dioksino[2,3-b]pyridin-7-yl-metyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ 366.
Eksempel 356
N-{(R)-2-[N'-(4-dimetylamino-benzyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+351.
Eksempel 357
N-hydroksy-N-((R)-2-{N'-[2-(5,6,7,8-tetrahydro-[l,8]naftyridin-2-yl)-etyl]-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ 378.
Eksempel 358
N-hydroksy-N-[(R)-2-(N'-kinolin-2-yl-metyl-hydrazinokarbonyl)-heptyl]-formamid.
MH+ 359.
Eksempel 359
N-hydroksy-N-{(R)-2-[N'-(l,2,3,4-tetrahydro-kinolin-2-yl-metyl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+363.
Eksempel 360
N-hydroksy-N-[(R)-2-(N'-kinoUn-6-yl-metyl-hydrazinokarbonyl)-heptyl]-formamid.
MH+ 359.
Eksempel 361
N-[(R)-2-(N'-benzofuran-2-yl-metyl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid.
MH+ 348.
Eksempel 362
N-[(R)-2-(N'-cyklopropylmetyl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid.
MH+ 272.
Eksempel 363
N-{(R)-2-[N'-(6-fluor-4H-benzo[l,3]dioksin-8-yl-metyl)-hydrazinokarboiiyl]-heptyl} -N-hydroksy-formamid.
MH+ 384.
Eksempel 364
N-hydroksy-N-{(R)-2-[N'-(4-metoksy-benzyl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ 338.
Eksempel 365
N-hydroksy-N-{(R)-2-[N'-(2-metoksy-benzyl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ 338.
Eksempel 366
N-hydroksy-N-{(R)-2-[N'-(tetrahydro-furan-3-yl-metyl)-hydrazinokarbonyl]-heptyl}-formamid.
MH+ 302.
Eksempel 367
N-[(R)-2-(N'-furan-3-yl-metyl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid. MH+ 298.
Eksempel 368
N-{(R)-2-[N'-(2,3-dihydro-benzo[l,4]dioksin-6-yl-metyl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ 366.
Eksempel 369
N-{(R)-2-[N'-(2,3-dihydro-benzo[l,4]dioksin-2-yl-metyl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid.
MH+ 366.
Eksempel 370
N-hydroksy-N- {(R)-2- [N '-(2-fenoksy-ety l)-hy drazinokarbonyl] -heptyl} -forma mid. MH+ 338.
Eksempel 371
N-{(R)-2-[N'-((S)-2,3-dihydroksy-propyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
MH+ 292.
Eksempel 372
N-hydroksy-N-{(R)-2-[N'-(5-metyl-isoksazol-3-yl-metyl)-hydrazinokarbonyl]-heptyl} -formamid.
MH+313.
Eksempel 373
N-((R)-2-{N'-[l-(l-benzo[l,3]dioksol-5-yl-metanoyl)-piperidin-4-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ 449.
Eksempel 374
N-((R)-2-{N'-[l-(l-benzofuran-2-yl-metanoyl)-piperidin-4-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid.
MH+ 445.
Eksempel 375
N-hydroksy-N-{(R)-2-(N'-{l-[l-(7-metoksy-benzofuran-2-yl)-metanoyl}-piperidin-4-yl}-hydrazinokarbonyl)-heptyl]-formamid.
MH+ 475.
Eksempel 376
N-{(R)-2-[N'-(l-benzyl-piperidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid.
391.
Eksempel 377
N-[(R)-2-(N'-{l-[l-(3,4-diklor-fenyl)-metanoyl]-piperidin-4-yl}-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid.
MH+ 474.
Eksempel 378
N-[(R)-2-(N'-{l-[l-(2,3-diklor-fenyl)-metanoyl]-piperidin-4-yl}-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid.
MH+ 474.
Eksempel 379
N-hydroksy-N-[(R)-2-(N'-{l-[l-(4-metyl-piperazin-l-yl)-metanoyl]-pentyl}-hydrazinokarbonyl)-heptyl]-formamid.
MH+414.
Fremstilling 24
N-[(R)-2-(hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid Til en løsning av N'-{(R)-2-[(benzyloksyformylamino)metyl]heptanoyl]-hydrazinkarboksylsyre benzylester (1 mmol) i EtOH (10 ml) ble det tilsatt 10% Pd/C (50 mg). Blandingen ble hydrogenert i 5 timer ved romtemperatur og deretter filtrert gjennom celitt. Filtratet ble fordampet og renset med HPLC hvilket ga N-[(R)-2-(hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid som et glass.
MH+218.
Eksempel 380
N-[(R)-2-(N'-benzyl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid. N-[(R)-2-(hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid (50 mg, 0,23 mmol) og benzaldehyd (24 mg, 0,23 mmol) ble løst i metanol (2 ml) under argon under nærvær av 4Å molekylsikt (50 mg), omrørt i 1 time og avkjølt til 0°C. Til blandingen ble det tilsatt en krystall metylorange indikator og tilstrekkelig metanolisk HC1 til å holde løsningen sur (rød farge). Natriumcyanoborhydrid (17 mg, 0,28 mmol) ble tilsatt, sammen med tilstrekkelig metanolisk HC1 for å holde løsningen sur (rød indikator). Systemet ble varmet til romtemperatur,om rørt i to dager, nøytralisert med natriumbikarbonatløsning og ekstrahert med etylacetat (3x). Det organiske sjiktet ble tørket over vannfritt na-triumsulfat, konsentrert til tørrhet og renset med preparativ HPLC hvilket ga tittelforbindelsen.
MH+ 308.
Forbindelser med formel (1) og deres farmasøytisk akseptable salter kan administreres på standard måte for antibiotiske midler, f.eks. oralt, parenteralt, sublingualt, dermalt, transdermalt, rektalt, via inhalering eller via bukkal administrasjon.
Sammensetninger med formel (1) og deres farmasøytisk akseptable salter som er aktive når de gis oralt kan formuleres som siruper, tabletter, kremer og sugetabletter. En sirup-formulering vil generelt bestå av en suspensjon eller løsning av forbindelsen eller salt i en væskebærer f.eks.etanol, peanøttolje, olivenolje, glyserin eller vann med et smaks-eller farvestoff. Hvor sammensetningen er i form av en tablett, kan en hvilken som helst farmasøytisk bærer som rutinemessig anvendes ved fremstilling av passende formuleringer anvendes. Eksempler på slike bærere inkluderer magnesiumstearat, terra alba, talkum, gelatin, akasia, stearinsyre, stivelse, laktose og sukrose. Der sammensetningen er i form av en kapsel, er en hvilken som helst rutinemessig innkapsling egnet, f.eks. anvendelse av ovenfor nevnte bærere i et hardt gelatinkapselskall. Der sammensetningen er i form av en myk gelatinskallkapsel, kan en hvilken som helst farmasøytisk bærer som rutinemessig anvendes for fremstilling av dispersjoner eller suspensjoner anvendes, f.eks. vandige gummier, celluloser, silikater eller oljer, og inkorporeres i et mykt gelatinkapselskall.
Typiske parenterale sammensetninger består av en løsning eller suspensjon av en forbindelse eller et salt i en steril vandig eller ikke-vandig bærer som eventuelt inneholder en parenteralt akseptabel olje, f.eks. polyetylenglykol, polyvinylpyrrolidon, lecitin, ara-cisolje eller sesamolje.
Typiske sammensetninger for inhalering er i form av en løsning, suspensjon eller emul-sjon som kan administreres som et tørt pulver eller i form av en aerosol ved anvendelse av vanlige drivmidler, slik som diklordifluormetan eller triklorfluormetan.
En typisk stikkpilleformulering innbefatter en forbindelse med formel (1) eller et farma-søytisk akseptabelt salt derav som er aktivt når det administreres på denne måten, med binde- og/eller smøremidler, f.eks. polymere glykoler, gelatiner, kakaosmør eller andre lavtsmeltende vegetabilske vokser eller fettstoffer eller deres syntetiske analoger.
Typiske dermale og transdermale formuleringer innbefatter en vanlig vandig- eller ikke-vandig vehikkel, f.eks. en krem, salve, lotion eller pasta eller er i form av et medisinsk plaster eller en membran.
Foretrukket er sammensetningen i enhetsdoseringsform, f.eks. en tablett, kapsel eller oppmålt aerosoldose, slik at pasienten kan administreres dette i en enkelt dose.
Hver doseringsenhet for oral administrasjon inneholder foretrukket fra 0,1 mg til 500 mg/kg, og foretrukket fra 1 mg til 100 mg/kg, og hver doseringsenhet for parenteral administrasjon inneholder foretrukket fra 0,1 mg til 100 mg/kg, av en forbindelse med formel (1) eller et farmasøytisk akseptabelt salt derav, beregnet som den frie syren. Hver doseringsenhet for intranasal administrasjon inneholder egnet 1-400 mg og foretrukket 10-200 mg pr. person. En topisk formulering inneholder egnet 0,01 til 5,0% av en forbindelse med formel (1).
Det daglige doseringsregimet for oral administrasjon er egnet ca. 0,01 mg/kg til 40 mg/kg av en forbindelse med formel (1) eller et farmasøytisk akseptabelt salt derav beregnet som den frie syren. Det dagelige doseringsregimet for en parenteral administrasjon er egnet ca. 0,001 mg/kg til 40 mg/kg av en forbindelse med formel (1) eller et farmasøytisk akseptabelt salt derav beregnet som den frie syren. Det daglige doseringsregimet for intranasal administrasjon og oral inhalering er egnet ca. 10 til ca. 500 mg/person. Den aktive ingrediensen kan administreres fra 1 til 6 ganger daglig, tilstrekkelig til å oppnå ønsket aktivitet.
Ingen uakseptable toksikologiske effekter er forventet når forbindelsen ifølge oppfinnelsen administreres.
Den biologiske aktiviteten til forbindelsene med formel (1) demonstreres ved følgende test:
Biologisk analyse
S. aureus eller E. coli PDF-aktivitet måles ved 25°C ved anvendelse av kontinuerlig
enzymbundet undersøkelse utviklet av Lazennec & Meinnel ("Formåte dehydrogenase-coupled spectrophotometric assay of peptide deformylase", AnaLBiochem. 1997,244, s. 180-182), med mindre modifikasjoner. Reaksjonsblandingen innbefattes i 50 (il med 50 mM kaliumfosfatbuffer (pH 7,6), 15 mM NAD, 0,25 U formatdehydrogenase. Substrat-peptidet, f-Met-Ala-Ser, inkluderes ved KM-konsentrasjonen. Reaksjonen trigges ved tilsetning av 10 nM Defl-enzym og absorbansen måles i 20 minutter ved 340 nm.
Analyse av antimikrobiell aktivitet
Helcelleantimikrobiell aktivitet ble bestemt av buljonmikrofortynning ved anvendelse av "the National Committee for Clinical Laboratory Standards" (NCCLS) anbefalt fremgangsmåte, dokument M7-A4, "Methods for Dilution Susceptibility Tests for Bac-teria that Grow Aerobically". Forbindelsen ble testet i togangers serievise fortynninger som varierte fra 0,06 til 64 mcg/ml. Et panel på 12 stammer ble evaluert i denne under-søkelsen. Dette panelet besto av følgende laboratoriestammer: Staphylococcus aureus Oxford, Staphylococcus aureus WCUH29, Enterococcus faecalis I, Enterococcus faecalis 7, Haemophilus influenzae Ql, Haemophilus influenzae NEMC1, Moraxella catarr-halis 1502, Streptococcus pneumoniae 1629, Streptococcus pneumoniae N1387, Streptococcus pneumoniae N1387, E. coli 7623 (AcrABEFD+) og E. coli 120 (AcrAB-). Minimum inhiberingskonsentrasjon (MIC) ble bestemt som laveste konsentrasjon av forbindelse som inhiberte visuell vekst. En speilavleser ble anvendt for å assistere ved bestemmelse av MIC-sluttpunktet.

Claims (5)

1. Forbindelse,karakterisert vedformel (1):
hvori: R er valgt fra: C2-6alkyl; C2- 6 alkenyl; C2-6alkynyl; eller (CH2)n-C3-6karbocyklus; hvor hver C2-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, (CH2)n-C3^-karbocyklus eventuelt er substituert med Ci-3-alkoksy, halogen eller C1.3alkylsulfanyl eller (CH2)n-R4, hvor R4 er fenyl, furan, benzofuran, tiofen, benzotiofen, tetrahydrofuran, tetrahydropy- ran, dioksan, 1,4-benzodioksan eller benzo[l,3]dioksol; hvor R4 eventuelt er substituert med en eller flere substituenter valgt fra Cl, Br, I, C1.3 alkyl eller C1-2alkoksy; hvor hver Ci-3-alkyl eller Ci-2-alkoksy som definert ovenfor for R4 eventuelt er substituert med ett til tre F-atomer; RI og R2 er uavhengig valgt fra: hydrogen, C1.3substituert alkyl, C2-3substituert alkenyl, C2-3substituert alkylnyl, (CH2)n-C3-6substituert karbocyklus, aryl, heteroaryl og heterocyklisk; hvori aryl er fenyl, naftyl, tetrahydronaftyl, bifenyl, indanyl, antracyl eller fenantryl; heteraryl er benzimidazolyl, benzotiazolyl, benzoisotiazolyl, benzotiofenyl, benzopyra- zinyl, benzotriazolyl, benzotriazinyl, benzo[l,4]dioksanyl, benzo furanyl, 9H-a-karbolinyl, cinnolinyl, 2,3-dihydro[l,4]dioksino[2,3-b]-pyridinyl, furanyl, fu-ro[2,3-b]pyridinyl, imidazolyl, imidazolidinyl, imidazopyridinyl, isoksazolyl, isotiazolyl, isokinolinyl, indolyl, indazolyl, indolizinyl, naftyridinyl, oksazolyl, oksotiadiazolyl, oksadiazolyl, ftalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl, fenazinyl, pyrazolyl, pyridyl, pyrazolopyrimidinyl, pyrazolopyridinyl, pyrroli-zinyl, pyridazyl, pyrazinyl, pyrimidyl, 4-okso-l,2-dihydro-4H-pyrrolo[3,2,l-ij]-kinolin-4-yl, kinoksalinyl, kinazolinyl, kinolinyl, kinolizinyl, tiofenyl, triazolyl, triazinyl, tetrazolopyrimidinyl, triazolopyrimidinyl, tetrazolyl, tiazolyl eller tiazolidinyl; karbocyklisk er en ikke-aromatisk cyklisk hydrokarbonrest som har fra tre til syv kar bonatomer, heterocyklisk er en tre- til syv-leddet ring inneholdende en eller flere heteroatomære enheter valgt fra S, SO, S02, O, N eller N-oksid; hvori: den tre- til 7-leddete ringen som definert for hver heterocyklisk er mettet eller har en eller flere grader av umettethet; eller hver heterocyklisk er kondensert til en eller flere eventuelt substituerte heterocykliske ring(er), arylring(er), heteroaryl-ring(er), eller karbocykliske ring(er) som definert ovenfor; hvori Ci-3substituert alkyl, som definert for RI og R2 ovenfor, eventuelt er substituert med minst en substituent valgt fra Ci-3-alkyl eventuelt substituert med ett til tre fluoratomer, C2-3-alkenyl, C2-3-alkynyl, Ci-2-alkoksy eventuelt substituert med ett til tre fluoratomer, sulfanyl, Ci-3-alkylsufanyl, sulfinyl, sulfonyl, okso, hydroksy, merkapto, amino, guanidino, karboksy, aminokarbonyl, aryl, aryloksy, heteroaryl, heteroaryloksy, heterocyklisk, aminosulfonyl, sulfonylamino, karboksyamid, ureido, nitro, cyano eller halogen; C2-3substituert alkenyl, som definert for RI og R2, er eventuelt substituert med minst en substituent valgt fra Ci-3-alkyl eventuelt substituert med ett til tre F-atomer, amino, aryl, cyano eller halogen; C2-3substituert alkynyl, som definert for RI og R2, er eventuelt substituert med minst en substituent valgt fra Ci-3-alkyl (eventuelt substituert med ett til tre F-atomer), amino, aryl eller halogen; hvert aryl, heteroaryl, heterocyklyl, eller karbocyklisk, henholdsvis, som definert over, er eventuelt videre substituert med minst en substituent valgt fra C1.3substituert alkyl, C2-3substituert alkenyl, C2-3substituert alkynyl, heteroaryl, usubstituert heterocyklisk, aryl, Ci_3-alkoksy, aryloksy, aralkoksy, acyl, aroyl, heteroaroyl, acyloksy, aroyloksy, heteroaroyloksy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, karboksyamid, aminokarbonyl, karboksy, okso, hydroksy, merkapto, amino, nitro, cyano, halogen eller ureido; Y er O, CH2eller en kovalent binding; og n er et heltall på fra 0 til 2; eller et farmasøytisk aseptabelt salt derav.
2. Forbindelse ifølge krav 1,karakterisertvedatR2er hydrogen.
3. Forbindelse ifølge krav 2,karakterisert vedat den har følgende absolutte konfigurasjon:
eller et farmasøytisk akseptabelt salt derav.
4. Forbindelse,karakterisert vedat den er valgt fra gruppen som består av: N-hydroksy-N-[(R)-2-(N'-pyridin-2-yl-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-{(R)-2-[N'-(3-metoksy-fenyl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(4-trifluorme1yl-pyrimidin-2-yl]-hydrazinokarbonyl]-heptyl} -formamid, N-{(R)-2-[N'-(4-cyano-fenyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(2,6-dimetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydrolcsy-N-[(R)-2-(^'-ldnoksalin-2-yl-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-((2R)-2-{N'-(3,4-dihydro-kinoksalin-2-yl)-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N- {(R)-2-[N'-( 1,3,4-trimetyl- lH-pyrazolo[3,4-b]pyridin-6-yl)-hydrazinokarbonyl]-heptyl}-formamid, 4-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl-hydrazino)-benzensulfonamid, N-hydroksy-N-[(2R)-2-(cykloheksylmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -propyl]-formamid, N-hydroksy-N-[(2R)-2-(cykopentylmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -propyl]-formamid, N-{(R)-2-[N'-(dimetyl-trifluorme hydroksy-formamid, N-hyaVoksy-N-{(R)-2-[N'-(6-trilfuormetyl-pyridazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N- {(R)-2 - [N' -(6-trifluormetyl-pyrimidin-4-y l)-hydrazinokarbony 1] - heptyl} -formamid, N-hydroksy-N-{(R)-2-[N'-(5-metyl-[l,2,4]triazolo[1.5-a]pyrimidin-7-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydrolcsy-N-{(R)-2-p^'-(9H-purin-6-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-{(R)-2-[N'-(5-cyano-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-((2R)-2-{[N'-(pyrimidin-2-yl)-hydrazino]karbonyl}-heptyl)-formamid, N-hydrolcsy-N-((2R)-2-(cyklobutylmetyl)-3-okso-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -propyl)-formamid, N-hydroksy-N-{(R)-2-[N'-(6-imidazol-l-yl-pyrimidin-4-yl)-hydrazinonkarbonyl]-heptyl} -formamid, N- [(R) -2-(N' -benzo [ 1,2,4] triazin-3 -yl-hydrazinokarbonyl)-heptyl] -N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(7-metoksy-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-hydroksy-N-{(R)-2-[N'-(l-metyl-lH-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-((R)-2-{N'-[6-(5-klor-pyridin-3-yl-oksy)-pyridazin-3-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydrolcsy-N-[(2R)-2-({N'-[6-(lH-pyrrol-l-yl)-3-pyirdazinyl]-hydrazino}-karbonyl)-heptyl] -formamid, N-hydroksy-N-((2R)-2-{[N'-(9-metyl-9H-purin-6-yl)-hydrazino]-karbonyl}-heptyl)-formamid, N-hydroksy-N- {(R)-2-[N-( {6-morfolin-4-yl} -9H-purin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-{(R)-2-[N'-(6-fluor-pyridin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydrolcsy-N-((2R)-2-{[N'-(l-metyl-lH-pyrazolo[3,4-d]pyrimidin-4-yl)-hydrazino]-karbonyl} -heptyl)-formamid, N-{(R)-2-[N'-(4-amino-6-isopropyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(2,5-dimetyl-4-nitro-2H-pyrazol-3-yl)-hydrazinokarbonyl]-heptyl^ hydroksy-formamid, N-{(R)-2-[N'-(3-klor-l-me1yl-lH-pyrazolo[3,4-d]pyrimidin-6-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-{(R)-2-[N'-(6-dimetylamino-9H-purin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-[(2R)-4-cyklopropyl-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-butyl]-formamid, N-hydroksy-N-((2R)-2-(cyklopropylmetyl)-3-okso-3-{N'-[4-(trilfuormetyl)-pyrimidin-2-yl]-hydrazino} -propyl)-formamid, N-hydroksy-N-{(R)-2-[N'-metyl-N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, 2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifiuormetyl-pyrimidin-5 -karboksylsyre metylester, 2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5 -karboksylsyre, N-{(R)-2-[N'-(5-fluor-4-metoksy-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(4-dimetylamino-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(2R)-2-[(N'-{6-[(2-hydroksyetyl)amino]-l,3-dihydro-2H-purin-2-yliden} -hydrazino)-karbonyl]-heptyl} -formamid, N-{(R)-2-[N'-(5-fluor-4-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(5-fluor-4-metylamino-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, 2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5 -karboksylsyre dimetylamid, N-hydroksy-N-{(R)-2-[N'-(3-okso-3,4-dihydro-kinoksalin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-{(R)-2-butoksy-2-[N'-(4-trilfuormetyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, 2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5 -karboksylsyre (2-fluor-fenyl)-amid, 2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5 -karboksylsyre tert-butylamid, N-hydroksy-N-((R)-2- {N' -[(1 -piperidin-1 -yl-metanoyl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-{(R)-2-[N'-(5-cyano-4-trifluorme1yl-pyrimidin-2-yl)-hydrazinokarbonyl]-hepty^ hydroksy-formamid, N-hydroksy-N-[(2R)-2-({N'-[9-(4,4,4-trifiuorbutyl)-1.9-dihydro-2H-purin-2-yliden]-hydrazino} -karbonyl)-hepty 1] -formamid, N-hydroksy-N-((R)-2-{N'-[(l-morfolin-4-yl-metanoyl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, 2-(T^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5-karboksylsyrebenzylamid, N-hydroksy-N-[(2R)-3-[N'-(l,2,4-benzotriazin-3-yl)-hydrazino]-2-(cykloheksylmetyl)-3 -oksopropyl] -formamid, N-hydrolcsy-N-((2R)-2-(cykloheksylmetyl)-3-{N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino}-3-oksopropyl)-formamid, 2-[2-((2R)-2-{[formyl(hydroksy)amino]metyl}heptanoyl)hydrazino]-N-metyl-N-2-pyridinyl-4-(trifluormetyl)-5-pyrimidinkarboksamid, 2-[2-((2R)-2-{[formyl(hydroksy)amino]metyl}heptanoyl)hydrazino]-N-metyl-N-fenyl-4-(trifluormetyl)-5 -pyrimidinkarboks amid, 2-(N'-{(R)-2-[(formyl-hydroksy-amino)metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5 -karboksylsyre morfolin-4-ylamid, N-hydroksy-N-((R)-2-{N'-[(^'-fenyl-hydrazinokarbonyl)-trifiuormetyl-pyrimidin-2-yl] -hydrazinokarbonyl} -heptyl)-formamid, 2-CN'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-4-trifluormetyl-pyrimidin-5 -karboksylsyre piperidin-1 -ylamid, 2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino-4-trifluormetyl-pyrimidin-5-karboksylsyre pyrrol-1 -ylamid, N- {(R)-2- [N' -(dimetylamino-fluor-pyrimidin-2 -yl)-hydrazinokarbonyl] -heptyl} -N-hydroksy-formamid, N-((R)-2-{N'-[(etyl-metyl-amino)-fluor-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-((2R)-2 -(cyklopentylmetyl)-3 - {N' - [7 -(metyloksy)-1,2,4-benzotriazin-3 - yl]-hydrazino}-3-oksopropyl)-formamid, N-hydrolcsy-N-{(R)-2-p^'-(l-metyl-lH-benzoimidazol-2-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-{(R)-2-[N'-(4-azetidin-l-yl-5-fluor-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(4-cyMopropylamino-5-fluor-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-[(R)-2-(N-benzo[l,2,4]triazin-3-yl-hydrazinokarbonyl)-3-cyklopentyl-propyl]-N-hydroksy-formamid, N-hydroksy-N- {(R)-2 - [N' -(morfolin-4-yl-trifluormetyl-pyrimidin-2 -yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-[(R)-2-(N'- {[(2-hydroksy-etyl)-metyl-amino]-trifluormetyl-pyrimidin-2-yl} -hydrazinokarbonyl)-heptyl} -formamid, N-hydroksy-N-((R)-2-{N'-[(4-metyl-piperazm-l-yl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-((2R)-2-(cykloheksylmetyl)-3-{N'-[4-(cyklopropylamino)-5-fluor-pyrimidin-2-yl]hydrazino}-3-oksopropyl)-formamid, N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-(cyklopropylamino)-5-fiuor-pyrimidin-2-yl]hydrazino}-3-oksopropyl)-formamid, N-hydroksy-N-[(2R)-3-{N'-[4-(azetiaUn-l-yl)-5-fluor-pyrimidin-2-yl]-hydrazino}-2-(cyklopentylmetyl)-3-oksopropyl]-formamid, N-hydroksy-N-[(2R)-5-metyl-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heksyl] -formamid, N-[(R)-2-(N'-benzo[l,2,4]tirazin-3-yl-hydrazinokarbonyl)-5-metyl-heksyl]-N-hydroksy-formamid, N-hydroksy-N-[(2R)-5-metyl-2-({N'-[7-(metyloksy)-l,2,4-benzotriaziri-3-yl]-hydrazino} -karbonyl)-heksyl] -formamid, N- {(R)-2-[N'-(7-klor-benzo[l ,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-(morfolin-4-yl)-6-(trifluormetyl)-pyrimidin-1 -yl]-hydrazino} -3-oksopropyl)-formamid, N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-[(2-hydroksyetyl)-(metyl)-amino]-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-3-oksopropyl)-formamid, N-hydroksy-N-[(2R)-6-metyl-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid, N-hydroksy-N-((2R)-2-{[N'-(l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-6-metylheptyl)-formamid, N-hydroksy-N- {(R)-2 - [N' -(5 -metyl-benzo[ 1,2,4]triazin-3 -yl)-hydrazinokarbonyl] - heptyl} -formamid, N-((R)-2-{N'-[(4-etyl-piperazin-l-yl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N- {(R)-2 - [N' -(piperazin-1 -yl-trifluormetyl-pyrimidin-2 -yl)-hydrazinokarbonyl]-heptyl}-formamid, N-{(R)-2-[N'-(7-fluor-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-[(2R)-2-({N'-[4-(4-etyl-l-piperazinyl)-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -karbonyl)-6-metylheptyl] -formamid, N-hydroksy-N-[(2R)-6-metyl-2-({N'-[4-(piperazin-l-yl)-6-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid, N-hydroksy-N-[(2R)-6-metyl-2-({N'-[4-(4-metyl-piperazin-l-yl)-6-(trifiuormetyl)-pyrimidin-2 -yl] -hydrazino } -karbonyl)-heptyl] -formamid, N-hydroksy-N-((2R)-2-{[N'-(7-klor-l,2,4-benzotriazin-3-yl)hydrazino]karbonyl}-6-metylheptyl)-formamid, N-hydroksy-N-((2R)-6-metyl-2- {[N'-(5-metyl-1,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl} -heptyl)-formamid, N-hydroksy-N-((2R)-2- {[N'-(7-fluor-1,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl} -6-metylheptyl)-formamid, N-hydroksy-N-((R)-2-{N'-[(2-metoksy-etylamino)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-[(2R)-6-metyl-2-({N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydrazino} -karbonyl)-hepty 1] -formamid, N-hydrolcsy-N-[(R)-2-(^'-{[4-(2-hydroksy-etyl)-piperazin-l-yl]-trifluormetyl-pyrimidin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-((R)-2- {N' -[(4-pyrimidin-2-yl-piperazin-1 -yl)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-((R)-2-{N'-[(2-hydroksy-etylamino)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N- {(R)-2-[N'-(7-trifluormetyl-benzo[l ,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N- {(R)-2 - [N' -(6-metyl-benzo[ 1,2,4]triazin-3 -yl)-hydrazinokarbonyl] - heptyl} -formamid, N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(5-metyl-l,2,4-benzotriazin-3-yl)hydrazino]-3-oksopropyl}-formamid, N-hydrolcsy-N-[(2R)-2-({N'-[4-(trifluormetyl)-pyrimidm-2-yl]-hydrazino}-karbonyl)-oktyl]-formamid, N-hydroksy-N-((2R)-2-{[N'-(l,2,4-benzotriazin-3-yl)hydrazino]-karbonyl}-oktyl)-formamid, N-hydroksy-N-[(2R)-2-({N'-[7-(metyloksy)-l,2,4-benzotriazin-3-yl]-hydra karbonyl)-oktyl]-formamid, N-hydroksy-N- {(R)-2 - [N' -(7-metyl-benzo[ 1,2,4]triazin-3 -yl)-hydrazinokarbonyl] - heptyl} -formamid, N- {(R)-2-[N'-(6-klor-benzo[l ,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(5-metoksy-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-hydroksy-N-{(R)-2-[N'-(l-metyl-2-okso-l,2-dihydro-pyridin-4-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-((R)-2- {N' -[(N' -pyridin-2-yl-hydrazino)-trifluormetyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-((R)-2-{N'-[4-(4-etyl-piperazin-l-yl)-6-metyl-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(4,6-dimetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-trifluormetyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydrolcsy-N-[(R)-2-(N'-isoldnolin-l-yl-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-[(R)-2-(N'-kinolin-2-yl-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-2-[N'-(l-benzyl-2-okso-l,2-aUhydro-pyridin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-okso-4H-pyrido[l,2-a][l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(4-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-{(R)-2-[N'-(l-butyl-2-okso-l,2-dihydro-pyridin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(9-metyl-4-okso-4H-pyrido[l,2-a][l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydrolcsy-N-{(R)-2-[N'-(6-okso-4-trifluormetyl-1.6-dihydro-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(metyl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-hydroksy-N- {(R)-2 - [N' -(5 -trilfuormetyl-pyridin-2 -yl)-hydrazinokarbonyl] -heptyl} - formamid, N-{(R)-2-[N'-(6-etoksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydrolcsy-N-[(R)-2-(^'-pyrido[2,3-e]-[l,2,4]triazin-3-yl-hydrazinokarbonyl)-heptyl]-formamid,
N-((R)-2- {N'-[ 1 -(1 -etyl-propyl)-2-okso-1,2-dihydro-pyridin-4-yl]-hydrazinokarbonyl} - heptyl)-N-hydroksy-formamid, N-hydroksy-N-((R)-2- {N'-[2-okso-1 -(3-trifluormetyl-benzyl)-1,2-dihydro-pyridin-4-yl] -hydrazinokarbonyl} -heptyl)-formamid, N-hydroksy-N-{(R)-2-<r>N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(6-metoksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N- {(R)-2-[N'-(2-okso-1 -kinolin-8-yl-metyl- l,2-dihydro-pyridin-4-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydrolcsy-N-[(R)-2-(N'-{2-okso-l-[2-(5,6,7,8-tetrahya^o-[1.8]naftyridin-2-yl)-etyl]-dihydro-pyridin-4-yl}-hydrazinokarbonyl)-heptyl]-formamid, N- {(R)-2- [N' -(4,6-bis-etylamino- [1,3,5 ] triazin-2-yl)-hydrazinokarbonyl] -heptyl} -N-hydroksy-formamid, N-{(R)-2-[N'-(bis-dimetylamino-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(4,6-di-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-((R)-2- {N' -[4-(4-metyl-piperazin-1 -yl)-6-propylamino-[ 1,3,5]triazin-2-yl] -hydrazinokarbonyl} -heptyl)-formamid, N-{(R)-2-[N'-(dimetylamino-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydrolcsy-N-{(R)-2-p^'-(6-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-((R)-2-{N'-[5-(5-fenyl-[l,3,4]oksadiazol-2-yl)-pyridin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-{(R)-2-[N'-(7-tert-butyl-l,4-diokso-l,2,3,4-tetrahydro-pyrido[3,4-d]pyridazin-5-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-((R)-2- {N' -[4-etylamino-6-(4-metyl- [ 1,4]diazepan-1 -yl)- [ 1,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-((R)-2-{N'-[4-etylamino-6-(4-etyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(6-trifluorme1yl-pyridin-2-yl)-hydrazinokarbonyl]-hepty formamid, N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-morfolin-4-yl-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(4-metyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(4,6-dimetyl-2-pyrimidinyl)-hydrazino]-3-oksopropyl}-formamid, N-hydroksy-N- {(R)-2 - [N' -(4-metyl-6-pyrrolidin-1 -yl-metyl-pyrimidin-2 -yl)-hydrazinokarbonyl]-heptyl}-formamid, N- {(R)-2- [N' -(4-dimetylaminometyl-6-metyl-pyrimidin-2 -yl)-hydrazinokarbonyl] - heptyl} -N-hydroksy-formamid, N-hydroksy-N-((R)-2-{N'-[4-metyl-6-(4-metyl-piperazin-l-yl-metyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydrolcsy-N-{(R)-2-p^'-(5-metyl-pyridin-2-yl)-hydraziriokarbonyl]-heptyl}-formamid,
N-((R)-2- {N'-[dimetylamino-(4-metyl-[ 1,4]diazepan-1 -yl)-[l ,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydrolcsy-N-{(R)-2-p^'-(4-metyl-6-pyrrolidin-l-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-((R)-2- {N' -[4-metyl-6-pyrrolidin-1 -yl-piperidin-1 -yl)-[ 1,3,5]triazin-2-yl] -hydrazinokarbonyl} -heptyl)-formamid, N-((R)-2-{N'-[(etyl-metyl-amino)-metyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-((R)-2-{N'-[(4-(4-etyl-piperazin-l-yl)-6-metyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-[(2R)-7,7,7-trifluor-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -karbonyl)-hepty 1] -formamid, N-hydroksy-N-((2R)-7,7,7-trifluor-2-{[N'-(5-metyl-l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-heptyl)-formamid, N-hydroksy-N-((2R)-7,7,7-tirfluor-2-{[N'-(7-metyl-l,2,4-benzotriazin-3-yl)-hydrazino]-karbonyl}-heptyl)-formamid, N-hydroksy-N-{(R)-2-[N'-(4-metylamino-6-morfolin-4-yl-[l,3,5]-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-((R)-2-{N'-[4-(4-etyl-piperazin-l-yl)-6-mety^^ hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(4-e1ylamino-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydr^in heptyl} -N-hydroksy-formamid, N-hydrolcsy-N-{(R)-2-[N'-(4,6,7-trimetyl-7,8-dmydro-pterin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-hydroksy-N-{(R)-2-[N'-(4,6,7-trimetyl-pteridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydrolcsy-N-{(R)-2-[N'-(metoksymetoksymetyl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-((R)-2-{N'-[4-metyl-6-(l-piperidin-2-yl-metanoyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, 2-(^'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-6-metyl-pyrimidin-4-karboksylsyre cyklopropylamid, 2-CN'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-6-metyl-pyrimidin-4-karboksylsyre diisopropylamid, N-{(R)-2-[N'-(5-cyano-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(4,6-dietyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-4-cyklopentyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-butyl} -N-hydroksy-formamid, N-{(R)-4-cyklopentyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-butyl} -N-hydroksy-formamid, N- {(R)-4-cyklopentyl-2- [N' -(5 -metyl-benzo [1,2,4] triazin-3 -yl)-hydrazinokarbonyl]-butyl} -N-hydroksy-formamid, N-hydroksy-N-((R)-2-{N'-[6-(4-metyl-piperazin-1 -yl-metyi)-pyridin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-((R)-2-{N'-[5-(4,6-dimetolcsy-pyrimidin-2-yl)-pyirdm-2-yl]-hydrazirionkarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(dietylamino-me1yl-[l,3,5]triazin-2-yl)-hya,razinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydrolcsy-N-[(R)-2-(^'-{[(2-metoksy-etyl)-metyl-amino]-metyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid, N-((R)-l-{N'-[4-(2,6-dimetyl-morfolin-4-yl)-6-metyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(5-fluor-4-metyl-6-morfo heptyl} -N-hydroksy-formamid, N-{(R)-2-[N'-(4-etyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(etyl-metyl-amino)-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-he<p>tyl}-N-hydroksy-formamid, N-((R)-2-{N'-[4-etyl-6-(4-etyl-piperazin-1 -yl)-[ 1,3,5 ]triazin-2-yl]-hydrazinokarbonyl} - heptyl)-N-hydroksy-formamid, N-((R)-2-{N'-[5-fluor-4-metyl-6-(4-metyl-piperazin-l-yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-((R)-2- {N' -[5-fluor-4-metyl-6-(4-metyl- [ 1,4]diazepan-1 -yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-4-cyklopentyl-2-[N'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-butyl}-N-hydroksy-formamid, N-[(R)-2-(N'-{etyl-[(2-metoksy-etyl)-metyl-amino]-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid, N-{(R)-2-[N'-(dimetylamino-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(4-cyklopropylamino-6-metyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-{(R)-2-cykloheksyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid, N-{(R)-2-cykloheksyl-2-p^'-(7-metoksy-benzo[l,2,4]tirazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid, N-{(R)-2-cykloheksyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-p^'-(4-trifluormetyl-pyrimidm-2-yl)-hydrazinokarbonyl]-pentyl}-N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-pentyl} -N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-pentyl} -N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-<r>N'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-pentyl}-N-hydroksy-formamid, N-((R)-2-{N'-[etyl-(metyl-pyridin-2-yl-amino)-[l,3,5]triazin-2-yl]-hyd heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(4-cyklopropylamino-6-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydroksy-N-[(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-3-(l-metyl-cyklopentyl)-propyl]-formamid, N-hydroksy-N-[(R)-2-[N'-(7-metoksy-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-3-(1 -metyl-cyklopentyl) -propyl]-formamid, N-hydroksy-N- {(R)-3 -(1 -metyl-cyklopentyl)-2-[N' -(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-propyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(4-isopropyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(2R)-2-(cyklopentylmetyl)-3-[N'-(4-metyl-2-pyirmidinyl)-hydrazino]-3-oksopropyl} -formamid, N-hydroksy-N-[(2R)-6,6,6-trifluor-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -karbonyl)-heksyl] -formamid, N-{(R)-2-[N'-(5,7-dimetyl-benzo[l,2,4]tirazin-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(3,6-dimetyl-pyrazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid,
N-((R)-2- {N' -[4-(4-etyl-piperazin-1 -yl)-6-isopropyl-[ 1,3,5]triazin-2-yl]-hydrazinokarbonyl}-hq)tyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(4-dimetylamino-6-isopropyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydroksy-N- {(R)-2 - [N' -(metyl-trifluormetyl-pyridin-2 -yl)-hydrazinokarbonyl] - heptyl} -formamid, 2-(N'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl} -hydrazino)-6.N.N-trimetyl-isonikotinamid, N-hydrolcsy-N-[(2R)-2-({N'-[3-amino-6-(trifluormetyl)-pyridiri-2-yl]-hydrazino}-karbonyl)-heptyl]-formamid, N-hydroksy-N-[(R)-2-(N'-{4-isopropyl-6-[(2-metoksy-etyl)-metyl-amino]-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-3-cyklopentyl-2-[N'-(4-etyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-morfolin-4-yl-6-propyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid,
N-((R)-2- {N' -[4-(4-etyl-piperazin-1 -yl)-6-propyl- [ 1,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-5,5-dimetyl-2-[N'-(4-trifluorme1yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid, N-{(R)-5,5-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid, N-{(R)-5,5-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid, N-{(R)-5,5-dimetyl-2-p^'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid, N-{(R)-4-etyl-2-p^'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazino-karbonyl]-heksyl}-N-hydroksy-formamid, N-{(R)-4-etyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid, N-{(R)-4-e1yl-2-p^'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid, N-((R)-3-cyklopentyl-2- {N-[4-etyl-6-(4-etyl-piperazin-1 -yl)-[ 1,3,5]triazin-2-yl]-hydrazinokarbonyl}-propyl)-N-hydroksy-formamid, N-{(R)-3-cyklopentyl-2-[N'-(4-cyklopropylamino-6-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid, N-{(R)-4-etyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-(N'-{[(2-metoksy-etyl)-me1yl-amino]-propyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-2-[N'-(dimetylammo-propyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(4-etyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-isopropyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-{(R)-2-[N'-(4-cyklopropyl-6-morfolin-4-yl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydrolcsy-N-[(2R)-2-({N'-[4-(pyridin-2-yl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl] -formamid,
N-((R)-2- {N'-[4-cyklopropyl-6-(4-etyl-piperazin-1 -yl)-[l ,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(cyklopropyl-dimetylam heptyl} -N-hydroksy-formamid, N-((R)-2-{N'-[cyklopropyl-(etyl-metyl-amino)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(4-cyklopropyl-6-pyrrolidin-l-yl[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-{(R)-2-[N'-(4,6-dicyklopropyl-[l,3,5]tirazin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-[(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-3-(2-metyl-cyklopentyl)-propyl]-formamid, N-[(R)-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-3-(2-metyl-cyklopentyl)-propyl]-N-hydroksy-formamid, N-hydrolcsy-N-[(R)-2-[<N>'-(4-tirfluometyl-pyrimidin-2-yl)-hydrazinokarbonyl]-3-(2-metyl-cyklopentyl)-propyl]-formamid, N-{(R)-2-[N'-(5-etyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N- {(2R)-2-(cyklopentylmetyl)-3-[N'-(7-metyl-1,2,4-benzotriazin-3-yl)-hydrazino]-3-oksopropyl}-formamid, N-hydroksy-N-[(2R)-2-(cyklopentylmetyl)-3-(N'-{4-etyl-6-[etyl(metyl)amino]-l,3,5-triazin-2-yl}-hydrazino)-3-oksopropyl]-formamid, N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-(dimetylamino)-6-etyl-l,3,5-triazin-2-yl]-hydrazino}-3-oksopropyl)-formamid,
N-((R)-2- {N'-[4-etyl-6-(4-isopropyl-piperazin-l -yl)-[l ,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-[(2R)-3-[N'-(6-klor-l,2,4-benzotriazin-3-yl)-hydrazino]-2-(cyklopentylmetyl)-3-oksopropyl]-formamid, N-{(R)-4,4-dimetyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heksyl} -N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-p^'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-heksyl}-N-hydroksy-formamid, N-hydroksy-N- {(R)-2-[N'-(5-fenyl-[ 1,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} - formamid, N-{(R)-2-[N'-(4-etyl-6-morfolin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]^ hydroksy-formamid, N-((R)-2-{N'-[4-etyl-6-(4-metyl-piperazin-1 -yl)-pyrimidin-2-yl]-hydrazinokarbonyl} - heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(5-etyl-4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-((R)-2-{N'-[4-etyl-6-(4-propyl-piperazin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid, N-hydroksy-N-((R)-2-{N'-[6-(4-pyrimidin-2-yl-piperazin-l-yl-metyl)-pyridiri-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-((R)-2-{N'-[6-(3-[l ,2,4]triazol-l-yl-metyl-[l ,2,4]triazol- l-yl)-pyridin-2-yl] -hydrazinokarbonyl} -heptyl)-formamid, N-{(R)-3-bicyklo[2,2,l]hept-7-yl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid, N-{(R)-3-bicyklo[2,2,l]hept-7-yl-2-[N'-(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-propyl}-N-hydroksy-formamid, N-hydrolcsy-N-[(R)-2-(^'-pyirdin-3-yl-hydrazinokarbonyl)-heptyl]-formamid, 4-{4-etyl-6-[2-((2R)-2-{[formyl(hydroksy)amino]-metyl}-heptanoyl)-hydrazino]-l,3,5-triazin-2-yl} -1 -metyl-1 -propylpiperazin-1 -iumj odid, N-{(R)-3-bicyklo[2,2,l]hept-7-yl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl] -propyl} -N-hydroksy-formamid, N- {(R)-2-[N'-(4-azetidin-1 -yl-6-etyl-[ 1,3,5]triazin-2-yl)-hydrazinokarbonyl]-heptyl} - N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(morfolin-4-yl-4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid. N-{(R)-2-cyklopentyl-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid. N-{(R)-2-cyklopentyl-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid, N-{(R)-2-cyklopentyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl} -formamid, N-hydroksy-N-{(R)-2-[N'-(7^ metyl-cykloheksyl)-etyl} -formamid, N-hydroksy-N-{(R)-2-(4-me1yl-cykloheksyl)-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-formamid, N-hydroksy-N- {(R)-2 -(4-metyl-cykloheksyl)-2- [N' -(morfolin-4-yl-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-formamid, N-hydroksy-N-{(R)-2-(4-metyl-cykloheksyl)-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-formamid, N-{(R)-2-[N'-(dimetylammo-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl]-N-hydroksy-formamid, N-{(R)-2-[N'-(6,7-dihydro-5H-cyklopentapyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-((R)-2-[N'-[4-etyl-6-((S)-2-hydroksymetyl-pyrrolidm-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl]-heptyl)-N-hydroksy-formamid, N-{(R)-2-[N'-(dimetylamino-pyirdin-3-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(dimetylammo-pyridin-4-yl-pyirmidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-N'-(5,6,7,8-tetrahydro-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-{(R)-2-[N'-(5,6-dihydro-[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-[5-(4-hydroksy-fenyl)-[l,2,4]triazin-3-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-[(R)-2-(^'-{[(2-dimetylamino-etyl)-metyl-amino]-etyl-[l,3,5]triazin-2-yl}-hydrazinokarbonyl)-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(2-dimetylamino-kinazolin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(3-metansulfonyl-4,6-dimetyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-((R)-2-{N'-[4-etyl-6-(3-hydroksy-piperidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid, N-[(R)-2-(K'-[4,5']bipyrimidinyl-2-yl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid,
N-((R)-2- {N'-[(cyklopropyl-metyl-amino)-etyl-[l ,3,5]triazin-2-yl]-hydrazinokarbonyl} - heptyl)-N-hydroksy-formamid, N-((R)-2-{N'-[4-etyl-6-((R)-3-hydroksy-pyrrolidin-l-yl)-[l,3,5]triazin^ hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-[(R)-2-(N'-[3,3']bipyridinyl-5-yl-hydrø N-hydroksy-N-[(R)-2-(N'-(5-morfolin-4-yl-pyridin-3-yl)-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-{(R)-2-[N'-(4-pyridin-3-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-hq)tyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(5,6,7,8-tetrahydro-kinazolin-2-yl)-hydrazinokarbonyl]-heptyl} -formamid, N-[(R)-2-(N'- {[cyklopropyl-1 -(1 -metyl-piperidin-4-yl)-amino]-etyl-[ 1,3,5]triazin-2-yl} - hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid, N-((R)-2-{N'-[4-((R)-3-dimetylamino-pyrrolidin-l-yl)-6-etyl-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-[(R)-2-(>['-[5-(lH-pyrrol-2-yl)-pyridin-3-yl]-hydrazinokarbonyl)-heptyl] -formamid, N-hydroksy-N-[(R)-2-(N'-[(4-me1yl-piperazin-l-yl)-trifluormetyl-pyrimidin-4-yl]-hydrazinokarbonyl)-heptyl]-formamid, N-hydroksy-N-[(R)-2-(N'-(5-mran-3-yl-pyirdin-3-yl)-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-5,5-dimetyl-2-[N'-(4-trifluorme1yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-5,5-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N- {(R)-5,5 -dimetyl-2-(4-metyl-pyridin-2 -yl)-hydrazinokarbonyl] -heptyl} -N-hydroksy-formamid, N-{(R)-2-cykloheptyl-2-[N'-(4-trifluormetyl-pyrimidin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cykloheptyl-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cykloheptyl-2-[N'-(dimetylamino-etyl-[l,3,5]triazin-2-yl)-hydrazinokarbonyl]-etyl}-N-hydroksy-formamid, N-{(R)-2-cykloheptyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-etyl} -N-hydroksy-formamid,
N-((R)-2- {N' - [4-etyl-6-(4-hydroksy-piperidin-1 -yl)-[ 1,3,5 ]triazin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-{(R)-5,5-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-{(R)-2-[N'-(4-dimetylamino-kinazolin-2-yl)-hydrazinokarbonyl]-heptyl^ hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-pyridin-4-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-hq)tyl}-formamid, N-hydroksy-N-((R)-2-{N'-[4-(3-hydroksymetyl-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-((R)-2-{N'-[4-(4-hydroksymetyl-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-((R)-2-{N'-[4-etyl-6-(3-metoksy-piperidin-l-yl)-[l,3,5]triazin-2-yl-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl} -formamid, N-[(R)-2-{N'-[etyl-(etyl-metylammo)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-2-(4-metyl-cykloheksyl)-etyl}-N-hydroksy-formamid, N-[(R)-2-{N'-[etyl-(etyl-metylamino)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-2-(4-metyl-cykloheksyl)-etyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-2-(4-metyl-cykloheksyl)-etyl} -formamid, N-((R)-2-{N'-[4-(2,6-dimetoksy-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-((R)-2-{N'-[4-etyl-6-((R)-3-metoksy-pyrrolidin-l-yl)-[l,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid,
N-((R)-2- {N'-[4-etyl-6-(4-metoksy-piperidin-l -yl)-[l ,3,5]triazin-2-yl]-hydrazinokarbonyl}-hepytl)-N-hydroksy-formamid, N-hydroksy-N-[(R)-2-(^'-(6-pyrrolidm-l-yl-pyrimidin-4-yl)-hydrazinokarbonyl)-heptyl] -formamid, N-hydroksy-N-[(R)-2-(N'-[6-(4-metyl-piperazin-l-yl)-pyrimidin-4-yl])-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-2-[N'-(6-dimetylamino-pyrimidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(pyridin-4-yl-trifluormetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(pyridin-3-yl-trilfuormetyl-pyrimidin-4-yl)-hydrazinokarbonyl]-hq)tyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(2-e1ylamino-6-trifluormetyl-pyrimidm-4-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-hydroksy-N-((R)-2-{N'-[5-(4-metoksy-fenyl)-[l,2,4]triazin-3-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-hydroksy-N-((R)-2- {N' -[4-(2,3,4-trimetoksy-fenyl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-formamid, N-{(R)-4,4-dimetyl-2-p^'-(4-trifluormetyl-pyrimidm-2-yl)-hydrazinokar^ N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-[N'-(7-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-[N'-(5-metyl-benzo[l,2,4]triazin-3-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-{(R)-4,4-dimetyl-2-[N'-(4-metyl-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(6-morfolin-4-yl-pyrimidin-4-yl)-hydraziriokarbonyl]-heptyl} -formamid, N-hydroksy-N-[(R)-2-(^'-{5-[4-(2-hydroksy-etoksy)-fenyl]-[l,2,4]triazin-3-yl}-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-2-[N'-(4-furan-2-yl-pyrimidin-2-yl)-hydrazinokarbonyl]-heptyl} -N-hydroksy-formamid, N-((R)-2-{N'-[4-(3,5-dimetyl-isoksazol-4-yl)-pyrimidin-2-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-metyl-oksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, 2-CN'-{(R)-2-[(formyl-hydroksy-amino)-metyl]-heptanoyl}-hydrazino)-6-metyl-nikotinsyre, N-hydroksy-N-{(R)-2-[N'-(3-metoksy-pyridin-2-yl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N- {(2R)-2-[(N'- {4-[4-(metylsulfonyl)fenyl]-pyrimidin-2-yl} -hydrazino)-karbonyl]-heptyl} -formamid. N-hydroksy-N-[(2R)-2-({N'-[4-(furan-3-yl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl] -formamid, N-[(2R)-2-({N'-[4-(2-aminofenyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-heptyl]-N-hydroksy-formamid, N-hydroksy-N-[(2R)-2-({N'-[5-(5-metyl-l,3,4-oksadiazol-2-yl)-4-(trifluormetyl)-pyrimidin-2 -yl] -hydrazino } -karbonyl)-heptyl] -formamid, N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[5-(5-metyl-l,3,4-oksadiazol-2-yl)-4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-3-oksopropyl)-formamid, N-[(2R)-2-({N'-[6-(dimetylamino)-2-me^ heptyl] -N-hydroksy-formamid, N-[(2R)-2-({N'-[2-cyklopropyl-6-(dimetylamino)-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl]-N-hydroksy-formamid, N-hydrolcsy-N-[(2R)-4-(2-tienyl)-2-({N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino}-karbonyl)-butyl]-formamid, N-hydroksy-N-[(2R)-2-{[N'-(4-metyl-pyrimidin-2-yl)-hydrazino]karbonyl}-4-(2-tienyl)-butyl]-formamid, N-[(2R)-2-[(^'-{4-etyl-6-[etyl(metyl)amino]-l,3,5-triazin-2-yl}-hydrazino)-karbonyl]-4-(2-tienyl)butyl]-N-hydroksy-formamid, N-hydroksy-N-((2R)-3-okso-2-(2-tienylmetyl)-3-{N'-[4-(trifluormetyl)-pyrimidin-2-yl]-hydrazino} -propyl)-formamid, N-hydroksy-N-[(2R)-3-[N'-(4-metyl-pyrimidin-2-yl)hydrazino]-3-okso-2-(2-tienylmetyl)-propyl]-formamid, N-[(2R)-3-(N'-{4-etyl-6-[etyl(metyl)amino]-l,3,5-triazin-2-yl}-hydrazino)-3-okso-2-(2-tienylmetyl)-propyl]-N-hydroksy-formamid, N-hydrolcsy-N-[(2R)-2-({N'-[2-metyl-6-(pyridin-2-yl)-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl]-formamid, N-hydroksy-N- [(2R)-2-({N' - [6-(pyridin-2-yl-metyl)-pyridazin-3 -yl] -hydrazino} - karbonyl)-heptyl]-formamid, N-hydroksy-N-[(2R)-2-({N'-[2-metyl-6-(morfolin-4-yl)-pyrimidin-4-yl]-hydrazino}-karbonyl)-heptyl]-formamid, N-hydroksy-N-[(2R)-2-({N'-[6-(morfolin-4-yl)-2-(trifluormetyl)-pyrimidin-4-yl]-hydrazino} -karbonyl)-hepty 1] -formamid, N-hydroksy-N- {(2R)-2-[(N'- {4-[metyl-(pyridin-2-yl)-amino]-pyrimidin-2-yl} - hydrazino)-karbonyl]-heptyl}-formamid, N-hydroksy-N-((2R)-2-(cyklopentylmetyl)-3-{N'-[4-cyklopropyl-6-(dimetylamino)-1,3,5-triazin-2-yl]-hydrazino} -3-3-oksopropyl)-formamid, N-benzo[l,3]dioksol-5-yl-metyl-hydrazinkarboksylsyre tert-butylester, N- [(R) -2-(N' -benzo [1,3 ]dioksol-5 -yl-metyl-hydrazinokarbony l)-heptyl] -N-hydroksy-formamid, N-{(R)-2-[N'-(2,3-dihydro-[l,4]dioksino[2,3-b]pyridin-7-yl-metyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(4-dimetylamino-benzyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-((R)-2-{N'-[2-(5,6,7,8-tetrahydro-[1.8]naftyridin-2-yl)-etyl]-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-[(R)-2-(^'-kinolin-2-yl-metyl-hydrazinokarbonyl)-hepty^ N-hydroksy-N- {(R)-2 - [N' -(1,2,3,4-tetrahydro-kinolin-2-y l-metyl)-hydrazinokarbonyl] - heptyl} -formamid, N-hydroksy-N-[(R)-2-CN'-kinolin-6-yl-metyl-hydrazinokarbonyl)-heptyl]-formamid, N- [(R) -2-(N' -benzofuran-2 -yl-metyl-hydrazinokarbonyl)-heptyl] -N-hydroksy-formamid, N-[(R)-2-CN'-cyklopropylmetyl-hydrazinokarbonyl)-heptyl]-N-hydroksy-formamid, N-{(R)-2-[N'-(6-fluor-4H-benzo[l,3]dioksin-8-yl-metyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(4-metoksy-benzyl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(2-metoksy-benzyl)-hydrazinokarbonyl]-heptyl}-formamid, N-hydroksy-N-{(R)-2-[N'-(tetrahydro-furan-3-yl-metyl)-hydrazinokarbonyl]-heptyl}-formamid, N-[(R)-2-(N'-mran-3-yl-me1yl-hydrazinokarbonyl)-heptyl]-N-hyaVoksy-formamid, N-{(R)-2-[N'-(2,3-dihydro-benzo[l,4]dioksin-6-yl-metyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-{(R)-2-[N'-(2,3-dmydro-benzo[l,4]dioksm-2-yl-metyl)-hydrazinolcarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-rN'-(2-fenoksy-etyl)-hydrazinokarbonyl]-heptyl}-formamid, N-{(R)-2-[N'-((S)-2,3-dihydroksy-propyl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-hydroksy-N-{(R)-2-[N'-(5-metyl-isoksazol-3-yl-metyl)-hydrazinokarbonyl]-heptyl}-formamid, N-((R)-2-{N'-[ 1-(1-benzo[ 1,3]dioksol-5-yl-metanoyl)-piperidin-4-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-((R)-2-{N'-[l-(l-benzofuran-2-yl-metanoyl)-piperidin-4-yl]-hydrazinokarbonyl}-heptyl)-N-hydroksy-formamid, N-hydroksy-N- {(R)-2-(N' - {1 - [ 1 -(7-metoksy-benzofuran-2-yl)-metanoyl} -piperidin-4-yl}-hydrazinokarbonyl)-heptyl]-formamid, N-{(R)-2-[N'-(l-benzyl-piperidin-4-yl)-hydrazinokarbonyl]-heptyl}-N-hydroksy-formamid, N-[(R)-2-(K'-{l-[l-(3,4-diklor-fenyl)-metanoyl]-piperidin-4-yl}-hydrazinokarbonyl)-heptyl] -N-hydroksy-formamid, N-[(R)-2-(N'- {1 -[1 -(2,3-diklor-fenyl)-metanoyl]-piperidin-4-yl} -hydrazinokarbonyl)-heptyl] -N-hydroksy-formamid, N-hydroksy-N-[(R)-2-(N'- {1 -[ 1 -(4-metyl-piperazin- l-yl)-metanoyl]-pentyl} - hydrazinokarbonyl)-heptyl]-formamid, N- [(R) -2-(N' -benzyl-hyd razinokarbonyl)-hepty 1] -N-hydroksy-formamid, eller et farmasøytisk akseptabelt salt derav.
5. Anvendelse av en forbindelse ifølge krav 1, for fremstilling av et medikament forbe-handling av en bakteriell infeksjon.
NO20045675A 2002-05-31 2004-12-28 Peptiddeformylaseinhibitorer samt anvendelse derav NO335263B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38445702P 2002-05-31 2002-05-31
PCT/US2003/017054 WO2003101442A1 (en) 2002-05-31 2003-05-30 Peptide deformylase inhibitors

Publications (2)

Publication Number Publication Date
NO20045675L NO20045675L (no) 2004-12-28
NO335263B1 true NO335263B1 (no) 2014-10-27

Family

ID=29712035

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045675A NO335263B1 (no) 2002-05-31 2004-12-28 Peptiddeformylaseinhibitorer samt anvendelse derav

Country Status (25)

Country Link
US (1) US7919528B2 (no)
EP (1) EP1509218A4 (no)
JP (1) JP4563798B2 (no)
KR (2) KR101032823B1 (no)
AP (1) AP1795A (no)
AR (1) AR039916A1 (no)
AU (1) AU2003247445C1 (no)
BR (1) BRPI0311318B1 (no)
CA (1) CA2487805C (no)
EA (1) EA007786B1 (no)
EC (1) ECSP045466A (no)
IL (1) IL164973A (no)
IS (1) IS7610A (no)
MX (1) MXPA04011951A (no)
MY (1) MY133625A (no)
NO (1) NO335263B1 (no)
NZ (1) NZ536103A (no)
OA (1) OA12823A (no)
PE (1) PE20040528A1 (no)
PL (1) PL213139B1 (no)
TW (1) TWI304059B (no)
UA (1) UA78563C2 (no)
UY (1) UY27813A1 (no)
WO (1) WO2003101442A1 (no)
ZA (1) ZA200408315B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229673D0 (en) * 2002-12-19 2003-01-29 British Biotech Pharm Antibacterial agents
WO2005005456A2 (en) * 2003-07-08 2005-01-20 Glaxo Group Limited Peptide deformylase inhibitors
JP2007502825A (ja) * 2003-08-15 2007-02-15 スミスクライン・ビーチャム・コーポレイション ペプチドデホルミラーゼ阻害剤
TW200624429A (en) * 2004-09-07 2006-07-16 Glaxo Group Ltd Novel cysteine protease inhibitors
US20080161249A1 (en) * 2004-11-17 2008-07-03 Smithkline Beecham Corporation Use of Novel Antibacterial Compounds
CN101166740B (zh) * 2005-04-25 2010-12-29 诺瓦提斯公司 用作肽脱甲酰基酶(pdf)抑制剂的咪唑并[1,2-a]吡啶衍生物
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
WO2007067904A2 (en) * 2005-12-06 2007-06-14 Smithkline Beecham Corporation Peptide deformylase inhibitors
WO2007067906A2 (en) * 2005-12-09 2007-06-14 Smithkline Beecham Corporation Peptide deformylase inhibitors
EP1918284A1 (en) * 2006-10-30 2008-05-07 Glaxo Group Hydrazinopyrimidines as cysteine protease inhibitors
EP2028182A1 (en) * 2007-08-21 2009-02-25 Glaxo Group Limited Cysteine protease inhibitors
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
JP5959537B2 (ja) 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
AR085698A1 (es) * 2011-03-09 2013-10-23 Glaxosmithkline Llc Inhibidores de la peptido desformilasa
BR112014027564B1 (pt) * 2012-05-08 2022-05-03 Bayer Pharma Aktiengellschaft Método para a preparação de compostos de triazol
WO2014141181A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property No 2 Limited Process for preparing peptide deformylase inhibitors
CN110452224B (zh) * 2019-08-30 2022-06-03 西南大学 嘧啶唑醇类化合物及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
DE69510198T2 (de) * 1994-05-28 1999-10-28 British Biotech Pharmaceuticals Ltd., Cowley Succinyl hydroxamsäure-, n-formyl-n-hydroxy-aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease-inhibitoren
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
BR9907689A (pt) * 1998-02-07 2000-11-14 British Biotech Pharm Agentes antibacterianos
US6239151B1 (en) * 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
GB9827805D0 (en) 1998-12-16 1999-02-10 British Biotech Pharm Antibacterial agents
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
JP2002541197A (ja) * 1999-04-09 2002-12-03 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 抗菌剤
WO2001010835A1 (en) * 1999-08-10 2001-02-15 British Biotech Pharmaceuticals Limited Antibacterial agents
CN1217932C (zh) * 1999-08-10 2005-09-07 英国生物技术药物有限公司 抗菌剂
AR028075A1 (es) * 2000-05-05 2003-04-23 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
DE10040783A1 (de) 2000-08-21 2002-03-07 Merck Patent Gmbh AZA-Aminosäurederivate (Faktor X¶a¶-Inhibitoren 15)
WO2002041886A1 (en) * 2000-11-23 2002-05-30 British Biotech Pharmaceuticals Ltd Ydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections
AR032920A1 (es) * 2001-03-01 2003-12-03 Smithkline Beecham Corp Compuestos inhibidores de las peptido-deformilasas y medios para tratar infecciones bacterianas utilizando dichos inhibidores
WO2004052919A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Peptide deformylase inhibitors
WO2005005456A2 (en) 2003-07-08 2005-01-20 Glaxo Group Limited Peptide deformylase inhibitors
JP2007502825A (ja) 2003-08-15 2007-02-15 スミスクライン・ビーチャム・コーポレイション ペプチドデホルミラーゼ阻害剤
US20080161249A1 (en) 2004-11-17 2008-07-03 Smithkline Beecham Corporation Use of Novel Antibacterial Compounds
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази

Also Published As

Publication number Publication date
TW200403211A (en) 2004-03-01
EA007786B1 (ru) 2007-02-27
MXPA04011951A (es) 2005-03-31
BRPI0311318B1 (pt) 2016-05-10
AR039916A1 (es) 2005-03-09
AP1795A (en) 2007-11-05
ECSP045466A (es) 2005-01-28
JP4563798B2 (ja) 2010-10-13
AU2003247445C1 (en) 2009-10-29
KR20100121553A (ko) 2010-11-17
EA200401628A1 (ru) 2005-04-28
US20050222412A1 (en) 2005-10-06
BR0311318A (pt) 2005-02-22
PE20040528A1 (es) 2004-08-26
TWI304059B (en) 2008-12-11
UA78563C2 (en) 2007-04-10
WO2003101442A1 (en) 2003-12-11
IL164973A0 (en) 2005-12-18
US7919528B2 (en) 2011-04-05
JP2006501155A (ja) 2006-01-12
UY27813A1 (es) 2003-12-31
NZ536103A (en) 2007-09-28
PL373798A1 (en) 2005-09-19
IL164973A (en) 2011-09-27
ZA200408315B (en) 2006-12-27
PL213139B1 (pl) 2013-01-31
EP1509218A4 (en) 2008-03-26
AU2003247445B2 (en) 2009-02-26
AP2004003156A0 (en) 2004-12-31
NO20045675L (no) 2004-12-28
IS7610A (is) 2004-12-22
CA2487805C (en) 2012-11-27
MY133625A (en) 2007-11-30
OA12823A (en) 2006-07-11
EP1509218A1 (en) 2005-03-02
KR20050013114A (ko) 2005-02-02
AU2003247445A1 (en) 2003-12-19
KR101032823B1 (ko) 2011-05-06
CA2487805A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
NO335263B1 (no) Peptiddeformylaseinhibitorer samt anvendelse derav
JP5328816B2 (ja) アミロイドβの調節薬
EP3087070B1 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
AU2008314632B2 (en) Heteroaryl compounds and uses thereof
US7244735B2 (en) Heterocyclic protein kinase inhibitors and uses thereof
AU2004263148A1 (en) Aminotriazole compounds useful as inhibitors of protein kinases
OA11856A (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors.
MX2007004488A (es) Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
CZ187497A3 (en) Sulfonamide derivative, process of its preparation and use
KR20110044974A (ko) 키나아제 억제제 화합물로서의 치환된 피리다진 카르복사마이드 화합물
JP2006501155A5 (no)
WO2008072850A1 (en) Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
NZ508170A (en) Pyrimidin-aminomethyl-pyridine derivatives, their preparation and their use in the control of helicobacter bacteria
US7507726B2 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees